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Glucagon-like peptide-1 (GLP-1) is an incretin and neuropeptide primarily known for its role in 
glucose homeostasis. GLP-1 also has potent anti-obesogenic potential, and is known to inhibit 
food intake, food reward, and diet-induced obesity. In addition, brain GLP-1 increases heart rate 
and mediates effects of acute stress. Within the brain, GLP-1 is produced by preproglucagon 
(PPG) neurons in the caudal brainstem.  
Although the potential role of GLP-1 has been studied through pharmacological activation of 
brain GLP-1 receptors, little is known about the cellular properties and physiological role(s) of 
PPG neurons. 
In this thesis, a complementary array of in vitro and in vivo techniques was used to study the 
physiological roles of PPG neurons. In vitro Ca2+ imaging revealed that PPG neuron activity is 
modulated by a range of compounds relaying signals of energy balance, satiety, and visceral 
illness. In vivo, I selectively manipulated PPG neurons in mice using chemogenetic tools. 
Activation of PPG neurons dramatically reduced feeding, supporting a role for brain-derived 
GLP-1 in appetite control. Although selective inactivation of PPG neurons had no effect on ad 
libitum feeding, large meal- or stress-induced reductions in food intake were abolished when 
PPG neurons were silenced. 
In freely-behaving mice, systemic GLP-1 receptor activation had no effect on arterial blood 
pressure, but increased heart rate via stimulation of the sympathetic nervous system. Although 
permanent ablation of PPG neurons had no effect on heart rate and blood pressure, selective 
activation of PPG neurons using chemogenetic tools increased heart rate.  
These results provide the first evidence of the physiological role played by the GLP-1 producing 
neurons in the caudal brainstem. Activity of these neurons is modulated by diverse neural and 
humoral signals. They are critically important in the prevention of overeating as well as stress-
induced hypophagia and may contribute to central nervous mechanisms of cardiovascular 
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The obesity epidemic is arguable the most severe health challenge of this century. The 
prevalence of overweight more than doubled between 1980 and 2013, with 2.1 billion people 
overweight or obese in 2013 (Ng et al. 2014). Obesity increases the risk of diabetes, some types 
of cancer, and cardiovascular disease (Mokdad et al. 2003; Carreras-Torres et al. 2017), the latter 
of which was the primary cause of death in the world in 2012 (WHO 2016).  
At the heart of obesity lies appetite regulation. Bodyweight is maintained by stringently 
regulated physiological processes and slight dysregulation of these processes results in 
significant weight gain. Obesity can in turn trigger the development of metabolic syndrome, the 
medical term for the combination of obesity, diabetes, and hypertension. Food consumption is 
regulated by a complex set of hormonal and neural mechanisms (Suzuki et al. 2012). Long-term 
cues of energy balance as well as short term signals of satiation, reward, and stress all affect 
appetite, motivation to eat, and energy expenditure. 
Glucagon-like peptide-1 (GLP-1) is a potent regulator of food intake within the brain. Initially 
discovered as an enhancer of insulin secretion (Holst et al. 1987; Wang et al. 1995), its many 
beneficial effects have been delineated over the last two decades and are now known to include 
cardioprotection (Bose et al. 2005; Ban et al. 2008; Ussher and Drucker 2012; Basalay et al. 
2016), maintenance of blood glucose levels (Alcántara et al. 1997; Toft-Nielsen et al. 1999), 
decreased drug reward (Egecioglu et al. 2013b; Graham et al. 2013; Skibicka 2013), 
neuroprotection (Holscher 2013; Hansen et al. 2015), and decreased appetite and bodyweight 
(Tang-Christensen et al. 1996; Turton et al. 1996; Flint et al. 1998).  
As more effort is put into uncovering the therapeutic potential of GLP-1, additional effects are 
emerging, some of which may be damaging to health. For example, GLP-1 is now known to 
increase heart rate, a potentially detrimental effect in patients who already have cardiovascular 
pathology due to obesity (Barragán et al. 1994; Yamamoto et al. 2002; Robinson et al. 2013; 
Smits et al. 2016; Bremholm et al. 2017). GLP-1 is expressed in the gut and in neurons in the 
central nervous system (CNS) and many of its effects have been attributed to activation of GLP-
1 receptors (GLP-1Rs) within the brain. This thesis presents novel insight into the role of the CNS 
GLP-1 system in food intake, stress, and cardiovascular control.  
Chapter 1 - Introduction 
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1.1 GLP-1 – structure and function 
1.1.1 Proglucagon undergoes tissue-specific posttranslational processing 
GLP-1 is expressed from the glucagon (GCG) gene. From this gene, the preproglucagon (PPG) 
mRNA is transcribed, which is translated to form the proglucagon prohormone (Holst 2007). 
Proglucagon undergoes tissue-specific, differential post-translational processing as shown in Fig 
1.1 (Mojsov et al. 1986). Glucagon is secreted from α-cells in the endocrine pancreas (Sutherland 
and De Duve 1948), whereas GLP-1 is produced in enteroendocrine L-cells in the gut (Ørskov et 
al. 1986), as well as PPG neurons in the CNS (Jin et al. 1988). Full-length GLP-1 is truncated to 
form the biologically active form, GLP-1(7-36)amide (Holst et al. 1987; Orskov et al. 1988; 
Wettergren et al. 1993), and GLP-1 is now widely used to denote the biologically active GLP-1(7-
36)amide.  
 
1.1.2 Peripheral GLP-1 regulates blood glucose levels 
Peripherally, GLP-1 is released from L-cells into the bloodstream in response to the presence of 
macronutrients in the gut (Kreymann et al. 1987; Gribble et al. 2003; Vilsboll et al. 2003; 
Reimann et al. 2008). From the blood, GLP-1 reaches the pancreas where it acts on β-cells to 
Fig 1.1 Tissue-specific post-translational processing of the proglucagon hormone. In neurons in 
the CNS and enteroendocrine L-cells in the intestine, proglucagon is processed by prohormone 
convertase-1/3 (PC-1/3) into glicentin-related pancreatic polypeptide (GRPP), oxyntomodulin, 
GLP-1, intervening peptide-2 (IP-2), and GLP-2. In pancreatic α-cells, proglucagon is processed by 
PC-2 into glucagon, IP-1, major proglucagon fragment (MPF), and GRPP.  
Chapter 1 - Introduction 
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enhance the secretion of insulin in response to glucose (Holst et al. 1987; Kreymann et al. 1987; 
Mojsov et al. 1987; Wang et al. 1995), while inhibiting the release of glucagon from α-cells 
(Orskov et al. 1988). In addition, GLP-1 increases glucose uptake by peripheral tissues (Alcántara 
et al. 1997). These potent effects of GLP-1 on glucose homeostasis have led to the use of GLP-1 
analogues in the treatment of diabetes. Investigations of the role of GLP-1 have been greatly 
facilitated by the use of two long-acting GLP-1 analogues, exendin-4 (Ex4) (Thorens et al. 1993) 
and liraglutide (Larsen et al. 2001), as well as the selective GLP-1R antagonist, exendin-9 (Ex9) 
(Thorens et al. 1993).  
1.1.3 Central actions of GLP-1 
Although initially identified as an incretin, it was quickly discovered that GLP-1 dramatically 
reduces food intake in rodents (Tang-Christensen et al. 1996; Turton et al. 1996; Meeran et al. 
1999; Williams et al. 2009) and humans (Flint et al. 1998; Gutzwiller et al. 1999; Astrup et al. 
2009). The effect on feeding was largely thought to be mediated by activation of GLP-1Rs in the 
brain (Turton et al. 1996; Meeran et al. 1999). Central GLP-1, here referring to GLP-1 acting 
within the CNS, has since been found to affect a range of physiological processes:  
1) When injected into the brain, GLP-1 not only decreases food intake, but also induces nausea 
and conditioned taste aversion in rats and mice (Thiele et al. 1997; Lachey et al. 2005). 2) GLP-1 
enhances cognitive function and memory through neuroprotection (Oka et al. 2000; During et 
al. 2003; Abbas et al. 2009; Holscher 2013; Hansen et al. 2015). 3) Central GLP-1 increases 
thermogenesis via hypothalamic AMPK (AMP-activated protein kinase) and activation of the 
sympathetic nervous system (Yamamoto et al. 2002; Lockie et al. 2012; Beiroa et al. 2014). 4) 
Brain GLP-1R activation increases heart rate in rats (Barragán et al. 1994; Yamamoto et al. 2002) 
and mice (Griffioen et al. 2011). 5) Central GLP-1 attenuates the rewarding effects of food 
(Dickson et al. 2012) and psychostimulant drugs (Egecioglu et al. 2013b; Skibicka 2013; Tuesta 
et al. 2017). 6) Finally, evidence is emerging for a role of central GLP-1 in the physiological 
responses to acute stress (Kinzig et al. 2003; Maniscalco et al. 2012, 2015; Ghosal et al. 2013, 
2017; Holt and Trapp 2016). 
1.1.4 The source of central GLP-1 
The source of GLP-1 acting within the brain is a much-debated topic. It remains unclear whether 
peripheral GLP-1 can readily cross the blood-brain barrier (Orskov et al. 1996; Kastin et al. 2002; 
Kastin and Akerstrom 2003). Kastin et al. (2002) found evidence for the entry into brain tissue 
of a radio-labelled, stable GLP-1 analogue, 125I-Ala8Ser-GLP-1. However, Orskov et al. (1996) 
presented convincing evidence that only the circumventricular organs (CVOs), areas in which 
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the blood-brain barrier is leaky, are accessible to circulating GLP-1. Importantly, GLP-1 is rapidly 
degraded in the bloodstream by dipeptidylpeptidase-IV (DPP-IV) and has a half-life of two mins 
with no intact GLP-1 remaining 10 mins after injection (Kieffer et al. 1995). This rapid elimination 
of biologically active GLP-1 from the bloodstream makes it unlikely that peripherally released 
GLP-1 reaches the brain in sufficient amounts to activate brain GLP-1Rs. Indeed, it is thought 
that only 25% of released GLP-1 reaches the liver (Holst and Deacon 2005; Holst 2007), and 
although GLP-1 was found to increase in the hepatic portal vein after intake of a meal in rats, no 
GLP-1 was detected in the vena cava (Punjabi et al. 2014), suggesting most of the peptide is 
degraded before it reaches the brain circulation. Considering these findings, it is likely that GLP-
1Rs behind the blood-brain barrier are activated by GLP-1 released from a central source.  
1.2 The anatomy of the central GLP-1 system 
1.2.1 GLP-1 is produced by cells in the olfactory bulb, brainstem, and spinal cord 
Within the brain, GLP-1 is expressed by PPG neurons found in the caudal brainstem, the olfactory 
bulb, and in the dorsal horn of the spinal cord near the lumbar enlargement (Jin et al. 1988; 
Larsen et al. 1997a; Merchenthaler et al. 1999; Llewellyn-Smith et al. 2011, 2015; Thiebaud et 
al. 2016). These cells have been identified through their immunoreactivity to GLP-1 (Jin et al. 
1988; Rinaman 1999b; Zheng et al. 2015b); by detecting the PPG mRNA through in situ 
hybridisation (Larsen et al. 1997a; Merchenthaler et al. 1999); and recently via the development 
of a transgenic mouse expressing yellow fluorescent protein (YFP) under the control of the 
glucagon promoter (Reimann et al. 2008; Hisadome et al. 2010; Llewellyn-Smith et al. 2011). 
Because the glucagon promoter drives PPG expression, YFP is selectively produced in PPG cells 
in the brain (Hisadome et al. 2010; Llewellyn-Smith et al. 2011) and intestine (Reimann et al. 
2008), as well as in glucagon-producing α-cells in the pancreas (Reimann et al. 2008). Based on 
these methods, similar distributions of GLP-1 or PPG expression have been found in mice 
(Hisadome et al. 2010; Llewellyn-Smith et al. 2011), rats (Merchenthaler et al. 1999; Rinaman 
1999b), macaques (Vrang and Grove 2011), and humans (Zheng et al. 2015a), suggesting the 
central GLP-1 system is conserved within mammals. 
PPG neurons in the caudal medulla are arranged in two clusters of cells, with the largest 
population of neurons in the nucleus of the solitary tract (NTS), situated lateral of the dorsal 
motor nucleus of the vagus and dorsal of the hypoglossal nucleus. A smaller group of neurons is 
found in the intermediate reticular nucleus (IRT) extending towards the ventral surface of the 
medulla (Jin et al. 1988; Merchenthaler et al. 1999; Hisadome et al. 2010; Llewellyn-Smith et al. 
2011). In addition, a few cells are located along the midline dorsal of the central canal (Llewellyn-
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Smith et al. 2011). PPG neurons in the caudal brainstem are considered to be glutamatergic 
(Trapp and Cork 2015; Zheng et al. 2015b) and do not express choline acetyl transferase (ChAT) 
or tyrosine hydroxylase (TH), indicating they are neither cholinergic nor catecholaminergic 
(Larsen et al. 1997a; Hisadome et al. 2010; Llewellyn-Smith et al. 2013). Along with GLP-1 and 
glutamate, PPG neurons express the remaining products of tissue-specific posttranslational 
processing of the proglucagon hormone (Fig 1.1): Oxyntomodulin, GRPP, and GLP-2. 
Oxyntomodulin inhibits food intake by activating GLP-1Rs in the brain (Dakin et al. 2001; Baggio 
et al. 2004b), whereas GLP-2 acts on the GLP-2 receptor to inhibit food intake in rats (Tang-
Christensen et al. 2000) and mice (Lovshin and Drucker 2013), suggesting PPG neurons, with all 




Brainstem PPG neurons project to nuclei throughout the brain, many of which are involved in 
autonomic control, including the paraventricular nucleus of the hypothalamus (PVN) and the 
ventrolateral medulla (VLM) (Fig 1.2) (Vrang et al. 2007; Llewellyn-Smith et al. 2011, 2013). 
Recently, NTS PPG neurons were found to send close appositions to sympathetic preganglionic 
neurons in the central autonomic area (CAA) and intermediolateral nucleus (IML) of the spinal 
cord (Llewellyn-Smith et al. 2015). This projection pattern suggests PPG neurons may be 
important in the control of the activity of the sympathetic nervous system. Notably, olfactory 
bulb PPG neurons are considered to be interneurons or short-axon cells and are therefore 
Fig 1.2 The brain GLP-1 system. GLP-1 is expressed by PPG neurons in the nucleus of the solitary 
tract (NTS), the intermediate reticular nucleus (IRT), and the olfactory bulb (OB). PPG neurons are 
also found in the deep dorsal horn of the spinal cord (not shown). From the NTS and IRT, PPG 
neurons project to a range of forebrain and brainstem nuclei as well as areas of the spinal cord. 
Nucleus Accumbens (NAc), lateral septum (LS), bed nucleus stria terminalis (BNST), paraventricular 
nucleus of the thalamus (PVT). Paraventricular (PVN), dorsomedial (DMH), arcuate (Arc), and 
mammillary (MM) hypothalamic nuclei. PAG: Periaqueductal gray area, LC: Locus coeruleus, VLM: 
Ventrolateral medulla, RPa:  Raphé pallidus. IML: Intermediolateral nucleus, CAA: Central 
autonomic area. Drawing based on (Franklin and Paxinos 2008). 
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thought not to contribute to GLP-1 signalling in the rest of the brain (Merchenthaler et al. 1999; 
Thiebaud et al. 2016).  
1.2.2 GLP-1Rs are widely expressed in the brain 
GLP-1Rs are found throughout the CNS from the olfactory bulb to lamina 5-10 of the sacral part 
of the spinal cord (Larsen et al. 1997a; Merchenthaler et al. 1999; Cork et al. 2015). Furthermore, 
GLP-1Rs are expressed in peripheral vagal afferent cell bodies in the nodose ganglion (Nakagawa 
et al. 2004; Bucinskaite et al. 2009; Iwasaki et al. 2017) and in vagal afferent terminals in the 
hepatic portal vein (Vahl et al. 2007). Due to lack of antibodies reliably detecting GLP-1R, the 
expression pattern has been investigated using GLP-1 binding assays (Goke et al. 1995), in situ 
hybridisation (Merchenthaler et al. 1999), and more recently transgenic mice expressing a 
fluorescent reporter in GLP-1R-producing neurons (Richards et al. 2014; Cork et al. 2015). 
In accordance with the projection pattern of GLP-1 neurons (Fig 1.2), dense expression of GLP-
1Rs is found in areas implicated in control of energy balance, including several hypothalamic 
nuclei: PVN, the arcuate nucleus (Arc), and the dorsomedial hypothalamus (DMH) 
(Merchenthaler et al. 1999; Cork et al. 2015). In addition, GLP-1Rs are found in the mesolimbic 
system with high expression in the paraventricular nucleus of the thalamus (PVT), the dorsal 
lateral septum (dLS), the amygdala, and the bed nucleus stria terminalis (BNST) (Merchenthaler 
et al. 1999; Cork et al. 2015). In rats, GLP-1Rs are also present in the nucleus accumbens (NAc) 
and the ventral tegmental area (VTA) (Merchenthaler et al. 1999) and these regions have been 
found to receive direct input from NTS GLP-1-expressing neurons (Dossat et al. 2011; Alhadeff 
et al. 2012). Interestingly, only few cells were found in these areas in the mouse (Cork et al. 
2015), suggesting species differences may exist.  
As well as in nuclei involved in the control of energy balance, GLP-1R expression is found in areas 
associated with regulation of the sympathetic nervous system and physiological responses to 
stress, including the PVN, VLM, spinal cord, central amygdala and the dLS (Merchenthaler et al. 
1999; Cork et al. 2015). Notably, these areas are also innervated by PPG neurons (Vrang et al. 
2007; Llewellyn-Smith et al. 2011, 2013).  
Finally, dense GLP-1R expression is present in CVOs: the subfornical organ, the area postrema 
(AP), and the median eminence, as well as in neurons in the hippocampus (Goke et al. 1995; 
Merchenthaler et al. 1999; Cork et al. 2015). These areas receive little innervation from PPG 
neurons (Llewellyn-Smith et al. 2011, 2013), and the endogenous source of GLP-1 acting at these 
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sites remains unknown. It is possible these GLP-1Rs detect GLP-1 in the bloodstream or 
cerebrospinal fluid (Orskov et al. 1996; Hsu et al. 2015). 
1.3 PPG neurons monitor general homeostasis 
With their location in the NTS, PPG neurons are ideally situated to receive and relay signals of 
changes in the body’s internal environment (Grill and Hayes 2012). Homeostasis is a tightly 
controlled equilibrium, which ensures the optimal working conditions for the organism. Energy 
balance, core temperature, blood glucose, and blood pressure are stringently monitored and 
regulated through neural and hormonal mechanism. Dysregulation of those mechanisms can 
lead to obesity, diabetes, and cardiovascular disease. Interestingly, the body copes well with 
repeated challenges to homeostasis, including visceral illness, inflammation, and changes in 
blood glucose in response to food consumption. To counteract these challenges and restore 
homeostasis, the body initiates a range of physiological and behavioural processes. Following 
intake of a large meal for example, insulin is released to restore euglycaemia while food intake 
is suppressed. These processes may rely on recruitment of PPG neurons and central GLP-1. 
Two primary methods have been employed to investigate the regulation of PPG neuron activity. 
Detection of the product of the immediate early gene, cFOS, is a common technique for 
assessing neuronal activity (Sagar et al. 1988). Simultaneous immunostaining for the cFOS 
protein and GLP-1 has revealed a range of systemic stimuli, which activate PPG neurons in vivo. 
More recently, the development of the PPG-YFP mouse (Reimann et al. 2008) has allowed 
identification of live PPG neurons in in vitro brainstem sections (Hisadome et al. 2010). This has 
facilitated the use of patch-clamp electrophysiology to investigate the cellular properties of PPG 
neurons (Hisadome et al. 2010, 2011). Fig 1.3 illustrates the proposed regulation of PPG neuron 
activity as detailed in the following sections. 




Approximately 75% of PPG neurons in the NTS are spontaneously active with regular firing of 
action potentials at 1.9±0.2 Hz (Hisadome et al. 2010). A smaller population (19%) was found to 
be burst firing and less than 10% were electrically silent (Hisadome et al. 2010).  
In accordance with the role of central GLP-1 in the control of feeding, gastric distension induces 
cFOS expression in GLP-1-producing neurons in the NTS of rats (Vrang et al. 2003). The satiating 
effect of gastric distension was later shown to be dependent on hindbrain GLP-1R signalling, 
suggesting distension of the stomach induces release of GLP-1 centrally (Hayes et al. 2009). 
Furthermore, patch-clamp electrophysiology of PPG neurons in mice revealed that stimulation 
of the solitary tract (ST), which conveys afferent sensory information to the NTS, evokes 
glutamatergic excitatory postsynaptic potentials in PPG neurons. These data suggest gastric 
distension activates vagal afferents, which relay the signal via the ST to PPG neurons in the NTS 
(Hisadome et al. 2010) (Fig 1.3). There is no direct evidence for activation of NTS PPG neurons 
in response to vagal afferent stimulation in vivo.  
The satiation hormone leptin directly depolarises mouse PPG neurons in vitro (Hisadome et al. 
2010). The existence of leptin receptors (lepRs) on PPG neurons appears to be species-specific 
with clear evidence for lepR expression in mice (Goldstone et al. 1997; Hisadome et al. 2010; 
Garfield et al. 2012), but no expression in rats (Huo et al. 2008). In spite of this, leptin and GLP-
1 have been shown to interact to reduce food intake in rats (Goldstone et al. 1997; Williams et 
al. 2006; Zhao et al. 2012), suggesting the existence of a link between the two systems also in 
rats. In particular, GLP-1R-mediated satiation disappeared after a 24-hour fast, but could be 
rescued with continuous infusion of leptin (Williams et al. 2006). Cholecystokinin-8 (CCK-8) also 
activated a subset of NTS PPG neurons in mice. In contrast to the direct effect of leptin, this 
Fig 1.3 Regulation of PPG neuron 
activity. PPG neurons receive input 
from the solitary tract (ST), which 
relays information from the periphery 
to the NTS, including signals of 
interoceptive stress. LiCL, LPS, and 
CCK-8 may activate PPG neurons 
through this pathway. Similarly, the 
NTS receives limbic input (LI) with 
signals of psychogenic stress. Finally, 
PPG neurons are directly activated by 
leptin, and CCK-8 activates these cells 
indirectly by stimulating adrenergic 
(Adr.) input onto glutamatergic (Glut.) 
cells resulting in increased firing of 
PPG neurons. Diagram expanded on 
from (Hisadome et al. 2011). 
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effect was indirect and depended on α1-adrenoceptor signalling and modulation of 
glutamatergic input, resulting in increased firing rate (Hisadome et al. 2011). Notably, other 
hunger-regulating hormones had no effect on PPG neuron activity, including peptide-YY, ghrelin, 
and GLP-1 itself (Hisadome et al. 2010).  
There is a noticeable lack of robust evidence for activation of PPG neurons in response to normal 
feeding. Sweetened milk has been shown to induce cFOS expression in NTS GLP-1-producing 
neurons (Gaykema et al. 2009). However, Linda Rinaman (1999a) found that even a large meal 
failed to activate PPG neurons in rats. Later her group did find that activation of PPG neurons is 
correlated with meal size, but that intake of a very large, unexpected meal is required to robustly 
activate these cells (Kreisler et al. 2014; Kreisler and Rinaman 2016), similarly to what is required 
for general neuronal activation in the NTS and AP (Rinaman et al. 1998).  
A more vigorous stimulus for PPG neurons appears to be visceral malaise. In rats, approximately 
60% of GLP-1-producing neurons expressed cFOS in response to interoceptive stress induced by 
intraperitoneal (i.p.) injection of LiCl, CCK-8, and lipopolysaccharide (LPS), all of which mimic 
situations of infection and general malaise (Rinaman 1999b). LiCl-induced cFOS expression in 
GLP-1-producing neurons was later confirmed in mice (Lachey et al. 2005) and the hypophagic 
response to LiCl was found to be attenuated by central GLP-1R inhibition in rats (Rinaman 
1999a). These data suggest PPG neurons are sensitive to general malaise. Furthermore, not only 
interoceptive stress, but also acute psychogenic stress in the form of 30 mins of restraint 
activated cFOS expression in GLP-1-producing neurons in the NTS (Maniscalco et al. 2015).   
1.4 GLP-1 regulates food intake through diverse mechanisms 
1.4.1 Central GLP-1 regulates food intake  
Since its role in food intake was first discovered (Tang-Christensen et al. 1996; Turton et al. 
1996), a complex system of GLP-1-mediated hypophagia has been revealed. GLP-1 or its 
analogues reduce food intake when injected directly into a range of brain regions. Table 1.1 
summarises findings using microinjections of GLP-1, Ex4, or Ex9 into different brain areas. The 
bulk of this evidence is based on studies in rats, with very limited data available on the food 
intake-suppressive effects of GLP-1R activation in mice. 
Three main brain systems are involved in the hypophagic response to GLP-1R stimulation (Table 
1.1). 1) Activation of brainstem GLP-1Rs has been shown to reduce chow intake in rats. 2) Several 
hypothalamic nuclei express GLP-1Rs (Merchenthaler et al. 1999; Cork et al. 2015) and injection 
of Ex4 or GLP-1 into these areas suppresses feeding in rats. Notably, one study confirmed the 
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ability of PVN and Arc nucleus GLP-1Rs to decrease food intake in mice. 3) Activation of GLP-1Rs 
in nuclei, which are part of the mesolimbic system, reduces food intake. Ex4 was found to 
hyperpolarise and decrease firing of neurons in the PVT. Considering the heavy innervation of 
this area from PPG neurons and the dense expression of GLP-1Rs in this area, this is a potentially 
critical nucleus for the control of food intake mediated by central GLP-1. 
The hypothalamus is a well-established site for the control of energy balance and brainstem 
nuclei, in particular the NTS, are emerging as important brain regions in food intake regulation. 
The hypothalamus and the NTS are both thought to primarily affect homeostatic feeding – that 
is feeding to meet the caloric needs of the organism. On the other hand, the mesolimbic system 
is considered a key regulator of hedonic food intake, defined as feeding beyond immediate 
caloric need or an increased motivation to eat (Skibicka 2013). A role for GLP-1 in reward is 
currently being cemented with suppressive effects being shown on hedonic food intake (Table 
1.1), as well as on the reinforcing effects of psychostimulants, including alcohol (Vallöf et al. 
2016), nicotine (Egecioglu et al. 2013a; Tuesta et al. 2017), cocaine (Graham et al. 2013; 
Sørensen et al. 2015; Schmidt et al. 2016), and amphetamine (Erreger et al. 2012; Egecioglu et 
al. 2013b).  
Microinjection of Ex4 into the ventral hippocampal formation (vHPF) of rats reduces intake of 
chow or western diet by decreasing average meal size during the dark cycle (Hsu et al. 2015). 
The effect of Ex4 was in part mediated by a decreased motivation to work for food, as seen by a 
reduction in the number of times rats were willing to press a lever to receive a sugar pellet (Hsu 
et al. 2015). The hippocampus is a curious site of GLP-1 action. No innervation from PPG neurons 
has been detected in this region (Llewellyn-Smith et al. 2011), however there is clear expression 
of GLP-1Rs (Merchenthaler et al. 1999; Cork et al. 2015) and GLP-1R-expressing neurons respond 
electrically to GLP-1 (Cork et al. 2015). The source of GLP-1 acting on hippocampal neurons is 
unknown. It was proposed by Hsu et al. (2015) that GLP-1 is released from PPG neurons into CSF 
and reaches the vHPF from there. This mode of volume transmission is presumably much slower 





Area Drugs Species Effects on food intake, food reward, and malaise References 
Brain i.c.v. GLP-1, Ex9 Rat GLP-1 dose-dependently decreased chow intake, whereas Ex9 increased intake in satiated, 
not hungry, rats. Ex4 attenuates food reward without inducing malaise. 
(Tang-Christensen et al. 1996; 












Hindbrain 4th i.c.v. Ex4 Rat Hindbrain Ex4 decreases chow intake. This was dependent on PKA and MAPK signalling. (Hayes et al. 2011a) 
NTS Ex4, Ex9 Rat NTS Ex4 preferentially decreases HFD intake. Chow intake is attenuated, when chow is the 
only source of calories. NTS Ex4 reduces food motivation and reward. GLP-1R inhibition 
increases chow intake and attenuates hypophagia induced by gastric distension.  
(Hayes et al. 2009; Alhadeff et al. 
2012; Alhadeff and Grill 2014) 
PBN Ex4, GLP-1, Ex9 Rat Intra-PBN Ex4 decreases HFD and chow intake, whereas Ex9 increases both. Ex4 decreases 
the motivation to work for sucrose pellets.  
(Alhadeff et al. 2014; Richard et 
al. 2014) 














i.c.v. 3rd i.c.v. GLP-1 Rat 3rd ventricle and lateral ventricle GLP-1 reduce food intake. (Schick et al. 2003) 
PVN Ex4, GLP-1, Ex9 Rat, 
mouse 
Ex4 decreases chow intake more potently than GLP-1. GLP-1 does not induce conditioned 
taste aversion. Ex9 increases chow intake in rats. 
(McMahon and Wellman 1998; 
Sandoval et al. 2008; Katsurada 
et al. 2014; Burmeister et al. 
2017) 
Arc Ex4, GLP-1, Ex9 Rat, 
mouse 
Intra-Arc Ex4 dose-dependently decreases food intake. Peripheral liraglutide was shown in 
one study to be dependent on the Arc and in another to work via a different area. 
(Secher et al. 2014; Burmeister 
et al. 2017) 
DMH/VMH GLP-1 Rat Intra-DMH and intra-VMH GLP-1 decreases chow intake.  (Schick et al. 2003) 
LH Ex4, GLP-1, Ex9 Rat Intra-LH Ex4 decreases chow intake and food motivation, and Ex9 increases both.   (Schick et al. 2003; López-












LS Ex4, Ex9 Rat Intra-LS Ex4 decreases chow and HFD intake as well as food motivation and reward without 
inducing malaise. Ex9 increases chow intake and dLS ex9 increases food reward. 
(Terrill et al. 2016) 
VTA Ex4, Ex9 Rat Intra-VTA Ex4 decreases chow intake and food reward. Intra-VTA Ex9 does not affect food 
intake.  
(Dickson et al. 2012; Mietlicki-
Baase et al. 2013) 
NAc Ex4, GLP-1, Ex9 Rat Intra-NAc Ex4 and GLP-1 attenuates food reward and intake of palatable, liquid diet. This 
appears to be specific for the NAc core, but does not induce release of dopamine. Intra-NAc 
GLP-1 does not induce malaise.  
(Dossat et al. 2011, 2013; 
Dickson et al. 2012; Mietlicki-
Baase et al. 2014) 
PVT Ex4, Ex9 Rat Intra-PVT Ex4 reduces chow and HFD intake, whereas Ex9 increases chow intake. Ex4 does 
not induce malaise and suppresses food-seeking behaviour and food reward. Ex4 
hyperpolarises and decreases firing of PVT neurons. 
(Ong et al. 2017) 
vHPF Ex4, Ex9 Rat Ex4 decreases intake of chow and western diet by reducing meal size and food motivation. (Hsu et al. 2015) 




1.4.2 Endogenous release of GLP-1 suppresses food intake in rats 
With the exception of the vHPF, the regions mentioned above all receive innervation from PPG 
neurons, suggesting these neurons could regulate both food intake and food reward (Larsen et 
al. 1997b; Llewellyn-Smith et al. 2011, 2013). In spite of abundant evidence for GLP-1-mediated 
hypophagia, few studies have addressed the role of centrally produced GLP-1.  
In 2011, Barrera et al. knocked down GLP-1 in the NTS of rats using short-hairpin RNA (shRNA). 
They reported a 50% reduction in GLP-1 levels and elevated food intake and bodyweight. This 
demonstrated for the first time a role for centrally produced GLP-1 in the regulation of normal 
feeding, although it is worth noting that the effects on bodyweight appeared to be mainly due 
to a less severe nadir in weight following stereotaxic surgery (Barrera et al. 2011). In support of 
the observations by Barrera et al. (2011), direct inhibition of GLP-1Rs in a range of areas 
increases food intake in rats (Table 1.1), although these results have not yet been reproduced in 
mice.  
In fact, in contrast to evidence from studies in rats, data from mice suggest central, endogenous 
GLP-1 may not play a major role in regulation of homeostatic food intake and bodyweight. Global 
genetic knock-out of the GLP-1R gene did not affect bodyweight or food intake, whereas glucose 
homeostasis was disrupted (Scrocchi et al. 1996). Similarly, selective knockdown of brain GLP-
1Rs did not affect bodyweight or feeding, although it did attenuate the hypophagic response to 
systemic liraglutide (Sisley et al. 2014).  
In summary, central GLP-1R stimulation suppresses food intake and attenuates the rewarding 
value of food. However, the role of endogenous GLP-1 in the control of feeding remains elusive 
with conflicting evidence from rats and mice.  
1.4.3 A role for intestinal GLP-1 in control of food intake 
The existence of GLP-1-producing cells in both the periphery and brain raises the question 
whether they make up two functionally, as well as anatomically, distinct systems. There is ample 
evidence that GLP-1 suppresses food intake when injected i.p. (Abbott et al. 2005; Williams et 
Table 1.1 Effects of GLP-1R stimulation or inhibition in a range of brain regions. Indicated are the 
areas targeted, drugs used, species investigated, and the outcome of the experiments as well as 
relevant references. Abbreviations: NTS: Nucleus of the solitary tract, PBN: parabrachial nucleus, 
lDTg: lateral dorsal tegmental area, PVN: paraventricular nucleus, Arc: Arcuate nucleus, DMH: 
dorsomedial hypothalamus, VMH: ventromedial hypothalamus, LH: lateral hypothalamus, LS: lateral 
septum, VTA: ventral tegmental area, NAc: nucleus accumbens, PVT: thalamic paraventricular 
nucleus, vHPF: ventral hippocampal formation, i.c.v.: intracerebroventricular, HFD: high-fat diet. 
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al. 2006, 2009, 2011) or directly into the blood stream (Rüttimann et al. 2009; Baumgartner et 
al. 2010; Zhang and Ritter 2012; Punjabi et al. 2014; Ronveaux et al. 2014). However, the relative 
contribution of central and peripheral GLP-1Rs is unknown. Williams et al. (2009) presented 
convincing evidence that peripheral GLP-1 plays a role in satiety in rats. First, peripheral 
suppression of GLP-1Rs increased food intake during light phase or after a large meal. Second, 
while the effects of i.p. GLP-1 were abolished by peripherally administered Ex9, inhibition of 
central GLP-1Rs did not affect the hypophagic effect of i.p. GLP-1, suggesting the effects of i.p. 
GLP-1 are mediated by peripheral GLP-1Rs.  
Experimental evidence now points to a role for vagal transmission in the effects of peripheral 
GLP-1. GLP-1Rs are expressed in the nodose ganglion (Kakei et al. 2002; Nakagawa et al. 2004; 
Richards et al. 2014), on vagal afferent terminals in the hepatic portal vein (Vahl et al. 2007), and 
in the gastric branch of the vagus nerve (Bucinskaite et al. 2009). Furthermore, GLP-1 depolarises 
(Gaisano et al. 2010) and increases intracellular [Ca2+] (Kakei et al. 2002; Iwasaki et al. 2017) in 
nodose ganglion neurons in vitro and elicits activity in gastric vagal afferents in vivo (Bucinskaite 
et al. 2009). Interestingly, knock-down of nodose ganglion GLP-1Rs increases meal size in rats 
without affecting daily food intake or bodyweight, suggesting vagal activation by GLP-1 regulates 
feeding behaviour (Krieger et al. 2015).  
1.5 Central GLP-1 mediates physiological responses to stress  
The literature on the role of GLP-1 in food intake regulation is extensive. However, the 
physiological context in which GLP-1-mediated hypophagia becomes important is less well-
studied. A reduction in food intake can be indicative of not only decreased caloric need 
(homeostatic feeding), but also of a change in the emotional state resulting in a decreased 
motivation to eat. Indeed, psychogenic stress in response to restraint dramatically suppresses 
feeding (Krahn et al. 1990). 
1.5.1 GLP-1 activates neuroendocrine pathways involved in stress regulation 
Stress is the collection of physiological and behavioural responses to physical and homeostatic 
challenges (Sawchenko et al. 2000; Dayas et al. 2001; Ulrich-Lai and Herman 2009). Appropriate 
stress responses are essential for the survival of the organism by allowing it to overcome 
aversive and potentially damaging conditions. Neural control of stress is complex and involves 
recruitment of neuroendocrine pathways resulting in activation of the sympathetic nervous 
system and the hypothalamus-pituitary-adrenal (HPA) axis (Ulrich-Lai and Herman 2009). 
Increased sympathetic outflow leads to an increase in heart rate and blood pressure, whereas 
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activation of the HPA axis increases the blood levels of stress hormones, adrenocorticotropic 
hormone (ACTH) and corticosterone (rodent equivalent of human cortisol).  
Exposing a rat to 5 mins on an elevated platform or 30 mins of restraint robustly activates cFOS 
expression in GLP-1-producing neurons (Maniscalco et al. 2015). Interestingly, the hypophagic 
response to acute stress is suppressed by i.c.v. infusion of GLP-1R antagonist, Ex9, indicating the 
central GLP-1 system is recruited to reduce food intake in response to stress (Maniscalco et al. 
2015).  
In support of a role for GLP-1 in stress, peripheral administration of GLP-1 activates the HPA axis 
in rodents and humans, and central delivery of the GLP-1R agonist, Ex4, increases blood 
corticosterone in rodents (Gil-Lozano et al. 2010). Notably, inhibition of corticosterone-releasing 
hormone (CRH) prevented the increase in ACTH and corticosterone, suggesting central GLP-1 
activates CRH-releasing neurons, most likely in the PVN (Larsen et al. 1997b; Sarkar et al. 2003). 
Indeed, GLP-1-positive axons innervate CRH-expressing PVN neurons (Sarkar et al. 2003), which 
are activated by GLP-1 in vitro (Katsurada et al. 2014) and in vivo (Larsen et al. 1997b). 
Furthermore, Kinzig et al. (2003) demonstrated that GLP-1R activation directly in the PVN 
increases blood ACTH and corticosterone levels. Interestingly, injections of GLP-1 directly into 
the amygdala increased anxiety-like behaviour, including reduced time spent in the open arms 
of an elevated plus maze (Kinzig et al. 2003).  
1.5.2 GLP-1-mediated tachycardia 
In addition to its stimulatory effects on the HPA axis, central GLP-1 may increase the activity of 
the sympathetic nervous system. Infusions of GLP-1 or Ex4 i.c.v. increases heart rate and blood 
pressure in rats (Barragán et al. 1999; Yamamoto et al. 2002). This cardiovascular response was 
correlated with activation of autonomic regulatory neurons, neurons in the spinal cord, and cells 
in the adrenal medulla suggesting recruitment of the sympathetic nervous system (Yamamoto 
et al. 2003). Unusually for caudal NTS neurons, PPG neurons directly innervate sympathetic 
preganglionic neurons in the spinal cord, supporting a role for central GLP-1 in autonomic 
regulation (Llewellyn-Smith et al. 2015).  
These data suggest that the central GLP-1 system does not simply decrease food intake in 
response to changes in energy demand, but rather contributes to the physiological response to 
interoceptive and psychogenic stress by increasing levels of stress hormones in the blood, 
increasing heart rate, decreasing food intake, and mobilising glucose (Holt and Trapp 2016). 
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1.6 Genetic tools to investigate the role of central GLP-1 
1.6.1 Cre-Lox technology 
The development of genetic tools over the last decade has revolutionised neuroscience 
research. In particular, the use of Cre-lox technology in combination with chemogenetic tools 
has elucidated, to name a few, the role of agouti-related peptide (AgRP) (Wu et al. 2012), 
calcitonin gene-related peptide (CGRP) (Campos et al. 2016), and CCK neurons (D’Agostino et al. 
2016) in appetite control; the importance of orexin neurons in the regulation of physical activity 
(Kosse et al. 2017); and a dorsal raphe nucleus → BNST circuit regulating fear and anxiety 
(Marcinkiewcz et al. 2016).  
Cre-recombinase (Cre) catalyses homologous recombination between short DNA sequences 
known as loxP sites (Hoess et al. 1982; Hoess and Abremski 1985). This facilitates selective 
deletion or expression of a gene of interest (GOI) in genetically defined cell populations. Cre 
expression is usually driven by a promoter, which defines the cell population under 
investigation. Promoter-driven expression ensures Cre is selectively expressed in the cells of 
interest. Cre-dependent expression of a GOI is commonly achieved in one of two ways (Fig 1.4):  
1) A translational STOP site is inserted in front of the GOI. This translational brake usually 
consists of one or several polyadenylation sequences as well as stop codons in all reading 
frames (Luche et al. 2007). The STOP site is flanked by loxP sites. In the absence of Cre, 
translation is hindered by the presence of the STOP site. In the presence of Cre, homologous 
recombination leads to excision of the STOP site and translation of the GOI is facilitated 
(Luche et al. 2007).  
2) The GOI is placed in reverse orientation for successful expression of the protein. Flanking 
the GOI are two antiparallel, heterotypic loxP sites. Two recombination events catalysed by 
Cre lead to inversion of the GOI allowing for stable expression (Schnutgen et al. 2003; Luche 
et al. 2007; Atasoy et al. 2008). This is commonly referred to as the FLEX-switch system 
(Atasoy et al. 2008). 
Cre-dependent GOIs can be introduced either at the embryo state or later using viral gene 
delivery. Adeno-associated viruses and lentiviruses are now widely used to express recombinant 
proteins in specific brain regions. This offers considerable advantages over Cre-dependent GOIs 
inserted into the genome. Firstly, it is spatially specific, with GOI expression being limited to the 
site of viral infection. Secondly, it is temporally specific. Mice can be injected as adults avoiding 
any compensatory mechanisms during development.  




1.6.2 Chemogenetic tools 
Cre-lox technology is widely used in combination with opto- and chemogenetics. These 
techniques rely on the transgenic expression of receptors or channels on the surface of cells, 
which allows the experimenter to manipulate the activity of the cells. In this thesis, I make use 
of three constructs to manipulate the activity of PPG neurons. 1) Diphtheria toxin subunit A 
(DTA) inhibits translation by inactivating eukaryotic elongation factor-2 (eEF-2). This inhibition 
of protein synthesis ultimately leads to cell death (Wu et al. 2014). 2) HM3Dq (Alexander et al. 
2009) and 3) HM4Di (Armbruster et al. 2007) are types of designer receptors exclusively 
activated by designer drugs (DREADDs), a tool developed to selectively activate or inactivate cell 
populations using an otherwise inert ligand. HM3Dq and HM4Di are G-protein coupled receptors 
modified from the human muscarinic acetylcholine receptor (AChR). They no longer respond to 
acetylcholine. Instead they are activated by clozapine-N-oxide (CNO). HM3Dq is coupled 
intracellularly to Gαq, whereas HM4Di is coupled to Gαi/o. Binding of CNO to the HM3Dq receptor 
 
 
Fig 1.4 Cre-dependent expression systems. In the Lox-STOP model, a translational STOP site 
hinders the expression of the gene of interest (GOI). Cre recombinase catalyses recombination 
between the two LoxP DNA recognition sites flanking the STOP site. This disinhibits expression of 
the GOI. In the FLEX-Switch model (Atasoy et al. 2008), the GOI is inserted in the reverse 
orientation resulting in no successful expression of the protein. The GOI is flanked by two 
antiparallel, heterotypic Lox sites, LoxP and Lox2272. Cre induces two steps of recombination 
between antiparallel lox sites leading to permanent inversion of the GOI and stable expression. 
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leads to increased electrical activity of the cells (Alexander et al. 2009), whereas stimulation of 
HM4Di leads to neuronal silencing (Armbruster et al. 2007). 
1.7 Overall hypothesis 
The evidence discussed highlights the wide-ranging effects of central GLP-1 and the diverse 
modulatory inputs to PPG neurons. The proposed role of central GLP-1 in distinct processes such 
as stress, reward, and homeostatic feeding raises many questions regarding the physiological 
function of GLP-1 within the brain. While pharmacological studies have addressed the 
importance of downstream targets of central GLP-1, there is presently little known about the 
physiological role of PPG neurons in food intake and stress.  
Based on this, I put forward the hypothesis that NTS PPG neurons regulate food intake, stress, 
heart rate, and blood pressure, and that PPG neuron activity is modulated by a range of 
compounds signalling satiety, energy balance, and visceral illness.  
To investigate this, I used genetic and surgical techniques in mice to monitor and manipulate 
the activity of NTS PPG neurons with the following aims: 
1. Further characterise NTS PPG neurons using in vitro Ca2+ imaging in brainstem slices. 
2. Determine the importance of NTS PPG neurons in food intake regulation by 
manipulating their activity in vivo. 
3. Elucidate the role of the GLP-1 system in cardiovascular control by using biotelemetry 
in awake, behaving mice.  
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2. Materials and Methods 
2.1 In vitro solutions and reagents 
2.1.1 Cloning 
Water: All water for cloning was molecular biology grade (Eppendorf) 
TRIzol (Life Technologies) 
Phusion high-fidelity polymerase (Life Technologies) 
Super optimal broth with catabolite repression (SOC) medium: 0.5% Yeast Extract, 2% tryptone, 




Green GoTaq Hot start polymerase master mix (Promega) 
Deoxynucleotides (dNTPs, New England Biololabs) 
Dithiothretiol (DTT, Invitrogen) 
RNaseOUT (Invitrogen) 
Superscript III Reverse Transcriptase (Invitrogen) 
Phire Hot Start II (Invitrogen) 
Maxiprep kit (PureLink, Invitrogen) 
Miniprep kit (GenElute, Sigma) 
PCR clean-up kit (GenElute, Sigma) 
MultiCore restriction buffer (Promega) 
Bovine Serum Albumin (BSA, Invitrogen) 
Agarose (QualexGold, Hybaid GmbH) 
TAE (50x, AppliChem) 
Ethidium bromide (0.5 µg/ml, Sigma) 
2.1.2 Cell culture 
DMEM culture medium (Sigma) 
L-glutamine (2mM, Sigma) 
FBS, 10x (Sigma) 
Non-essential amino acids (M7145, Sigma) 
Penicillin (50 units/ml, Sigma) 
Streptomycin (50 µg/ml, Sigma) 
IMDM culture medium (Gibco) 
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2.1.3 Virus production 
Water: All water was filtered using a 0.22 µM water filtering unit (Millipore) and autoclaved. 
CaCl2 (2.5 M, Sigma) 
Hepes-buffered saline (50 mM HEPES, 280 mM NaCl, 1.5 mM Na2HPO4) 
Tris buffer (20 mM) 
NaCl in 20 mM Tris buffer: 150 mM, 200 mM, 300 mM, 400 mM, 500 mM, 1M, 2M 
Phosphate-buffered saline tablets, PBS, (Gibco) 
Sodium deoxycholeate (0.5%, Sigma) 
Benzonase nuclease (50 u/ml, E-1014, Sigma) 
Heparin columns, HiTrap Heparin HP 1ml (GE Healthcare Life Sciences) 
Amicon Ultra centrifugal filter tubes (Millipore) 
2.1.4 Immunohistochemistry 
Formaldehyde solution (37% with 10-15% methanol, Sigma) 
Optimal cutting temperature medium, OCT, (Tissue-Tek, Sakura Finetek) 
Phosphate buffer (PB, 0.1 M Na2PO4 in water, pH 7.4) 
SuperFrost Plus microscope slides (VWR) 
Coverslip glasses (VWR) 
VectaShield antifade mounting media for fluorescence (Vector Laboratories) 
Antigen Antibody Origin Dilution Source 
GCaMP3 Anti-GFP Chicken 1:500 #AB13970, lot #623923, Abcam 
tdRFP/mCherry Anti-dsRed Rabbit 1:500 #632496, Clontech 
cFOS Anti-Fos Rabbit 1:400 #2250S, Cell Signalling Tech 
GLP-1 Anti-GLP-1 Rabbit 1:200 #T-4057, Peninsula 
Table 2.1. List of primary antibodies.  
Antigen Antibody Origin Dilution Source 
Chicken IgG Anti-chicken IgG Goat 1:1000 #A-11039, Life Technologies 
Rabbit IgG Anti-rabbit IgG Sheep 1:1000 #C2306, Sigma 
Table 2.2. list of secondary antibodies. 
2.1.5 In vitro imaging and electrophysiology solutions 
ACSF (in mM in dH2O): 3 KCl, 118 NaCl, 25 NaHCO3, 10 Glucose, 1 MgCl2, 2 CaCl2; pH 7.4 
Recovery solution (in mM in water): 3 KCl, 118 NaCl, 25 NaHCO3, 1.2 NaH2PO4, 2.5 Glucose, 7 
MgCl2, 0.5 CaCl2; pH 7.4 
High-Mg2+/low-Ca2+ ACSF (in mM in water): 2.5 KCl, 200 sucrose, 28 NaHCO3, 1.25 NaH2PO4, 7 
Glucose, 7 MgCl2, 0.5 CaCl2; pH 7.4 
Low-Cl- intracellular solution (in mM in water): 120 K-gluconate, 1 NaOH, 5 BAPTA, 1 MgCl2, 1 
CaCl2, 5 Hepes, 2 K2-ATP; pH 7.3  




2.2.1 In vitro Ca2+ imaging and patch-clamp electrophysiology 
All drugs were dissolved in dH2O as stocks, except for DNQX, which was dissolved in DMSO; TTX, 
which was dissolved at 1 mM in sodium-citrate buffer; and CNO, which was dissolved in saline. 
The final working concentration, indicated below, was made up in ACSF. 
(2R)-amino-5-phosphonovaleric acid (APV, 25 µM, Tocris)  
5-hydroxytryptamine hydrochloride (5-HT, 20 µM, Sigma) 
6,7-dinitroquinoxaline-2,3-dione (DNQX, 20 μM, Tocris)  
Adenosine triphosphate (ATP, 1 mM, Sigma) 
Carbachol (100 µM, Sigma) 
Cholecystokinin octapeptide (CCK-8, 100 nM, Tocris) 
Clozapine-N-oxide (CNO, 1 µM, Hello Bio) 
Glutamate (100 µM, Sigma) 
Granisetron (5 μM, Tocris) 
Interleukin-6 (IL-6, 2 nM, Preprotech) 
Ketanserin (1 µM, Tocris) 
Leptin (1 nM, gift from Novo Nordisk) 
Phenylbiguanide (PBG, 1 and 10 µM, Tocris) 
Tetrodotoxin (TTX, 0.5 μM, Cayman Chemical) 
 
2.2.2 In vivo food intake and biotelemetry 
All drugs for in vivo experiments were dissolved in saline (0.9% w/v NaCl). 
Atenolol (i.p., 2 mg/kg in 1 ml/kg saline, Sigma) 
CNO (i.p., 2 mg/kg in 5 ml/kg saline, Hello Bio) 
Ex4 (i.p., 10 µg/kg in 100 µl saline, Tocris) 
Ex9 (intra-dLS, 10 µg in 500 nl saline, American Peptides)  
GLP-1 (i.p., 100 µg/kg in 100 µl saline, Tocris) 
 
2.2.3 Surgery 
Ketamine (Vetalar, 50 µg/kg intramuscular, Zoetis) 
Medetomidine (Domitor, 1 mg/kg intramuscular, Orion Pharma) 
Atipamezol hydrochloride (Antisedan, 2.5 mg/kg intramuscular, Zoetis)  
Buprenorphine (0.5 mg/kg, subcutaneously) 
Carprofen (Rimadyl, 5 mg/kg, subcutaneously, Zoetis) 
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2.3 Cre-dependent viruses 
The following Cre-dependent recombinant adeno-associated viruses (rAAVs) were used to 
manipulate NTS PPG neurons and image GLP-1R-expressing neurons in the dLS.  
Name Protein encoded Application Source 
AAV8-mCherry-Flex-DTA mCherry or DTA Ablation UNC vectorcore 
AAV2-FLEX-HM3Dq:mCherry HM3Dq:mCherry Activation UNC vectorcore 
AAV8-FLEX-HM3Dq:mCherry HM3Dq:mCherry Activation VVF, ZNZ, Zurich 
AAV2-FLEX-HM4Di:mCherry HM4Di:mCherry Inhibition UNC vectorcore 
AAV8-FLEX-EGFP EGFP Control VVF, ZNZ, Zurich 
AAV1/2-FLEX-Perceval Perceval Control Made in house 
AAV1/2-FLEX-GCaMP3 GCaMP3 Ca2+ imaging Made in house 
Table 2.3. Cre-dependent viruses. 
2.4 Virus production 
2.4.1 AAV Plasmid amplification and purification 
Plasmids amplified routinely for AAV1/2 production were:  
• pH21, containing AAV1 Rev and Cap sequences 
• pRV1, containing AAV2 Rev and Cap sequences  
• pFΔ6, the adeno-virus helper plasmid  
Additionally, two AAV plasmids were amplified: 
• pAAV-CBA-FLEX-GCaMP3, containing a Cre-dependent ORF for the calcium indicator, 
GCaMP3 (Tian et al. 2009). 
• pAAV-CBA-FLEX-Perceval, containing a Cre-dependent ORF for the ATP indicator, 
Perceval (Berg et al. 2009), here used as a control construct. 
pAAV-CBA-FLEX-GCaMP3 was subcloned as described in section 2.4.3 and pAAV-CBA-FLEX-
Perceval was subcloned in the same way by James E. Richards. The Perceval ORF was a kind gift 
from Professor Guy Rutter, Imperial College London. 
Plasmids were defrosted on ice along with 100 µl XL-1 cells. Plasmid (100-200 ng) was added 
directly to bacteria. Ten mins later, the cells were heat-shocked at 42°C for 45 s to facilitate 
uptake of the plasmid and then returned to ice for two mins. SOC medium (250 µl) was added 
to the transformed bacteria, which were incubated at 37°C shaking at 225 rpm for one hour. 
Next, 30 µl of the bacterial solution was spread onto ampicillin-containing agar plates and left 
to incubate at 37°C overnight. As an exception, transformed bacteria containing the AAV helper 
plasmid pFΔ6 were not spread onto plates, but added directly into 600 ml growth medium, LB-
Broth, containing ampicillin (100 µg/ml). Following overnight incubation, bacterial colonies were 
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transferred to flasks containing 300 ml LB-Broth with ampicillin (100 µg/ml) and incubated for 
16-20 hours at 37°C shaking at 225 rpm. Following culture growth, plasmids were purified using 
a Maxiprep kit. Bacterial cells were pelleted by centrifugation at 1500 x g, resuspended, and 
lysed. Lysates were filtered and loaded onto an anion-exchange column. After washing, column-
bound DNA was eluted and then precipitated using isopropanol. DNA was pelleted at 4,500 x g 
for one hour, washed in 5 ml 70% ethanol, and resuspended in water.  
2.4.2 Plasmid digestion and electrophoresis 
For verification of correct plasmid amplification, purified DNA was digested. Reactions (20 µl) in 
water were set up containing 1 x MultiCore buffer, 0.5 unit of each restriction enzyme (Table 
2.4), 0.5 mg/ml BSA and 1 µg plasmid DNA. Reactions were incubated at 37°C for one hour and 
fragments were separated on a 1% agarose gel containing 0.5 µg/ml ethidium bromide. The gel 
was run at 60 V for one hour and fragments were visualised using UV light. 
Plasmid Enzymes Fragment sizes 
pH21 EcoRI 4.5 kb, 2.8 kb, and 0.2 kb 
pRV1 XbaI 7.5 kb and 3.8 kb 
pFΔ6 HindIII 5.5 kb, 3 kb, 3 kb, 2.3 kb, and 1.5 kb 
pAAV-CBA-FLEX-GCaMP3 EcoRI+EcoRV 5.6 kb, 1.4 kb 
pAAV-CBA-FLEX-Perceval EcoRI+EcoRV 5.6 kb, 2.5 kb 
Table 2.4. Digestions of plasmids using restriction enzymes. 
2.4.3 Subcloning of pAAV-CBA-FLEX-GCaMP3 
2.4.3.1 RNA EXTRACTION 
Live brainstem slices containing the NTS from a PPG-Cre/GCaMP3 transgenic mouse were 
prepared as described in section 2.7.1 and homogenised in TRIzol using a glass tissue 
homogeniser. To extract RNA, tissue homogenate was separated into lipid, protein, DNA, and 
RNA phases using 0.2 ml chloroform per 1 ml of homogenate. The sample was centrifuged for 
15 mins at 12,000 x g at 4°C after which three distinct phases were seen. The upper aqueous 
phase containing the RNA was precipitated using 0.5 ml isopropanol per ml of TRIzol. 
Precipitated RNA was pelleted at 12,000 x g at 4°C for 10 mins and resuspended in 1 ml 75% 
ethanol to wash. RNA was pelleted at 7,500 x g for 5 mins at 4°C and the supernatant carefully 
removed. The pellet was airdried, resuspended in RNase-free water, and stored at -80°C. 
2.4.3.2 GCAMP3 OPEN READING FRAME GENERATION 
GCaMP3 cDNA was generated from isolated mRNA by mixing 0.5 µM RT primer (Table 2.5), 500 
µM dNTPs, and 4 µl RNA (section 2.4.3.1) in nuclease-free water (total volume 13 µl). The sample 
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was incubated at 65°C for five mins followed by five mins on ice and then centrifuged briefly at 
7,500 x g. To the sample was added: 1 x First-Strand buffer, 50 mM DTT, 1 unit RNaseOUT and 
1 unit Superscript III (final volume 20 µl) and GCaMP3 cDNA was synthesised according to the 
following protocol:  
• 25°C 5 mins 
• 50°C 60 mins 
• 70°C 15 mins 
The GCaMP3 ORF was amplified by PCR using Phusion high-fidelity polymerase (primers in Table 
2.5). Primers were designed to contain restriction enzyme sites recognized by EcoRI and EcoRV, 
respectively (underlined in Table 2.5). GCaMP3 cDNA (2 µl) was added to 25 µl aqueous solution 
containing 1 x Phusion buffer, 1% DMSO, 0.5 µM forward and reverse primers, 200 µM dNTPs, 
and 1 unit Phusion HF polymerase. A PCR reaction was run: 
• Initial denaturation of DNA  98°C for 30 s 
• DNA denaturation    98°C for 10 s 
• Primer annealing   61°C for 30 s 
• Elongation    72°C for 45 s 
• Final elongation   72°C for 5 mins 
The amplicon size was determined using agarose gel electrophoresis as described in section 
2.4.2. The amplicon was purified using the GenElute PCR Clean-Up kit and stored at -20°C. 
2.4.3.3 SUBCLONING  
The GCaMP3 ORF and pAAV-FLEX backbone (pAAV-CBA-FLEX, kind gift from William Wisden) 
(Atasoy et al. 2008; Murray et al. 2011) were digested using EcoRI and EcoRV as described in 
section 2.4.2. Restriction reactions were incubated at 37°C for two hours and purified using the 
GenElute PCR Clean-Up kit. To ligate the ORF and backbone, 10 µl reactions were set up 
containing 1 x T4 ligase buffer, 1 unit T4 DNA ligase, and ORF and backbone DNA in a 3:1 molar 
ratio. A control ligation with no ORF was set up simultaneously. Ligation reactions were left at 
4°C overnight. Competent XL-1 cells were transformed with 1 µl of the ligated construct, pAAV-
CBA-FLEX-GCaMP3, as described in section 2.4.1 and spread onto ampicillin-containing agar 
plates. Colony PCR was performed the following day using primers listed in Table 2.5. Reactions 
were set up in water containing 1 x Phire Hot Start II buffer, 200 µM dNTPs, 0.5 µM forward and 
reverse primers and 1 unit Phire Hot Start II polymerase (20 µl total volume). P10 pipette tips 
were used to collect ten colonies from the agar plate. They were then submerged briefly into 
Phire reaction buffer and then dropped into 5-7 ml LB-Broth containing ampicillin (100 µg/ml). 
The PCR was run while waiting for the starter cultures to grow:  
35 cycles 
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• Initial denaturation of DNA  98°C for 30 s 
• DNA denaturation    98°C for 5 s 
• Primer annealing   62°C for 5 s 
• Elongation    72°C for 20 s 
• Final elongation   72°C for 1 min 
Resulting amplicons were resolved on a 1% agarose gel as described in section 2.4.2. Starter 
cultures were inoculated overnight at 37°C shaking at 225 rpm and DNA was isolated using a 
Miniprep kit. One clone was picked for further processing. LB-Broth (300 ml) containing 
ampicillin (100 µg/ml) was inoculated with 100 µl starter culture and left to grow at 37°C 
overnight. DNA was purified using a Maxiprep kit as described in section 2.4.1. The purified 
construct was digested (Table 2.4) and fragments separated using agarose gel electrophoresis 
(section 2.4.2). Finally, the correct orientation of the insert was confirmed by sequencing using 
primers designed to recognize sequences flanking the insert (Table 2.5).  
Application Binding Sequence 
First strand synthesis 3’ 5’–TAACGCAACGTACCTTCG–3’ 
ORF amplification 5’ 5’–GGTTCCAAGATATCATGGGTTCTCATCATCATCA–3’ 
ORF amplification 3’ 5’–CCGGTTAAGAATTCTTACTTCGCTGTCATCATTTG–3’ 
Colony PCR/Sequence 5’ 5’–GCTGTTAAAGCTTGAACCTC–3’ 
Colony PCR/Sequence 3’ 5’–ACGTGCTGGTTATTGTGCTG–3’  
Table 2.5. Primer sequences for subcloning. Restriction enzyme recognition sites are underlined.  
2.4.4 Cell culture 
Human embryonic kidney cells, AD293T cells (Stratagene, UK) were routinely cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) containing 10% heat-inactivated fetal bovine 
serum (FBS), 2 mM L-glutamine, 50 units/ml penicillin and 50 μg/ml streptomycin. Cells were 
passaged every three days and replaced when number of passages reached 30.  
2.4.5 Virus particle generation 
The rAAV production protocol was adapted from McClure et al. (2011). Two confluent T-75 flasks 
of AD293T cells were seeded in five 15 cm dishes. When the cells covered 70-80% of the dish 
the medium was changed to Iscove’s Modified Dulbecco’s Medium containing 5% FBS. Three 
hours later, cells were co-transfected with either pAAV-FLEX-Perceval or pAAV-FLEX-GCaMP3 
and helper plasmids pH21, pRV1, and pFΔ6 using CaPO4. 1650 µl 2.5 M CaCl2 was added to 12 
ml H2O. 62.5 µg AAV plasmid, 125 µg pFΔ6, 31.25 µg pRV1 and 31.25 µg pH21 were added to 
the CaCl2 solution and filtered through a 0.2 µm filter. HBS (2x, 13 ml) was added dropwise while 
vigorously agitating the DNA-CaCl2 solution. CaPO4-DNA complexes were allowed to form for 2 
mins and added dropwise to the cells. The next day, 16 hours after transfection, the medium 
30 cycles 
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was changed to DMEM. Two days later, 64 hours after transfection, cells were dissociated and 
pelleted by centrifugation at 800 x g. Cells were resuspended in 20 mM Tris and 150 mM NaCl 
and digested in 0.5% sodium deoxycholeate and 50 u/ml benzonase nuclease to release rAAV 
particles. Cell debris was removed by centrifugation at 3000 x g for 15 mins and the supernatant 
was passed through a 0.45 μm filter unit (Millipore, UK).  
2.4.6 Virus purification and concentration 
rAAV particles were bound to pre-equilibrated 1 ml heparin columns using a peristaltic pump at 
a flow rate of 0.5 ml/min. Viral particles were eluted by gradually increasing the concentration 
of NaCl in 20mM Tris (In the following way: 200 mM, 300 mM, 400 mM, 500 mM, 1 M, and 2 M 
NaCl). rAAV particles were concentrated using Amicon Ultra centrifugal filter tubes (Millipore) 
by centrifuging repeatedly at 2000 x g for 15 min. Concentrated virus was washed twice in 3.5 
ml phosphate-buffered saline (PBS) by centrifuging repeatedly at 2000 x g for 15 mins until virus 
volume reached 100-200 μl. Concentrated AAVs were stored as 5 μl aliquots at -80°C.  
2.5 Animals 
Wild-type male C57BL/6 mice were obtained from Harlan UK/US. Experiments were conducted 
in the UCL Biological Services Unit. The involvement of dLS GLP-1Rs in acute stress (Section 4.2.8) 
was studied at Florida State University, FL, USA, in collaboration with Dr Diana Williams. Mice 
were handled several times a week and kept on a 12h light/12h dark cycle with ad libitum access 
to water and food unless otherwise noted. They were fed normal chow (Teklad) or high-fat diet 
(HFD, 60% energy from fat, 15% from protein, custom made, TestDiet) as indicated and were 
group-housed when not subjected to biotelemetry or food intake measurements. 
2.5.1 Transgenic strains 
Transgenic mice were bred in-house. Transgenic mouse strains were kindly provided by Dr Frank 
Reimann and Professor Fiona M. Gribble:  
• Glu-Cre/Rosa26-GCaMP3/tdRFP heterozygous transgenic mice with GCaMP3 on one 
allele and tdRFP on the other were obtained by Dr Frank Reimann by crossing mice 
expressing Cre under the control of the glucagon promoter (Glu12-Cre (Parker et al. 
2012)) with a commercially available ROSA26-lox-stop-lox-GCaMP3 reporter strain (Jax 
strain 014538) (Zariwala et al. 2012). To optimise GCaMP3 expression levels this strain 
was selectively bred by me to produce two independent strains: Glu-Cre/Rosa26-
GCaMP3 (PPG-Cre/GCaMP3) or Glu-Cre/Rosa26-tdRFP (PPG-Cre/tdRFP).  
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• GLP-1R-Cre/Rosa26-tdRFP (GLP-1R-Cre/tdRFP) (Richards et al. 2014; Cork et al. 2015). 
This strain expresses Cre under the control of the GLP-1R promoter and tdRFP in a Cre-
dependent manner, resulting in Cre and tdRFP expression in GLP-1R neurons. 
2.5.2 Animal genotyping 
Mice were genotyped for breeding purposes. A small tissue biopsy was taken from the ear and 
digested using Proteinase K at 55°C for one hour. The presence of three transgenes as well as a 
tissue control β-catenin was verified using GoTaq mastermix (primer pairs in Table 2.6). 
Application Binding Sequence 
GCaMP3 5’ 5’–CTTCAAGATCCGCCACAAC–3’ 
GCaMP3 3’ 5’–TTGAAGAAGATGGTGCGCT–3’ 
Cre 5’ 5’–AATTGAGCTCATTTGGACTGCC–3’ 
Cre 3’ 5’–GTAGTCCCTCACATCCTCAGG–3’ 
tdRFP 5’ 5’–CTACAGGAACAGGTGGTGG –3’  
tdRFP 3’ 5’–CTGTTCCTGGGGCATGGC–3’ 
β-catenin 5’ 5’–AAGGTAGAGTGATGAAAGTTGTT–3’ 
β-catenin 3’ 5’–CACCATGTCCTCTGTCTATTC–3’ 
    Table 2.6. Primer sequences for genotyping.  
Reactions (25 µl) contained 12.5 µl GoTaq Green mastermix, 0.5 µM forward and reverse primer 
and 3 µl digested tissue sample. Double reactions were run (β-catenin and tdRFP in one and Cre 
and GCaMP3 in the other) under the following conditions: 
• Initial denaturation of DNA  95°C for 2 mins 
• DNA denaturation    95°C for 1 min 
• Primer annealing   58°C for 1 min 
• Elongation    72°C for 1 min 
• Final elongation   72°C for 5 mins 
Amplicons were separated and visualised on a 1% agarose gel as described in section 2.4.2.  
2.6 Immunohistochemistry 
2.6.1 Transcardial perfusion and tissue preparation 
Mice were anaesthetised using 1.4 g/kg urethane. The diaphragm was pierced and the heart 
exposed. A needle was inserted into the left ventricle and an incision was made into the right 
atrium to introduce an outlet for the perfusion solution. Using 50 ml syringes, the mouse was 
perfused with 50 ml of ice-cold 0.1 M phosphate buffer (PB) followed by 50 ml of ice-cold 4% 
formaldehyde/1% methanol in 0.1 M PB. The brain was extracted and post-fixed in 4% 
formaldehyde/1% methanol in 0.1 M PB at 4°C. The following day, the brain was transferred to 
30% sucrose in 0.1 M PB for cryoprotection. After infiltration of sucrose it was blocked without 
40 cycles 
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the use of a brain matrix. The brain was mounted onto a pedestal using OCT and sectioned on a 
cryostat (Bright Instruments, UK) into five series of 30 µm coronal sections, which were kept in 
0.1 M PB at 4°C for later use.  
2.6.2 Immunostaining procedure 
To prevent unspecific binding, sections were blocked for one hour in 0.1 M PB containing 1% 
BSA, 0.1% Triton X-100 and 10% serum from the origin species of the secondary antibody (Table 
2.2). The primary antibody (Table 2.1) was added to the blocking solution and sections were 
incubated overnight at 4°C gently agitated at 150 rpm. The next day, sections were washed 5 x 
5 mins in 0.1 M PB at room temperature, followed by incubation with the secondary antibody 
(Table 2.2) in blocking solution for two hours at room temperature gently agitated at 150 rpm. 
Sections were washed 5 x 5 mins in 0.1 M PB at room temperature and mounted onto positively 
charged microscope slides. A drop of VectaShield Antifade mounting media was added and the 
sections were covered with glass coverslips.  
Immunofluorescence was visualised on an upright widefield microscope (Leica) equipped with 
GFP (Chroma 49002, Excitation: 470±20 nm, Emission: 525±25 nm, dichroic mirror: 495 nm) and 
RFP (Chroma 49008, Excitation: 560±20 nm, Emission: 630±37 nm, dichroic mirror: 585 nm) filter 
cubes. Images were captured using a colour camera (Retiga 3000, QImaging) and the Q-Capture 
Pro 7 software (QImaging) and montages containing several frames were created using Image 
Composite Editor (Microsoft). Brightness and contrast were adjusted using Fiji image analysis 
software (Schindelin et al. 2012). 
2.7 In vitro imaging and electrophysiology 
2.7.1 Sample preparation 
Mice were deeply anaesthetised with isofluorane and decapitated. The brainstem or forebrain 
was removed and placed in ice-cold high-Mg2+/low-Ca2+ ACSF. Coronal sections (200 μm thick) 
were cut on a vibratome (Campden Instruments) and left in recovery solution at 34°C. After 45 
mins, sections were transferred to ACSF and left to adjust for a minimum of 30 mins. To maintain 
pH 7.4 and sufficient oxygenation, solutions were constantly bubbled with 95% O2/5% CO2.  
2.7.2 Ca2+ imaging 
Ca2+ imaging was performed in one of two configurations:  
1. On a widefield microscope (Zeiss Axioskop) with a 40x water immersion lens (0.8 
numerical aperture). The field diaphragm was restricted to reduce light scattering and 
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background fluorescence. GCaMP3 was excited using an LED light source (CoolLED 
pE300white; QImaging) at 460±25 nm for 250 ms every 5 s. Excitation was filtered at 
470±20 nm and emission was filtered at 515±17 nm (Chroma 59004). Images (12-bit) 
were captured on a charge-coupled device camera (Q-Click; QImaging). The LED light 
source and camera were controlled in Micro-Manager (Edelstein et al. 2014).  
2. Using a laser scanning microscope (Olympus FV-1000, pinhole fully open) with a 25x 
water immersion objective (1.05 numerical aperture). Here, GCaMP3 was excited using 
a laser (Showa Optronics) at 488 nM. Emitted light was detected using a photomultiplier 
tube. Images were captured using FV10-ASW (Olympus).  
I observed no difference in the response to compounds between the two systems, although 
bleaching only had to be corrected for when using the widefield microscope. Sections were 
continuously superfused with 32°C standard ACSF at a flow rate of 3-4 ml/min. All imaging was 
performed on PPG neurons in the NTS or GLP-1R-expressing neurons in the dLS.  
2.7.3 Patch-clamp electrophysiology 
As above, sections were continuously superfused with 32°C standard ACSF at a flow rate of 3-4 
ml/min. NTS PPG cells expressing GCaMP3 were located using the widefield setup described in 
section 2.7.2. Patch pipettes were pulled on a horizontal puller (Zeitz Instrumente) from thin-
walled borosilicate glass capillaries (3–7 MΩ, Harvard Apparatus). Pipettes were filled with low-
Cl- intracellular solution and fitted over the recording electrode. Cells were visualised for cell-
attached recordings with a differential interference contrast filter and approached using a 
micromanipulator (Scientifica). Positive pressure in the patch electrode minimised blockade of 
the pipette tip and facilitated penetration through the brain tissue. To avoid dilution of GCaMP3 
into the patch pipette, recordings were performed in the cell-attached configuration. Contact 
was made with the cell and positive pressure released. Light negative pressure was applied until 
resistance increased (usually 100 MΩ) and clear inward currents resulting from action potential 
firing were distinguishable from noise. Recordings were performed in voltage-clamp mode with 
a holding potential of -50 mV using an EPC-10 amplifier and PatchMaster software (both HEKA 
Elektronik). Currents were filtered at 1.5 kHz and digitized at 3 kHz.  
2.8 Stereotaxic injection  
2.8.1 Anaesthesia 
For stereotaxic injections, adult PPG-Cre/GCaMP3, PPG-Cre/tdRFP, and GLP-1R-Cre/tdRFP mice 
were anaesthetised using injectable anaesthesia (ketamine hydrochloride and medetomidine in 
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45μl H2O into the quadriceps) or isofluorane (1.5-2.5% at 1.5 L/min with 1.5 L/min O2). The 
absence of a pedal withdrawal reflex confirmed deep anaesthesia. The skull was fixed in a 
stereotaxic frame and a core temperature of 37°C maintained using a heating mat. 
2.8.2 Brainstem injections 
Injection needles were pulled on a horizontal puller and filled with virus using negative pressure. 
The nose of the mouse was pushed downwards, creating a right angle between the nose and 
the neck to expose part of the brainstem normally covered by the cerebellum. A longitudinal 
incision was made from the occipital bone to the first vertebra. Obex was exposed by parting 
overlying muscle layers and the dura mater was pierced using a 30g needle. Virus was injected 
bilaterally at the following coordinates from the obex:  
• 500 μm lateral 
• 100 μm rostral 
• 350 μm ventral 
For immunohistochemical verification, 50-100 nl was injected unilaterally. For all other studies, 
250 nl was injected bilaterally.  
Muscle and skin were sutured using 6-0 absorbable suture. If using injectable anaesthesia, the 
animal was reversed with Antisedan (2.5 mg/kg). Buprenorphine (0.5 mg/kg) and 100 μl saline 
were administered subcutaneously and the animal was left to recover in a 34°C chamber.  
2.8.3 dLS injections 
Mice were anaesthetised as described in section 2.8.1 and the skull placed in a stereotaxic frame 
with the teeth fixed in the tooth bar pointing forwards. A longitudinal incision was made from 
the front of the skull to the occipital bone. Bregma and Lambda were located and the skull was 
levelled horizontally by measuring the vertical offset between the two landmarks and limiting it 
to less than 100 µm by adjusting the stereotaxic frame. The periosteum and skull were pierced 
using a 25-gauge needle at the following coordinates from Bregma:  
• 260 µm rostral 
• 450 µm lateral 
• 2600 µm ventral 
Next, 100-200 nl virus was injected unilaterally. The skin was sutured using 6-0 absorbable 
suture and the mouse left to recover in a 34°C chamber. Post-surgery bodyweights were 
monitored daily. 
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2.9 Guide cannula implantation and infusions into dLS 
2.9.1 Cannulation Surgery 
Mice were anaesthetised using isoflurane (Section 2.8.1) and 5 mg/kg carprofen administered 
subcutaneously. The absence of a pedal withdrawal reflex confirmed deep anaesthesia and the 
skull was fixed in a stereotaxic frame. Core temperature of 37°C was maintained using a heating 
blanket. An incision was made from between the eyes to the occipital bone. The pericranium, 
the connective tissue covering the skull, was removed by scraping with the blunt side of the 
scalpel. This later ensured sufficient adhesion of the cement to the skull surface. A hole was 
pierced in the skull using a 25g needle at the following coordinates from Bregma: 
• 350 µm rostral  
• 260 µm lateral  
• 1600 µm ventral (injector protrudes further 1500 µm ventral).   
A 2 mm, 26-gauge guide cannula was inserted halfway and a drop of superglue applied under 
the base of the cannula before inserting it fully. Dental cement was prepared freshly and applied 
to the skull surrounding the cannula. Body weights were monitored daily following surgery. 
Correct placement of the cannula was verified histologically. 
2.9.2 Infusion via guide cannula 
Mice were habituated to handling prior to infusions. A 5 µl Hamilton syringe was filled with 
sterile water and connected to the injector. An air bubble was introduced and the drug (saline 
or Ex9) aspirated. The mouse was restrained and the dummy cap removed. The injector (1500 
µm protrusion after cannula) was inserted into the brain tissue via the guide cannula and fixed 
using an adapted dummy cap. The mouse was released and 500 nl Ex9 or saline only was infused 
over one min. After another min, the injector was retracted and the dummy cap replaced. 
2.10 Food intake measurements 
All food intake was measured using standard chow (Teklad) or vanilla Ensure liquid diet (Abbott, 
USA). Mice were weighed daily and habituated to 5 ml/kg i.p. saline injection and food intake 
measurements before experiments commenced. The role of central GLP-1 in food intake was 
investigated using four models (Table 2.7). The abbreviated names will be used and refer to all 
mice in that study, including mice expressing control constructs or receiving control infusions. 
At least 48 hours passed between food intake experiments on the same mouse. 
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PPG activation  HM3Dq FLEX-HM3Dq FLEX-Perceval N=4/4 6 M, 2 F 
PPG activation repeat HM3Dq-rep FLEX-HM3Dq - N=9 5 M, 4 F 
PPG ablation DTA FLEX-DTA FLEX-Perceval N=7/7 8 M, 6 F 
PPG acute inhibition HM4Di FLEX-HM4Di FLEX-EGFP N=12/11 9 M, 15 F 
dLS GLP-1R inhibition dLS-Ex9 Ex9 Saline N=7/5 12 M 
Table 2.7. Approaches to manipulate central GLP-1. The abbreviated names, the between-subject factors 
and the number and sex of subjects are listed. The within-subject factors depend on individual paradigms. 
2.10.1 Normal dark phase feeding 
The DTA study was a between-subjects design. The HM3Dq and HM4Di studies were mixed-
model designs, and the HM3Dq-rep study was designed to be counterbalanced within-subject. 
Three hours before dark onset, DTA, HM3Dq, HM3Dq-rep, and HMD4i mice were transferred to 
individual cages and their food was withdrawn. HM3Dq, HM3Dq-rep, and HM4Di mice were 
injected i.p. with saline or 2 mg/kg CNO at a dose volume of 5 ml/kg saline 30 mins prior to dark 
onset. Food was returned at dark onset and intakes measured manually at one, two, four, and 
21 hours after dark onset. Mice were then returned to their group-housed home cages.  
2.10.2 Fast-refeeding 
This study was designed to be between-subjects when using DTA mice and mixed-model when 
using HM4Di mice. DTA and HM4Di mice were fasted six hours into dark phase and left without 
food until the beginning of dark phase 18 hours later. HM4Di mice were injected i.p. with saline 
or 2 mg/kg CNO in saline at 5 ml/kg 30 mins before dark onset. Food was returned at dark onset 
and intakes were manually measured at one, two, four, and 21 hours after dark onset. 
2.10.3 Ensure feeding 
This study was conducted as a between-subjects design. DTA mice were housed in individual 
cages throughout the experiment. Their food was withdrawn three hours prior to dark onset. At 
dark onset, they were given vanilla Ensure liquid diet (Abbott, USA) for 15 mins after which chow 
was returned. The mice were trained to consume Ensure over seven days. Following stabilisation 
of intake, both Ensure intake and one hour chow intake were measured.  
2.10.4 Stress-induced hypophagia 
These studies were designed as mixed-model with every animal being exposed to stress only 
once. All animals in the HM4Di study received 2 mg/kg CNO in 5 ml/kg saline. All cannulated 
mice received one infusion of saline before starting the experiment to ensure infusions did not 
affect food intake adversely. Data from individual animals were collected over several days.  
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HM4Di and dLS-Ex9 mice were transferred to individual cages and their food was withdrawn. 
HM4Di mice received i.p. injections of 2 mg/kg CNO in 5 ml/kg saline 60-45 mins before dark 
onset. dLS cannulated mice received intra-dLS infusions of either 10 µg Ex9 or saline only (500 
nl) 45 mins before dark onset as described in section 2.9.2. 30 mins before dark onset, mice were 
restrained in transparent plastic bags with a breathing hole at the front. They were fixed in the 
bags using twist ties around their tails and the plastic bag. At dark onset, mice were released 
into their home cages and chow returned. Intake was measured at one hour, two hours, four 
hours, and 21 hours following dark onset.  
2.11 Glucose tolerance test 
Mice were fasted overnight for 16 hours from two hours prior to dark phase to two hours into 
light phase the next day. A small sample of blood was taken from the tail vein and the blood 
glucose concentration was measured using a glucose meter (Accu-Chek, Roche, UK). Glucose (1 
mg/kg) was injected i.p. and blood glucose concentration was measured 15, 30, 90, and 120 
mins after glucose injection.  
2.12 Tail-cuff measurements 
Blood pressure and heart rate of ten 7-10-week-old male naïve mice were measured using the 
CODA high throughput volume-pressure recording (VPR) tail-cuff system (Kent Scientific). Mice 
were placed in a perforated plexiglass tube, fixed tightly in place, and placed on a 32°C heat pad. 
An occlusion cuff and a VPR cuff were placed over the tail and 25 cycles were run.  Heart rate 
and blood pressure were determined from accepted runs. Five animals were transferred to HFD, 
five were kept on normal chow. Eight weeks later tail-cuff recordings were repeated as above. 
2.13 Biotelemetry probe implantation  
Male, 7-10-week-old, naïve or transgenic mice (PPG-Cre/tdRFP or PPG-Cre/GCaMP3) were 
anaesthetised using isofluorane (1.5-2.5% at 1.5 L/min) with 1.5 L/min O2. Body temperature 
was maintained at 37°C using a heat mat (World Precision Instruments). Prior to implantation, 
biotelemetry blood pressure probes (TA11-PA-C10, Data Science International) were rinsed in 
sterile saline and the tip of the catheter was filled with gel taking care to avoid any bubble 
formation, which would dampen the pressure transducer signal. An incision was made in the 
skin parallel to the trachea and the left carotid artery dissected out at the level of the carotid 
bifurcation. The artery was permanently occluded using non-absorbable 6-0 suture at the 
carotid bifurcation. The artery was then temporarily occluded proximally using non-absorbable 
6-0 suture and a small hole was cut in the artery with fine scissors. The tip of the catheter was 
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inserted into the carotid artery, the artery occlusion released and the catheter inserted 
completely into the aortic arch. The catheter was fixed using non-absorbable 6-0 suture and a 
subdermal pocket was created on the right flank of the mouse where the transmitter was 
inserted. The mouse was given analgesia (5 mg/kg carprofen, subcutaneously) and left to 
recover for at least seven days before baseline heart rate and blood pressure were recorded. All 
mice were kept in individual cages after implantation.  
2.14 Biotelemetry data acquisition  
All recordings were done over at least 25 hours at a sample rate of 500-1000 Hz using the 
Dataquest ART software (Data Science International). Locomotor activity is provided by the 
software and is based on the mouse’s distance from the centre of the platform and the location 
of the mouse in one of four quadrants. A larger number indicates a greater distance travelled in 
the 10 s bins. 
2.14.1 Pharmacology  
Pharmacological studies in biotelemetry probe-implanted animals were within-subject, 
counterbalanced designs.  
To investigate the effect of systemic GLP-1R activation, mice were injected i.p. with 100 μg/kg 
GLP-1, 10 μg/kg Ex4, or saline only. Mice were transferred to recording platforms the day before 
to habituate and were injected four hours into the light phase. All injections were 100 μl and 
experiments were performed using a within-subject design.  
For studies using atenolol, mice were injected i.p. with 2 mg/kg atenolol three hours and 45 mins 
into the light phase. 15 mins later, four hours into light phase, mice received a second injection 
of 10 μg/kg Ex4 or saline only. All injections were 100 μl. 
2.14.2 Ablation of PPG neurons  
This study was designed to be mixed-model with repeated measures over time and the between-
subject factor being the viral transgene (i.e. Perceval vs DTA). Baseline heart rate and blood 
pressure were recorded one week after biotelemetry probe implantation. Following baseline 
recordings, mice were stereotaxically injected (section 2.8.2) with AAV8-mCherry-FLEX-DTA or 
AAV1/2-FLEX-Perceval as control. Heart rate and blood pressure were recorded four and six 
weeks post-stereotaxic surgery. Nine weeks post-surgery mice were injected i.p. in a within-
subject counterbalanced design with 10 µg/kg Ex4 or saline as described in section 2.14.1. One 
week later, ten weeks post-surgery, mice were transferred to HFD (LabDiets). After one month 
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of HFD (14 weeks post-surgery), heart rate and blood pressure were recorded again. One week 
later (15 weeks post-surgery), mice were again injected i.p. with 10 µg/kg Ex4 or saline as before. 
Following the last recording, mice were anaesthetised using urethane and transcardially 
perfused (section 2.6.1). 
2.14.3 Chemogenetic activation of PPG neurons  
This study was a mixed-model design with drug treatment (saline or CNO) as a repeated measure 
and the between-subject factor being the expressed transgene (i.e. EGFP or HM3Dq). Mice 
implanted with biotelemetry probes (section 2.13) were stereotaxically injected with AAV2-
FLEX-HMD3q:mCherry or AAV2-FLEX-EGFP into the NTS (Section 2.8.2). They were handled daily 
and habituated to i.p. injections of 5 ml/kg saline. The day before injections, mice were 
transferred to biotelemetry platforms. The next day mice were injected i.p. with 2 mg/kg CNO 
in 5 ml/kg saline 4.5 hours prior to onset of the dark phase.  
2.15 Data processing and statistics  
2.15.1 Ca2+ imaging analysis  
Image stacks from in vitro Ca2+ recordings were imported into Fiji image analysis software 
(Schindelin et al. 2012). XY-drift was adjusted for using the StackReg plugin (Thevenaz et al. 
1998). The mean pixel intensity was measured from outlined regions of interest (ROIs) and an 
area representing background fluorescence. For time-lapse data recorded on the widefield 
microscope (see section 2.7.2), background intensity was subtracted from each ROI and 
recordings were adjusted for bleaching using a cubic polynomial function (Balkenius et al. 2015). 
Fluorescence intensity is reported as the relative change in intensity from baseline, ΔF/F0, with 
F0 defined as the mean fluorescence intensity five mins prior to the first stimulus and ΔF being 
the fluorescence intensity, F, at a given time n, Fn, minus F0. Data were plotted in Origin 9.0 
(OriginLab, US) and are presented as individual and mean traces.  
Responses were quantified by calculating the area under the curve (AUC) over ten mins during 
the stimulus, starting at the beginning of the stimulus. Data were not normally distributed and 
summary data are therefore presented as box plots with whiskers. The median is shown and 
whiskers indicate 10th and 90th percentiles. Statistical significance was determined using 
nonparametric tests, Wilcoxon (paired two-sample), Mann-Whitney U (unpaired two-sample), 
Friedman (repeated measures one-way ANOVA) or Kruskal-Wallis (one-way ANOVA). 
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2.15.2 Patch-clamp electrophysiology analysis 
Electrophysiological data was exported from PatchMaster into PulseFit (Both Heka Elektronik), 
from where traces were exported as ASCI files. Electrical events (i.e. currents corresponding to 
action potential firing) were detected using WinEDR (Strathclyde, UK) and a list of events and 
the interevent interval list were generated. A cell was determined to respond to drug treatment 
if the mean instantaneous firing frequency over one minute during the stimulus differed 
significantly compared to one minute prior to the stimulus, as determined by the unpaired 
Student’s T-test. The event list was imported into The R Project for Statistical Computing, R 3.3.1 
(R Core Team 2016) using RStudio (RStudio Team 2015). Firing rate was determined by creating 
10 s bins of events. Plots of firing frequency over time were created in R. For correlation between 
firing frequency and change in GCaMP3 fluorescence, ΔF/F0 was plotted against the change in 
firing frequency in 10s bins. A linear function was fitted using Origin (OriginLab, Northampton, 
MA, USA) and plotted in GraphPad Prism 7.00 (GraphPad Software, La Jolla, California, USA).  
2.15.3 Analysis of food intake experiments 
Food intake experiments were designed as exploratory. When possible, studies were designed 
to be within-subject and randomized. Raw data were processed in Microsoft Excel and plots 
were generated in GraphPad Prism 7.0. Outliers were identified using Iglewicz and Hoaglin's 
robust test for multiple outliers with a modified Z score of 3.5 (Iglewicz and Hoaglin 1993). 
Statistical analysis was performed in GraphPad Prism 7.0. Three-way mixed model ANOVAs were 
conducted in SPSS version 22.0 (IBM Corp, NY, USA). Three-way interactions are difficult to 
interpret and were followed up with relevant two-way ANOVAs. For transparency, non-
cumulative food intake data are presented as individual data points. Summary data are 
presented as mean±SEM. Statistical significance was tested using three-way mixed-model 
ANOVA, two-way mixed-model ANOVA, and simple main effects as indicated in figure legends 
and text. Results from three-way ANOVAs are presented in tables in the relevant sections. 
2.15.4 Analysis of biotelemetry data 
Raw biotelemetry data were extracted in 10 s bins using the DSI Analysis software and processed 
in Microsoft Excel and The R Project for Statistical Computing, R 3.3.1 (R Core Team 2016). 
Statistical significance was tested using two-way mixed-model ANOVA and simple main effects 
as indicated in figure legends and text.  
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3. Characterisation of PPG neurons in vitro using a 
genetically encoded Ca2+ indicator 
3.1 Background 
Despite the established importance of the central GLP-1 system in food intake regulation, little 
is known about the cellular properties of the source of central GLP-1, the PPG neurons. Until 
now studies have mainly employed two approaches to investigate the activity of PPG neurons: 
1. Patch-clamp electrophysiology for high temporal resolution recordings of neuronal 
activity at the single-cell level. 
2. Immunostaining for the product of the immediately early gene, cFOS, as a surrogate 
marker for recent increase in neuronal activity. 
Studies using these methods have elucidated important aspects of regulation of PPG neuron 
activity. In 1999, Linda Rinaman discovered that GLP-1-producing neurons in the rat NTS were 
activated by i.p. injections of interoceptive stressors LiCl, endotoxin (LPS) and CCK. Vrang et al. 
(2003) later demonstrated that GLP-1-producing neurons in the NTS are activated by gastric 
distention in rats. These studies were reliant on immunostaining to co-localise GLP-1 and cFOS 
to the same cells. More recently, the development of transgenic mouse models has 
circumvented the problem of reliably immunostaining for GLP-1. In our laboratory, Hisadome et 
al. (2010) used a transgenic mouse model, the PPG-YFP mouse (Reimann et al. 2008), to 
selectively record the electrical activity GLP-1-producing neurons in the NTS. Using patch-clamp 
electrophysiology they discovered that satiety hormones, leptin and CCK, activate PPG neurons 
in vitro (Hisadome et al. 2010, 2011).  
In this chapter, I aim to expand on this knowledge by investigating the modulation of PPG neuron 
activity by several compounds, including known satiety hormones and metabolic signals. To this 
end, I use a transgenic mouse expressing the genetically encoded Ca2+ indicator, GCaMP3, in 
PPG neurons only (Anesten et al. 2016; Holt et al. 2017). This mouse will be referred to as the 
PPG-Cre/GCaMP3 mouse. GCaMP3 is a modified enhanced green fluorescent protein (EGFP), 
which senses changes in intracellular [Ca2+] (Tian et al. 2009). It consists of a circularly permuted 
EGFP, which is fused at each terminal to calmodulin and the M13 peptide of myosin light chain, 
respectively (Nakai et al. 2001; Tian et al. 2009). Ca2+ enhances the binding of calmodulin to M13 
leading to a conformational change in the EGFP moiety, resulting in increased fluorescence 
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intensity. Neuronal activity can therefore be monitored by recording changes in GCaMP3 
fluorescence intensity. 
Ca2+ imaging was chosen as an experimental approach for two reasons:  
1. It is superior to cFOS immunostaining in terms of temporal resolution and reliability. 
cFOS immunostaining provides a binary yes/no answer to the question “does the 
compound activate these neurons?” (Sagar et al. 1988). However, not all cell 
populations reliably increase cFOS expression upon increased activity (Labiner et al. 
1993) and the detection of cFOS is dependent on the labelling protocol. GCaMP3 
imaging, in contrast, provides higher temporal resolution and reliable detection of small 
changes in neuronal activity from a wide range of tissues (Zariwala et al. 2012) and has 
shed light on processes such as object localisation (O’Connor et al. 2010), place cells 
(Dombeck et al. 2010) and motor memory (Huber et al. 2012).  
2. GCaMP3-based Ca2+ imaging leaves cells undisturbed and provides results from several 
cells simultaneously in contrast to patch-clamp electrophysiology. 
I sectioned live, coronal 200 µm-thick brainstem slices from PPG-Cre/GCaMP3 mice and imaged 
them using either a scanning or a widefield microscope, as described in Materials and Methods. 
The in vitro slice model allows preservation of local neuronal connections and leaves the cells in 
their microenvironment.  
Some technical considerations must be mentioned at this stage. Background fluorescence 
intensity was subtracted from widefield images to reduce the impact of light scattering on 
quantifications. All recordings are expressed as relative change in fluorescence (ΔF) from the 
mean over the first five minutes of the recording (F0), as described in Materials and Methods. 
This is to ensure no effect of differences in expression levels of GCaMP3 on interpretation of 
changes in intracellular [Ca2+].  
Importantly, changes in intracellular [Ca2+] are used as a surrogate marker for changes in 
neuronal activity. The method used here is not strictly quantitative, it does not provide accurate 
information on the absolute levels of Ca2+ in the cell and comparisons between recordings are 
therefore difficult. It is as such important that recordings serve as their own controls.  
In vitro brainstem slices from PPG-Cre/GCaMP3 mice were exposed to a range of peptides, 
neurotransmitters, and metabolic cues. The compounds of interest were chosen based on their 
involvement in food intake or homeostatic regulation and potential links with the central GLP-1 
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system. Elucidating these interactions in vitro could reveal new directions for research into the 
neural circuits underlying GLP-1-mediated regulation of food intake behaviour. 
In the next section, I will address the following questions: 
1. Is the PPG-Cre/GCaMP3 model suitable for monitoring changes in PPG activity? 
2. Do metabolic and homeostatic signals, such as leptin, CCK, IL-6, and hypoglycaemia, 
modulate PPG activity? 
3. Is PPG activity modulated by stimulation of acetylcholine and ATP receptors? 
4. What is the nature of 5-HT-mediated modulation of PPG activity and which receptors 
are involved? 
  




3.2.1 Using GCaMP3 to monitor activity of NTS PPG neurons in vitro 
To begin with, I wanted to confirm that the PPG-Cre/GCaMP3 mouse strain is suitable for 
monitoring neuronal activity in brainstem slices in vitro. In this strain, Cre expression is driven 
by the glucagon promoter, resulting in expression of Cre in L-cells in the gut (Chimerel et al. 
2014) and PPG neurons in the caudal brainstem (Anesten et al. 2016; Holt et al. 2017). Cre 
mediates recombination of two LoxP sites flanking a translational STOP site (Fig 3.1A). As 
explained in the Introduction, this leads to excision of the STOP site and enables expression of 
the GCaMP3 protein as detected with an anti-GFP antibody in Fig 3.1B.  
 
To ensure GCaMP3-expressing cells were in fact producing GLP-1, I double-stained fixed coronal 
brainstem slices for GLP-1 and GCaMP3 (Fig 3.2). GCaMP3 expression was detected in the caudal 
NTS, as in Fig 3.1, and filled the cytosol but was excluded from the nucleus (Fig 3.2 left panel). 
Immunodetection of GLP-1 revealed a punctuate stain in cells located in the NTS (Fig 3.2 middle 
panel). This was obvious at higher magnifications (Fig 3.2 bottom middle panel) and is most likely 
due to packaging of GLP-1 into vesicles. As seen in Fig 3.2 some cells were positive for GLP-1, 
but did not express GCaMP3, whereas all GCaMP3-positive cells were positive for GLP-1.  
Fig 3.1 The PPG-Cre/GCaMP3 mouse model for in vitro recording of PPG activity. A) Glucagon 
promoter (PPG-Cre) mice were crossed with mice encoding CAG-promoter-STOP-GCaMP3 in the 
Rosa26 locus. The Rosa26 locus is active in most cell types (Zambrowicz et al. 1997; Giel-Moloney et 
al. 2007). In cells with active glucagon promoter, including PPG neurons, Cre is produced and excises 
the STOP sequence flanked by loxP sites upstream of the GCaMP3 gene. This results in cytosolic 
expression of GCaMP3 in these cells. B) GCaMP3 was detected in the NTS with an anti-GFP antibody 
and is shown here in green. One side of the NTS is shown here. CC: Central canal. Scale bar: 100 µm.  




To further support this, a post-doctoral researcher in our laboratory cross-bred two transgenic 
strains (James E. Richards, unpublished). As explained in Materials and Methods, the PPG-
Cre/tdRFP strain (Parker et al. 2012) is identical to the PPG-Cre/GCaMP3 strain with the 
exception of the fluorescent reporter, which is tandem-dimer red fluorescent protein (tdRFP) 
(Luche et al. 2007), instead of GCaMP3. The PPG-Cre/tdRFP strain was created from the same 
BAC construct as the PPG-YFP mouse, with expression driven by the same promoter (Reimann 
et al. 2008; Parker et al. 2012). However, differences in expression are still possible. We 
therefore crossbred PPG-Cre/tdRFP mice with PPG-YFP mice. The PPG-YFP strain is well-
characterised (Hisadome et al. 2010, 2011, Llewellyn-Smith et al. 2011, 2013; Thiebaud et al. 
2016). As described in the Introduction, YFP expression is under control of the glucagon 
promoter and single-cell RT-PCR has verified that YFP-expressing cells express the PPG mRNA 
(Hisadome et al. 2010). In the offspring, there was an almost complete overlap between cells 
expressing YFP and tdRFP, suggesting we can use the PPG-Cre mouse to investigate and 
manipulate the PPG neurons (Unpublished). 
Having confirmed the validity of the PPG-Cre/GCaMP3 model, I wanted to test the ability of the 
GCaMP3 imaging system to detect changes in neuronal activity. I sectioned 200 µm-thick 
brainstem slices from PPG-Cre/GCaMP3 mice and performed simultaneous Ca2+ imaging and 
patch-clamp electrophysiology. Firing rate was monitored using cell-attached recordings to 
Fig 3.2 GCaMP3-positive neurons express GLP-1. PPG-Cre/GCaMP3 mice were perfuse-fixed and 
double-stained with anti-GFP (to detect GCaMP3, in green) and anti-GLP-1 (in magenta) antibodies. 
Shown here are two magnifications of cells from two different sections. White arrowheads indicate 
some of the double-positive neurons. Black arrowheads indicate neurons positive only for GLP-1. Scale 
bars: 30 µm (top panel) and 10 µm (bottom panel).  
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avoid breaking the cell membrane and diluting GCaMP3 in the patch-pipette. As seen in Fig 3.3A 
a reduction in intracellular [Ca2+] measured via change in fluorescence intensity was concurrent 
with a decrease in firing rate of the same neuron. This was observed repeatedly and analysis of 
four individual neurons revealed a positive correlation between change in firing rate and 
intracellular [Ca2+] (Fig 3.3B), demonstrating that ongoing electrical activity is linked with 
intracellular Ca2+ levels in PPG neurons. 
 
 
Having established that GCaMP3 fluorescence can be used as a surrogate marker for neuronal 
activity, I set out to investigate modulation of NTS PPG neuron activity. To start, I exposed the 
cells to 100 µM glutamate while monitoring fluorescence intensity changes (Fig 3.4). As seen 
from two representative cells in Fig 3.4A, GCaMP3 fluorescence intensity increased during 
application of 100 µM glutamate. Nine NTS PPG neurons shown in Fig 3.4B responded to 1 min 
of 100 µM glutamate exposure with a rapid increase in intracellular [Ca2+], which decreased after 
washout of glutamate to baseline levels. Glutamate (100 µM) increased GCaMP3 fluorescence 
intensity in 89% of 143 PPG neurons imaged, demonstrating that changes in intracellular [Ca2+] 
can be detected using in vitro imaging of GCaMP3 fluorescence intensity.  
Fig 3.3 Changes in GCaMP3 fluorescence intensity correlate with changes in firing rate. A) 
Representative Ca2+ imaging (top, red) and cell-attached voltage clamp (bottom, black) traces from 
a single PPG neuron. B) Correlation between changes in firing rate and percentage change in 
intracellular Ca2+ levels from baseline for four individual cells. Each cell is represented by a unique 
colour, individual data points are represented by dots and a linear fit to the data is plotted in the 
same colour (data from 3 mice). 





3.2.2 NTS PPG neurons are activated by leptin, IL-6, and CCK 
As mentioned in section 3.1, Hisadome et al. (2010, 2011) studied PPG neuron activity using 
patch-clamp electrophysiology. These experiments were fundamental in understanding the 
cellular properties of PPG neurons, which were found to be directly depolarised by leptin 
(Hisadome et al. 2010).  
Using Ca2+ imaging, I confirmed these findings by stimulating PPG-Cre/GCaMP3 coronal 
brainstem slices with 1 nM leptin (Fig 3.5A). Coronal brainstem slices from PPG-Cre/GCaMP3 
mice were superfused with 1 nM leptin for 3 mins, which elicited an increase in intracellular 
[Ca2+] as seen in images of representative cells (Fig 3.5A left) and traces from eight individual 
neurons (Fig 3.5A middle). Intracellular [Ca2+] was monitored in 15 PPG neurons from two 
different mice. All imaged neurons responded to leptin with an increase in GCaMP3 fluorescence 
intensity, suggesting the entire PPG neuron population is activated by leptin. Responses to leptin 
were quantified by calculating the area under the curve (AUC) for each individual cell (Fig 3.5A 
right panel). These data confirm the previous study from our laboratory and demonstrate that 
PPG neurons respond as a population to leptin with an increase in activity. 
Leptin bears structural similarities to members of the cytokine family and the lepR is closely 
related to class I cytokine receptors (Tartaglia et al. 1995; Frühbeck 2006). Interleukin-6 (IL-6) is 
a member of the cytokine family, which has been implicated in the regulation of food intake and 
energy expenditure (Molotkov et al. 1998; Wallenius et al. 2002; Jansson and Palsdottir 2015). 
Furthermore, IL-6 has been proposed to mediate the food-intake suppressive effects of GLP-1R 
Fig 3.4 Glutamate (100 µM) increases intracellular [Ca2+] in PPG neurons. Live coronal brainstem 
slices from PPG-Cre/GCaMP3 mice were exposed to 100 µM glutamate for 1 min. A) Two 
representative PPG neurons in the NTS, here pseudocoloured as shown on the right, before 
(baseline), during (glutamate) and after (wash) stimulation with 100 µM glutamate. Scale bar: 20 
µm. B) Fluorescence intensity expressed as a fraction of the intensity at the beginning of the 
experiment (ΔF/F0). Glutamate application is indicated with a black bar (glut). Traces from individual 
cells are plotted in grey and the average response is shown in dark blue. (N=9 somata). 
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Fig 3.5 PPG neurons respond to 1 nM leptin and 2 nM IL-6 with an increase in intracellular [Ca2+]. 
In vitro brainstem slices from PPG-Cre/GCaMP3 mice were exposed to 1 nM leptin or 2 nM IL-6 for 
3 mins. A) Left panel: Two representative NTS PPG neurons, here pseudocoloured as shown on the 
right, before (baseline), during (leptin) and after (wash) stimulation with 1 nM leptin. Scale bar: 10 
µm. Middle panel: Fluorescence intensity changes in response to 1 nM leptin expressed as a fraction 
of the intensity at baseline (ΔF/F0). Traces from individual cells are plotted in grey and the average 
response is shown in black (N=8). Right panel: Median AUC in response to 1 nM leptin. (N=15 somas, 
2 slices). B) Left panel: Fluorescence intensity changes in response to 2 nM IL-6 expressed as ΔF/F0. 
Traces from individual cells are plotted in grey and the average response is shown in black (N=6). 
Right panel: Median AUC in response to 2 nM IL-6 (N=25 somas, 4 slices). C) Top panel: 
Representative cell responding to 2 nM IL-6 before (baseline), during (0 mM Ca2+) and after (wash) 
removal of extracellular Ca2+. The period of 0 mM Ca2+ is indicated with a grey bar. Bottom panel: 
Median AUC in response to 2 nM IL-6 before (baseline), during (0 mM Ca2+) and after (wash) removal 
of extracellular Ca2+ (N=19-31 somas, 3 slices). Kruskal-Wallis ANOVA yielded a significant test 
statistic (51.42). ****p<0.0001 according to Dunn’s test compared to both baseline and wash. 
activation (Shirazi et al. 2013). The following data were published in collaboration with John-




To investigate the link between IL-6 and PPG neuron activity, I stimulated NTS PPG neurons with 
2 nM IL-6 for three minutes. This led to a clear increase in intracellular [Ca2+] in six individual 
neurons shown in Fig 3.5B left panel. A similar pattern was seen in all 25 cells imaged, suggesting 
IL-6 activates PPG neurons in the NTS (Fig 3.5B right panel). This was further substantiated by 
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data from John-Olov Jansson’s group demonstrating that PPG neurons in the NTS express IL-6 
receptor-α (Anesten et al. 2016).  
To investigate whether this increase in intracellular [Ca2+] is dependent on influx of Ca2+ from the 
extracellular space, I repeated the stimulation with IL-6 in normal ACSF containing 2 mM Ca2+ 
followed by stimulation in ACSF in which Ca2+ was replaced with Mg2+ (Fig 3.5C). In normal ACSF, 
intracellular [Ca2+] increased in 19 imaged NTS PPG neurons as before with a median AUC of 0.83 
ΔF/F0*mins. Removal of extracellular Ca2+ from the ACSF slowly decreased fluorescence in the 
PPG neurons. Notably, the Ca2+ response to 2 nM IL-6 was 96% smaller in the absence of 
extracellular Ca2+ with a median AUC of 0.026 ΔF/F0*mins (Fig 3.5C, p<0.0001). After 
replenishment of extracellular Ca2+ the response to IL-6 returned to a similar level as baseline 
with a median AUC of 0.66 ΔF/F0*mins (p=0.71). These data demonstrate that the cytokine IL-6 
activates NTS PPG neurons in vitro and that the resulting rise in intracellular [Ca2+] is dependent 
on influx from the extracellular space. 
In 2011, Hisadome et al. demonstrated a link between CCK and PPG neuron activity using patch-
clamp electrophysiology. Of 15 recorded PPG neurons, seven were indirectly activated by CCK-
8 via a noradrenergic-glutamatergic circuit. Here, I confirmed that a subset of PPG neurons is 
activated by CCK-8 (Fig 3.6). By monitoring the activity of several cells simultaneously, I gain 
more information on how PPG neurons respond to CCK as a population rather than single cells. 
Three imaged PPG cells are displayed in pseudocolouring in Fig 3.6A. Two somata increased 
intracellular [Ca2+] in response to 200 nM CCK-8, whereas one soma was unresponsive. Out of 
14 imaged cells, five responded to CCK-8 with an increase in intracellular [Ca2+] (Fig 3.6B). After 
washout of CCK-8, intracellular [Ca2+] returned to baseline. Nine cells exhibited no increase in 
[Ca2+] in response to CCK-8, demonstrating that only a subset of PPG neurons respond to CCK-8 
in vitro. In future experiments, sodium channel blocker tetrodotoxin (TTX) should be included in 
the ACSF to confirm that CCK-8 indirectly activates PPG neurons (Hisadome et al. 2011).  
 





3.2.3 PPG neurons are activated by hypoglycaemia 
The data presented above demonstrate that leptin, IL-6, and CCK-8 activate NTS PPG neurons in 
vitro, resulting in increased intracellular [Ca2+]. These compounds relay information on energy 
balance, visceral illness, and general homeostasis, signals which could be integrated by NTS PPG 
neurons. Next, I investigated the ability of a metabolic signal to regulate PPG neuron activity. 
The brainstem and in particular the dorsal vagal complex is a well-known site of glucosensing 
(Balfour et al. 2006; Thorens 2012; Lamy et al. 2014). Neurons and glia in this area have been 
shown to sense and respond to changing levels of extracellular glucose (Balfour and Trapp 2007; 
McDougal et al. 2013).  
To investigate whether PPG neurons within the NTS are part of the glucosensing population in 
the dorsal vagal complex, I exposed in vitro brainstem slices from PPG-Cre/GCaMP3 mice to 
varying concentrations of extracellular glucose. Sections were maintained in 10 mM glucose as 
in previous experiments. Following baseline in 10 mM glucose, the perfusate was changed to 
ACSF containing only 1 mM glucose. Hypoglycaemia elicited an increase in intracellular [Ca2+] 
(Fig 3.7), suggesting these cells are glucose-inhibited. Intracellular [Ca2+] slowly increased after 
reduction of extracellular glucose and plateaued after 7 mins of hypoglycaemia. This same 
pattern was observed in 45 of 47 PPG cells imaged with a median peak change in fluorescence 
intensity (peak ΔF/F0) of 0.17 (Fig 3.7C). As with CCK-8, future experiments should investigate 
whether these responses are direct or indirect using TTX.  
Fig 3.6 PPG neurons respond to 200 nM CCK-8 with an increase in intracellular [Ca2+]. Live coronal 
brainstem slices from PPG-Cre/GCaMP3 mice were exposed to 200 nM CCK-8 for 3 mins. A) Three 
representative NTS PPG neurons, here pseudocoloured as shown on the right, before (baseline), 
during (CCK-8) and after (wash) stimulation with 200 nM CCK-8. The black arrowhead indicates one 
cell that did not increase [Ca2+] in the presence of CCK-8. The white arrowheads indicate two 
responding somata. Scale bar: 10 µm. B) Fluorescence intensity expressed as ΔF/F0. Traces from 
individual cells are plotted in grey and the average response of responding cells (N=5) is shown in 
dark blue. The average trace of non-responding cells (N=7) is shown in black (N=12 somata in total). 
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Fig 3.7 PPG neurons respond to hypoglycaemia with a rise in intracellular [Ca2+]. Live coronal 
brainstem slices from PPG-Cre/GCaMP3 mice were exposed to 1 mM extracellular glucose for ten 
minutes. A) Representative NTS PPG neuron, here pseudocoloured as shown on the right, before (10 
mM, top), during (1 mM) and after (10 mM, bottom) stimulation with low glucose (1 mM). Scale bar: 
10 µm. B) Fluorescence intensity changes in response to low glucose expressed as ΔF/F0. Traces from 
individual cells are plotted in grey and the average response is shown in black. (N=10 somata). C) Heat 
map of 47 PPG cells responding to a decrease in glucose with a rise in intracellular calcium. At the top 
is shown a subset of experiments with slices exposed to 1 mM glucose for 15 mins. The bottom map 
displays a subset of experiments in which slices were exposed for only 10 mins. Red bars indicate the 
period of the recording in which glucose was changed from 10 mM to 1 mM  
 
 
The data presented here suggest that PPG neurons not only detect the presence of homeostatic 
and satiety signals CCK-8, leptin and IL-6, but also monitor the levels of extracellular glucose. 
Surprisingly, considering the putative role of central GLP-1 in satiety, low glucose levels 
increased the activity of PPG neurons. I will elaborate on this point in section 3.3.2 of the 
Discussion. These results provide important information on the modulation of PPG neurons 
activity by metabolic and homeostatic cues and present interesting avenues for future research 
into the link between these systems and central GLP-1.  
3.2.4 PPG neurons are activated by carbachol and ATP 
In the previous section, I addressed the regulation of PPG neuron activity by homeostatic and 
satiety signals. In this section, I turn to the modulation of PPG neurons by small-molecule 
transmitters released from glia and neurons.  
ATP is released from astrocytes in response to homeostatic stimuli such as low glucose, 
acidification of the microenvironment, hypoxia, and vagal stimulation (Gourine et al. 2010; 
McDougal et al. 2011, 2013; Accorsi-Mendonça et al. 2013; Marina et al. 2016). To investigate a 
potential link between gliotransmission and PPG neuron activity, I stimulated PPG neurons with 
1 mM ATP (Fig 3.8). 
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Fig 3.8 PPG neurons are activated by 1 mM ATP. Live coronal brainstem slices from PPG-Cre/GCaMP3 
mice were exposed to 1 mM ATP for one minute. A) Two representative NTS PPG neurons, here 
pseudocoloured as shown below, before (Baseline), during (ATP) and after (Wash) stimulation with 1 
mM ATP. White arrowheads indicate adjacent dendritic fibres responding to ATP. Scale bar: 10 µm. 
B) Fluorescence intensity changes in response to 1 mM ATP expressed as ΔF/F0. Traces from individual 
cells are plotted in grey and the average response is shown in black. (N=4 somata). C) Median AUC of 
PPG neuron responses after stimulation with ATP in the absence (-) and presence (+TTX, DNQX, APV) 
of synaptic inhibitors TTX (0.5 µM), DNQX (20 µM) and APV (25 µM). Responses were compared using 
Wilcoxon’s signed rank test for paired data. ****p<0.0001. N=15 somata, 2 slices.   
GCaMP3 fluorescence intensity increased in all imaged neurons (N=19) in response to 1 mM ATP 
(Fig 3.8). Additionally, dendritic processes near PPG neurons were activated in response to 1 
mM ATP (Fig 3.8A). Interestingly, the ATP-induced increase in PPG activity was abolished in the 
presence of TTX (0.5 µM) and glutamate receptor inhibitors DNQX (20 µM) and APV (25 µM) (Fig 
3.8C). This suggests the increase in intracellular [Ca2+] in response to ATP is either secondary to 
an increase in action potential firing and therefore suppressed by TTX, or dependent on input 
from other cells. These data demonstrate that 1 mM ATP is able to activate PPG neurons and 
provide an intriguing potential link between gliotransmission and central GLP-1, as suggested 
recently by Reiner et al. (2016). 
 
 
Next, I investigated the effect of cholinergic stimulation on PPG neuron activity. Acetylcholine 
excites neurons in the NTS via both muscarinic and nicotinic receptors (Shihara et al. 1999) and 
choline acyltransferase is expressed in dendrites in the NTS (Armstrong et al. 1988). Recently, a 
link has been suggested between central GLP-1 and nicotine, an AChR agonist (Tuesta et al. 
2017). In addition, smoking is known to suppress appetite and activate reward pathways, an 
effect which may depend on central GLP-1. I stimulated PPG neurons with 100 µM carbachol for 
3 mins. Carbachol is an AChR agonist, which activates both muscarinic and nicotinic receptors. 
Following a short baseline, sections were superfused with 100 µM carbachol, which led to a clear 
increase in intracellular [Ca2+] in a subset of NTS PPG neurons (Fig 3.9A,B). Out of 19 PPG neurons 
imaged, 13 increased intracellular [Ca2+] in response to cholinergic stimulation with a median 
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Fig 3.9 PPG neurons are activated by cholinergic stimulation. Live coronal brainstem slices from PPG-
Cre/GCaMP3 mice were exposed to 100 µM AChR agonist, carbachol, for three minutes. A) Two 
representative NTS PPG neurons, here pseudocoloured as shown below, before (baseline), during 
(carb.) and after (wash) stimulation with 100 µM carbachol. A responding cell is indicated with a white 
arrow head, a non-responding cell is indicated with a black arrow head. Scale bar: 10 µm. B) 
Fluorescence intensity changes in response to 100 µM carbachol expressed as ΔF/F0. Traces from 
individual cells are plotted in grey and the average response of responding cells is shown in black, 
whereas the average trace of non-responding cells is shown in red. (N=10 somata). C) Median AUC of 
PPG neuron responses after stimulation with 100 µM carbachol split into responding and non-
responding cells. N=19 somata, 2 slices.  
AUC of 0.76 ΔF/F0*mins (Fig 3.9C). Six PPG cells did not respond to 100 µM carbachol (Fig 3.9C). 
These data demonstrate that PPG neurons are activated by cholinergic stimulation. Future 
experiments should investigate whether this link is direct with muscarinic or nicotinic receptors 
expressed on the surface of PPG neurons, or whether it requires the activity of afferent inputs.  
 
 
3.2.5 Serotonergic modulation of the activity of NTS PPG neurons 
In the previous section, I presented data on the regulation of PPG neuron activity by the 
gliotransmitter, ATP, and the AChR agonist, carbachol. These small molecules are important 
transmitters in the NTS and both glio- and cholinergic transmission have been implicated in 
hypophagia (Jo et al. 2002; Reiner et al. 2016). I will now present data on serotonergic 
modulation of PPG neurons in vitro. These data were published in (Holt et al. 2017). 
5-HT (5-hydroxytryptamine, serotonin) is a key neurotransmitter in the regulation of both food 
intake and stress (Heisler et al. 1998, 2003, 2007; Marcinkiewcz et al. 2016). 5-HT serves diverse 
roles centrally and 5-HT receptor-expressing neurons are distributed throughout the brain. A 
range of 5-HT receptors have been implicated in the regulation of food intake including 5-HT1A 
(Dill et al. 2013), 5-HT3 (Hayes and Covasa 2006; Li et al. 2015), and 5-HT2C receptors (Tecott et 
al. 1995; Vickers et al. 1999, 2001). Interestingly, mice lacking 5-HT2C receptors failed to supress 
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food intake in response to i.p. GLP-1, suggesting there is a link between GLP-1 and serotonergic 
regulation of food intake (Asarian 2009; Nonogaki et al. 2011).   
In collaboration with Professor Ida Llewellyn-Smith, our group discovered dense serotonergic 
innervation of PPG neurons in the NTS (Holt et al. 2017). Out of 358 PPG neurons, 208 received 
close appositions from 5-HT-immunoreactive axons, with the percentage of PPG neurons 
contacted in each mouse varying between 50 % and 80 % (Holt et al. 2017).  
Based on this, I investigated if 5-HT would modulate the activity of NTS PPG neurons in 
brainstem slices in vitro. NTS PPG neurons were exposed to 20 µM 5-HT for one min (Fig 3.10). 
Only one PPG soma increased intracellular [Ca2+] in response to 5-HT, although all cell bodies 
(N=8) were activated by 100 µM glutamate (Fig 3.10B). In total, only four out of 39 imaged PPG 
somata responded to 20 µM 5-HT with an increase in intracellular [Ca2+]. However, dendrites 
adjacent to PPG somata were activated by 5-HT and had transient spikes in intracellular [Ca2+] 
(Fig 3.10C). Although cells were only exposed to 5-HT for one minute dendritic spikes persisted 
for 3.5±0.2 mins. This contrasted with glutamate-induced, dendritic [Ca2+] spikes, which quickly 
disappeared following washout of glutamate (Fig 3.10C). 
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Fig 3.10 5-HT evokes intracellular [Ca2+] changes mainly in distal PPG dendrites. 
Live coronal brainstem slices from PPG-Cre/GCaMP3 mice were exposed to 20 
µM 5-HT for one min followed by stimulation with 100 µM glutamate for one min. 
A) Two representative NTS PPG neurons, pseudocoloured as indicated below the 
images, before (Baseline), during (5-HT) and after (Wash) stimulation with 20 µM 
5-HT. White arrows indicate dendrites with transient rises in intracellular [Ca2+]. 
Scale bar: 25 µm. B) Somatic fluorescence intensity changes in response to 20 µM 
5-HT expressed as ΔF/F0. Traces from individual cells are plotted in grey and the 
average response of responding cells is shown in blue, whereas the average trace 
of non-responding cells is shown in red. (N=8 somata). C) Dendritic fluorescence 
intensity changes in response to 20 µM 5-HT expressed as ΔF/F0. Traces from 




Dendritic [Ca2+] spikes induced by 5-HT were found to be concentration-dependent with only 
limited activity following stimulation with 2 µM 5-HT compared to 20 µM or 200 µM (Fig 3.11). 
One way non-parametric ANOVA yielded a Friedman statistic of 92.57 (p<0.0001) and Dunn’s 
multiple comparison’s test revealed that both 20 µM and 200 µM 5-HT elicited statistically 
significant larger responses than 2 µM (p<0.0001 for both), but no difference between the 
response to 20 µM and 200 µM 5-HT, suggesting the response is at its maximum at 20 µM. No 
further PPG somata were recruited at higher concentrations of 5-HT, suggesting the reason for 
the limited somatic response is not insufficient stimulation of 5-HT receptors (not shown). 
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Fig 3.11 5-HT-evoked dendritic [Ca2+] spikes are concentration-dependent. In vitro coronal brainstem 
slices from PPG-Cre/GCaMP3 mice were exposed to 2, 20, and 200 µM 5-HT for one min. A) Two 
independent recordings showing NTS PPG neurons responding to 2, 20, and 200 µM 5-HT. Traces from 
individual dendrites are plotted in grey and the mean response is shown in red. N=17 (top panel), N=7 
(bottom panel). B) Median AUCs of dendritic Ca2+ spikes in response to 2, 20, and 200 µM 5-HT. (N=88 
dendrites in each condition). *p<0.0001, n.s.: not significant (p>0.99) according to Dunn’s adjusted 
multiple comparison’s test. 
 
 
To investigate the source of Ca2+ for these 5-HT-induced dendritic spikes, I repeated the 
stimulation with 20 µM 5-HT in the presence and absence of 2 mM extracellular Ca2+ (Fig 3.12). 
Removal of Ca2+ reduced dendritic [Ca2+] spikes in response to 20 µM 5-HT by 69±12% 
(p<0.0001). While this suggests the source of Ca2+ for 5-HT-induced dendritic spikes is the 
extracellular space, I cannot exclude that prolonged exposure to Ca2+-free extracellular solution 
provokes release from and depletion of intracellular Ca2+ stores (Williams et al. 1977; Weber et 
al. 2001).    






I next asked whether the dendritic [Ca2+] spikes are dependent on the activity of neighbouring 
cells and voltage-gated sodium channels. To this end, I stimulated PPG neurons with 20 µM 5-
HT in the absence and presence of synaptic inhibitors TTX (0.5 µM) and DNQX (20 µM). DNQX 
was chosen based on previous observations by our laboratory showing that more than 90% of 
spontaneous excitatory post-synaptic potentials were supressed in the presence of DNQX 
(Hisadome et al. 2010, 2011).  
5-HT-evoked dendritic [Ca2+] spikes were unchanged in the presence of TTX and DNQX (Fig 3.13), 
suggesting PPG neurons express functional 5-HT receptors and that the dendritic spikes are 
independent of action potential firing.  
Fig 3.12 5-HT-evoked dendritic [Ca2+] spikes are dependent on extracellular [Ca2+]. Live coronal 
brainstem slices from PPG-Cre/GCaMP3 mice were exposed to 20 µM 5-HT in the presence of 2 mM 
or 0 mM extracellular Ca2+. A) Dendritic fluorescence intensity changes in response to 20 µM 5-HT 
expressed as ΔF/F0. Sections were first exposed to 20 µM 5-HT in the presence of 2 mM extracellular 
Ca2+ after which extracellular Ca2+ was removed and the sections restimulated with 20 µM 5-HT. The 
period with 0 mM Ca2+ is indicated by a grey bar. B) Median AUC of dendrites responding to 20 µM 5-
HT in the presence (5-HT) and absence (in 0 mM Ca2+) of extracellular Ca2+. ****p<0.0001 according 
to Wilcoxon matched pair signed rank test.  





The data presented until now have demonstrated that PPG neurons respond directly to 5-HT 
with dendritic spikes in intracellular [Ca2+]. These spikes were dependent on extracellular Ca2+ 
but did not require action potential firing or glutamatergic input, suggesting NTS PPG neurons 
express functional 5-HT receptors. I wanted to further dissect the mechanism underlying these 
[Ca2+] spikes and set out to determine which 5-HT receptors were involved in the response. To 
this end, I used selective agonists and antagonists for several 5-HT receptor subtypes.  
Most 5-HT receptor subtypes can be detected in the NTS (Sévoz-Couche et al. 2000; Jordan 
2005). In particular both 5-HT2 and 5-HT3 receptors are involved in the regulation of food intake 
(Vickers et al. 2001; Hayes and Covasa 2005, 2006; Schuhler et al. 2005; Li et al. 2015). I therefore 
assessed the contribution of each receptor subtype to the dendritic Ca2+ response to 5-HT.  
Fig 3.13 5-HT-evoked dendritic [Ca2+] spikes are independent of action potentials and glutamatergic 
input. In vitro coronal brainstem slices from PPG-Cre/GCaMP3 mice were exposed to 20 µM 5-HT in 
the absence and presence of 0.5 µM TTX and 20 µM DNQX. A) Dendritic fluorescence intensity changes 
in response to one minute 20 µM 5-HT in the presence and absence of TTX and DNQX. Traces from 
individual dendrites are plotted in grey and the average response is shown in red. TTX and DNQX 
application in indicated with a grey bar. N=12 dendrites. B) Median AUCs of dendritic Ca2+ spikes in 
response to 20 µM 5-HT in the absence (5-HT) and presence (+TTX+DNQX) of synaptic inhibitors. 
(N=55 dendrites in each condition). n.s.: not significant according to Wilcoxon matched-pairs signed 
rank test (p=0.56). 
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Fig 3.14 5-HT3 receptors are not involved in the dendritic Ca2+ response to 5-HT. A) Stimulation with 
5-HT3 receptor agonist PBG does not elicit Ca2+ spikes in PPG dendrites. Left panel: Dendritic 
fluorescence intensity changes in response to one min 10 µM 5-HT3 receptor agonist or 20 µM 5-HT. 
Traces from individual dendrites are plotted in grey and the mean response is shown in red. N=7 
dendrites. Right panel: Median AUCs of dendritic Ca2+ spikes in response to 1 µM PBG (N=32 
dendrites), 10 µM PBG (N=25 dendrites), and 20 µM 5-HT (N=37 dendrites) (3 mice). Kruskal-Wallis 
rendered a Chi-Square value of 45.9 (p<0.0001). Post-hoc comparisons revealed no statistically 
significant difference between 1µM and 10µM PBG (p>0.999) but showed that the responses to 
20µM 5-HT were significantly different to both 1µM and 10µM PBG (p<0.0001). B) 5-HT evoked 
dendritic Ca2+ spikes are unaltered by 5-HT3 receptor inhibition. Left panel: Dendritic fluorescence 
intensity changes in response to one min 20 µM 5-HT in the absence and presence of 5-HT3 receptor 
antagonist granisetron (5 µM). Traces from individual dendrites are plotted in grey and the mean 
response is shown in red. Application of 5 µM granisetron is indicated with a grey bar. N=9 dendrites. 
Right panel: Median AUCs of dendritic Ca2+ spikes in response to 20 µM 5-HT before (white box) and 
during (grey box) granisetron. (N=32 dendrites, 3 mice), n.s.: not significant according to Wilcoxon 
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Phenylbiguanide (PBG) is a selective 5-HT3 receptor agonist (Ireland and Tyers 1987; Chen et al. 
1991). I used it here at two concentrations (1 and 10 µM) to stimulate PPG neurons in vitro. Two 
concentrations of PBG failed to elicit [Ca2+] spikes, whereas dendritic [Ca2+] rises were clearly 
seen following 20 µM 5-HT (Fig 3.14A). Kruskal-Wallis one-way ANOVA yielded a significant test 
statistic of 45.9 (p<0.0001) and Dunn’s multiple comparisons test revealed a significantly larger 
Ca2+ response in 5-HT-stimulated dendrites compared to both 1 and 10 µM PBG (Fig 3.14A right 
panel, p<0.0001 for both). These findings were further supported by experiments using the 5-
HT3 receptor antagonist granisetron (5 µM). Granisetron failed to inhibit the dendritic response 
to 20 µM 5-HT with no difference in the response to 20 µM 5-HT before and during granisetron 
(Fig 3.14B, p=0.32). These data suggest that 5-HT3 receptors are not involved in serotonergic 
modulation of NTS PPG neurons.   
Next, I investigated the potential involvement of 5-HT2 receptors in the response to 5-HT. I 
stimulated NTS PPG neurons with 20 µM 5-HT in the absence and presence of a 5-HT2 receptor 
antagonist, ketanserin (1 µM). Inhibition of 5-HT2 receptors attenuated the dendritic [Ca2+] 
response to 20 µM 5-HT by 77±6 % (Fig 3.15A, p<0.0001). Because of the proposed link between 
central GLP-1 and 5-HT2C receptors and because of 5-HT2C receptors’ known role in the 
regulation of food intake, I next tested whether PPG dendrites can be activated by the selective 
5-HT2C receptor agonist WAY161,503. In support of a role for 5-HT2C receptors in the generation 
of PPG dendritic [Ca2+] spikes, 5 µM WAY161,503 elicited transient [Ca2+] rises in a total of five 
individual sections from five mice (Fig 3.15B).  
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Fig 3.15 NTS PPG neurons are activated by 5-HT via 5-HT2 receptors and 5-HT2C receptor activation 
elicits dendritic Ca2+ spikes. A) 5-HT2 receptor inhibition attenuates the dendritic response to 5-HT. 
Left panel: Dendritic fluorescence intensity changes in response to one min 20 µM 5-HT in the 
presence and absence of 5-HT2 receptor antagonist ketanserin (1 µM) expressed as relative change 
in fluorescence from baseline, ΔF/F0. Traces from individual dendrites are plotted in grey and the 
mean response is shown in red. Ketanserin application is indicated with a grey bar. N=6 dendrites. 
Right panel: Median AUCs of dendritic Ca2+ spikes in response to 20 µM 5HT before (white box) and 
during (grey box) 1 µM ketanserin (N=17 dendrites, 3 mice). ****p<0.0001, Wilcoxon matched-pairs 
signed rank test. B) 5-HT2C receptor activation elicits Ca2+ spikes in PPG dendrites. Left panel: Traces 
showing individual dendritic fibres responding to the 5-HT2C receptor agonist WAY161,503 (5 µM) 
with an increase in intracellular Ca2+ (N=9 dendrites). Traces from individual dendrites are plotted in 
grey and the average response is shown in red. Right panel: Median AUC of dendrites responding to 
WAY161,503 (N=32 dendrites, 5 mice).   
 
 
Having discovered a potential role for 5-HT2C receptors in the activation of PPG dendrites, I was 
curious how this was related to electrical activity at the level of the soma. I monitored the 
spontaneous firing patterns of NTS PPG neurons using loose-patch recordings in the cell-
attached configuration.  
Spontaneous firing was recorded in 16 cells, which were stimulated with 20 µM 5-HT for 3 mins 
(Fig 3.16). Spontaneous firing rates were similar to those seen for PPG neurons previously 
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(Hisadome et al. 2010, 2011). Student’s t-test revealed 12 of 16 cells recorded were electrically 
responsive to 20 µM 5-HT. Five cells were found to increase their firing rate by 1.3±0.2 Hz (Fig 
3.16A), seven reduced their firing rate by -1.0±0.2 Hz (Fig 3.16B) and four cells showed no 
response to 20 µM 5-HT (Fig 3.16C). Friedman one-way ANOVA yielded a significant test statistic 
in the activated cells (Friedman statistic: 8.4, p=0.0085) and in the inhibited cells (Friedman 
statistic: 10.57, p=0.0027), but not in the non-responding cells (Friedman statistic: 0.133, 
p>0.99). There was a significant increase in firing rate in the activated cells (p=0.013) and a 
significant decrease in the inhibited cells (p=0.023), but no effect of 5-HT in the non-responding 
cells (p>0.99), demonstrating that 20 µM 5-HT can have different effects on firing rate in 
different neurons. 
Having found that a subset of PPG neurons was inhibited by 20 µM 5-HT, I next addressed the 
question, which 5-HT receptor is involved in this response. 5-HT5 and 5-HT1 are inhibitory 
receptors and couple to the Gi/o pathway (McCorvy and Roth 2015). The 5-HT1A receptor was of 
particular interest because of its known involvement in appetite regulation (Dill et al. 2013). I 
therefore tested whether the selective 5-HT1A receptor antagonist, WAY-100,635 (Forster et al. 
1995), was able to abolish the reduction in firing rate seen in a subset of PPG neurons.  
Fig 3.17A shows a representative simultaneous recording of intracellular [Ca2+] (top, red) and 
spontaneous firing rate (bottom, black). 5-HT (20 µM) completely abolished action potential 
firing. This decrease in electrical activity was accompanied by a decrease in intracellular [Ca2+] 
confirming the correlation between changes in firing rate and intracellular [Ca2+] (Fig 3.17A top 
left and Fig 3.3). Inhibition of 5-HT1A receptors prevented the 5-HT-induced reduction in both 
intracellular [Ca2+] and spontaneous firing frequency. Interestingly, 5-HT1A suppression increased 
both intracellular [Ca2+] and firing rate independent of 5-HT application, suggesting these cells 
receive ongoing serotonergic inhibitory input mediated by 5-HT1A receptors (Fig 3.17A).  
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Fig 3.16 NTS PPG neuron electrical activity is modulated by 5-HT. Representative traces of 
spontaneous firing rates of PPG neurons either activated (A), inhibited (B) or unaffected (C) by three 
minutes stimulation with 20 µM 5-HT. Below each representative trace are shown periods of the 
original voltage-clamp recordings from timepoints i, ii, iii and iv. D) Median firing rate of activated 
(N=5), inhibited (N=7) and unresponsive cells (N=4) before (white box), during (dark grey box) and after 
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Fig 3.17 Inhibition of PPG neuron electrical activity by 5-HT is dependent on 5-HT1A receptors. A) Left 
panels: Representative traces of spontaneous firing rate (middle left) and GCaMP3 fluorescence 
intensity (top left, i.u.: intensity units) of the same PPG neuron recorded in loose-patch configuration. 
Applications of 20 µM 5-HT are marked with black bars and dark grey boxes and application of 5-HT1A 
receptor antagonist WAY-100,635 is marked by a light grey box. Original cell-attached recordings from 
timepoints i, ii, iii and iv are shown in the bottom left panel. Right panels: Median AUC (top, N=7) and 
firing rate (bottom, N=4) of PPG somata stimulated with 5-HT in the absence (white boxes) and 
presence (grey boxes) of WAY-100,635. **p<0.01 (paired Student’s t-test); *p<0.05 (Wilcoxon’s signed 
rank test) (N=4 cells, 4 mice). B) Left panel: The dendritic Ca2+ response to 5-HT in the presence of 20 
µM WAY-100,635 (n=6 dendrites). WAY-100,635 application is indicated with a light grey box. Right 
panel: Median AUC of dendritic responses to 5-HT alone from previous experiments (n=248 dendrites) 
and to 5-HT in the presence of WAY-100,635 (n=20 dendrites (3 mice)). n.s.: not significant (p=0.91) 
according to Mann-Whitney test. 
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Cell-attached recordings from four independent PPG somata displayed a similar pattern to the 
cell shown in Fig 3.17 with firing rate decreasing by -1.3±0.1 Hz in response to 5-HT (Fig 3.17A 
bottom right). The 5-HT-induced decrease in action potential firing was completely abolished by 
5 µM WAY-100,635 (p=0.0047, Student’s paired t-test). Similarly, somatic Ca2+ recordings of 
seven cells showed a clear attenuation of the inhibitory response to 5-HT in the absence of 5-
HT1A signalling (Fig 3.17A top right). The 5-HT response was reduced by 91±6 % in the presence 
of WAY-100,635.  
Interestingly, inhibition of 5-HT1A receptors did not result in 5-HT-induced somatic excitation of 
PPG neurons. Furthermore, the dendritic [Ca2+] response to 5-HT was not altered in the presence 
of WAY-100,635 (Fig 3.17B, p=0.91). These data suggest activation of 5-HT1A receptors does not 
explain the lack of propagation of the dendritic [Ca2+] spikes to somata in response to 5-HT.  
In summary, I have demonstrated a link between serotonergic signalling and PPG activity. This 
link is multifaceted and consists of both inhibitory and excitatory effects. 5-HT-induced dendritic 
spikes were dependent on 5-HT2 receptors and activation of 5-HT2C receptors led to clear 
transient [Ca2+] rises in PPG dendrites. However, I also demonstrated that a subset of PPG 
neurons was inhibited at the somatic level and that the reduction in firing rate was dependent 
on 5-HT1A receptor signalling.  
  




In this chapter, I investigated the cellular regulation of PPG neuron activity by metabolic signals, 
hormones, and neurotransmitters. Figure 3.18 summarises the results presented here along 
with known inputs from the literature. Using in vitro Ca2+ imaging, I demonstrated that satiety 
hormones CCK and leptin increase intracellular [Ca2+] in PPG neurons (Figs 3.5 and 3.6). Similarly, 
the cytokine IL-6 led to a rise in cytosolic [Ca2+] and NTS PPG neurons were inhibited by high 
extracellular glucose levels (Figs 3.5 and 3.7). PPG neurons were activated by ATP in an indirect 
manner and carbachol, an AChR agonist, increased intracellular [Ca2+] in a subset of PPG neurons 
(Figs 3.8 and 3.9). 5-HT modulated the activity of PPG neurons in a heterogenous way: Some 
cells increased firing in response to 5-HT, while others had decreased firing (Fig 3.16). 
Furthermore, distal dendrites showed 5-HT2C receptor-mediated dendritic [Ca2+] spikes that 
failed to propagate to the soma (Fig 3.10).  
3.3.1 The activity of NTS PPG neurons is modulated by signals of satiety 
In vitro Ca2+ imaging revealed that the satiety hormone leptin activated PPG neurons as observed 
previously using patch-clamp electrophysiology (Fig 3.5) (Hisadome et al. 2010). Leptin has long 
been known to reduce food intake in both humans and rodents (Zhang et al. 1994; 
Pelleymounter et al. 1995; Schwartz et al. 1996; Larsson et al. 1998; Klok et al. 2007; Patel and 
Ebenezer 2008). It is released from adipose tissue into the bloodstream and acts on brain lepRs 
to supress feeding (Campfield et al. 1995). The hypothalamus has been thought to be its main 
site of action (Cowley et al. 2001; Pinto et al. 2004; Takahashi and Cone 2005). However, the 
caudal brainstem is another key site for the food intake-suppressive effects of leptin (Grill et al. 
2002; Hosoi et al. 2002; Huo et al. 2007).  
Although several studies have found a link between central GLP-1 and leptin (Goldstone et al. 
1997, 2000; Williams et al. 2006), the expression of lepRs by NTS PPG neurons is controversial 
with evidence suggesting lepRs are expressed by PPG neurons in mice (Goldstone et al. 1997; 
Hisadome et al. 2010; Garfield et al. 2012), but not in rats (Huo et al. 2008). I presented evidence 
for a link between central GLP-1 and leptin in mice. However, I did not confirm that the effect 
of leptin on PPG neuron activity is via direct activation of lepRs expressed on PPG neurons. 
Importantly, this has been demonstrated previously using patch-clamp electrophysiology 
(Hisadome et al. 2010). Although leptin, in contrast to GLP-1, is considered a long-term 
suppressor of food intake (Attele et al. 2002; Klok et al. 2007), these data suggest that it partly 
regulates feeding via activation of the central GLP-1 system.  
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PPG neurons were also activated by the inflammatory cytokine IL-6, which is known to play a 
role in food intake and obesity (Wallenius et al. 2002). We have found that PPG neurons express 
functional IL-6 receptors and respond to IL-6 with an influx of Ca2+ (Fig 3.5) (Anesten et al. 2016). 
Interestingly, GLP-1-induced suppression in feeding has been shown to be partially dependent 
on IL-6 receptor signalling (Shirazi et al. 2013). Whether this reflects a disease-state rather than 
regulation of homeostatic feeding is unclear, and it is possible that the link between IL-6 and 
GLP-1 in the regulation of food intake is mainly relevant during times of inflammation (Cahlin et 


















Fig 3.18 Proposed regulation of PPG neuron activity based on experimental evidence and literature. 
Compounds newly discovered to regulate PPG neuron activity were added to Fig 1.3. In black are 
shown compounds, which were investigated in this chapter. In grey are compounds previously shown 
to affect PPG neuron activity as described in Introduction. Using Ca2+ imaging, PPG neurons were 
found to be activated by AChR agonist, carbachol, and hypoglycaemia. The underlying mechanisms 
are unknown. ATP indirectly activated PPG neurons. Interleukin-6 (IL-6) increased intracellular [Ca2+] 
in PPG neurons, which were found to express IL-6 receptor-α (IL-6Rα). 5-HT modulated PPG activity 
by inducing dendritic Ca2+ spikes via 5-HT2 receptors (5-HT2R) and by decreasing firing rate via 5-HT1A 
receptors. Leptin and cholecystokinin (CCK) were confirmed to activate PPG neurons. ST: Solitary tract, 
LI: Limbic input, LPS: Lipopolysaccharide. Adr.: adrenergic neuron, Glut.: glutamatergic neuron. 
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I also demonstrated that CCK, another satiety hormone, increases intracellular [Ca2+] in a subset 
of NTS PPG neurons. Hisadome et al. (2011) similarly found that CCK increases firing frequency 
indirectly in approximately 50% of PPG neurons. It is unclear whether the lack of response in the 
remaining neurons is due to severing of inputs in the in vitro slice preparation or whether it 
reflects the existence of different subpopulations of PPG neurons.  
The origin of CCK acting on PPG neurons is uncertain. CCK-immunoreactive fibres and cell bodies 
are present in the NTS of rats (Takagi et al. 1984). NTSCCK neurons are activated by feeding and 
reduce food intake through NTS → PBN and NTS → PVN circuits in mice (D’Agostino et al. 2016; 
Roman et al. 2016, 2017). A NTSCCK → NTSPPG indirect connection could provide an additional 
pathway for postprandial suppression of appetite. Alternatively, CCK released from the gut 
crosses the blood-brain barrier to activate CCK receptors in the CNS. Peripheral injection of CCK 
activates GLP-1-producing neurons in rats (Rinaman 1999b) and reduces food intake (McCann 
et al. 1989; Asin et al. 1992; Zhang and Ritter 2012). Importantly, peripheral injection of CCK also 
causes interoceptive stress and malaise (Ervin et al. 1995; Rinaman 1999b) and it is possible that 
food intake-suppressive effects of high levels of peripheral CCK are mainly mediated by 
induction of nausea (Verbalis et al. 1986; Shillabeer and Davison 1987; McCann et al. 1989). Both 
CCK and IL-6 could therefore signal states of illness rather than postprandial satiety via activation 
of NTS PPG neurons. The relative contributions of central and peripheral CCK in the activation 
of PPG neurons remains unknown. 
3.3.2 PPG neurons as glucosensors 
PPG neurons were found to increase their activity in response to a decrease in extracellular 
glucose (Fig 3.7). Other appetite-regulating neuronal populations have been found to be 
inhibited by high levels of extracellular glucose including hypothalamic AgRP-expressing cells 
(Muroya et al. 1999; Fioramonti et al. 2007; Marston et al. 2011), which are essential for the 
onset of feeding (Luquet et al. 2005). In contrast, satiety-inducing cells such as hypothalamic 
POMC-expressing neurons are excited by high levels of extracellular glucose (Ibrahim et al. 2003; 
Parton et al. 2007). Considering the putative role of NTS PPG neurons in satiety, it was surprising 
to find that they are inhibited by high levels of glucose rather than excited. Our laboratory has 
evidence from patch-clamp experiments, which suggests that PPG neurons are in fact glucose-
excited during the dark phase and glucose-inhibited during the light phase (Hisadome et al., 
unpublished). A similar circadian regulation of GLP-1 secretion from the gut has been suggested 
(Gil-Lozano et al. 2014), suggesting both peripheral and central GLP-1-producing cells are 
“tuned” to respond to changes in metabolic cues during times of the day with usually high intake 
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of food, i.e. the dark phase in rodents. Future experiments should address the circadian rhythm 
of increases in PPG somatic [Ca2+] in response to low glucose and whether this response is 
reversed during the dark phase.  
It remains unclear how glucose-inhibited cells sense glucose, but there is some evidence that it 
is dependent on glucokinase and an intracellular drop in ATP during hypoglycaemia (Dunn-
Meynell et al. 2002; Kang et al. 2006). However, there is also compelling evidence that the 
inhibitory effect of glucose on orexin neuron firing is independent of changes in intracellular 
glucose or ATP and is mediated by a potassium current (Burdakov et al. 2006). I observed a 
delayed increase in intracellular [Ca2+] in response to hypoglycaemia, with several minutes 
passing between application and response. This was different to all other stimuli and suggests 
that the main mechanism of glucosensing in PPG neurons is dependent on metabolism of 
glucose, not direct activation of a glucose-sensitive current. Future experiments should address 
the importance of glucokinase in PPG glucosensing. If glucose-inhibition is dependent on the 
activity of glucokinase, inhibition of glucokinase should rapidly increase the activity of PPG 
neurons, as was seen for NPY neurons (Zhou et al. 2011).   
Notably, I only investigated the response to relatively large changes in extracellular glucose (10 
→ 1 mM glucose), and could therefore not distinguish between high and low glucose sensitivity. 
Future experiments should address this by introducing gradual steps in glucose concentrations 
(e.g. 10 mM → 5 mM → 2.5 mM → 0.5 mM).   
3.3.3 ATP activates PPG neurons suggesting a link between astrocytes and GLP-1 
I demonstrated here that ATP is a potent stimulator of PPG neuron activity in an indirect manner. 
Intracellular [Ca2+] of both dendrites and somata was elevated in response to 1 mM ATP (Fig 
3.8). The primary source of extracellular ATP in the brain is astrocytes, which sense the brain 
microenvironment, including pH and glucose levels (Teschemacher et al. 2015). Interestingly, 
astrocytes have been shown to partly mediate the anorexic effects of hindbrain GLP-1R 
activation (Reiner et al. 2016), indicating some crosstalk between central GLP-1 and astrocytic 
signalling. The data presented here suggest that this communication occurs in the opposite 
direction as well, with ATP increasing the activity of PPG neurons.  
Astrocytes have recently been implicated in the regulation of food intake via inhibition of AgRP 
neurons (Yang et al. 2015). Similar to what I observed in these experiments, ATP was found to 
indirectly regulate AgRP neuron activity. Since astrocytes in the NTS are known to be glucose-
inhibited (McDougal et al. 2013), this could provide a parallel mechanisms by which changes in 
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extracellular glucose modulate PPG neuron activity. I did not investigate whether glucose 
directly affects the activity of PPG neurons by including TTX in the experimental solutions. It 
therefore remains a possibility that glucose-induced inhibition of astrocytic ATP release leads to 
decreased glutamatergic input to PPG neurons and decreased firing. 
3.3.4 Activation of PPG neurons through acetylcholine receptor stimulation 
The AChR agonist carbachol increased intracellular [Ca2+] in a subset of PPG neurons, revealing 
a potential link between central GLP-1 and cholinergic signalling (Fig 3.9). Both nicotine, an 
agonist of the nicotinergic AChR, and acetylcholine activate most neurons in the NTS (Yettefti et 
al. 1997; Shihara et al. 1999). In particular, NTS to PVN projecting neurons are activated in 
response to nicotine (Feng and Uteshev 2014) and NTS second order neurons are activated by 
acetylcholine to regulate the sympathetic response to peripheral chemoreflexes (Furuya et al. 
2014; Zoccal et al. 2014). GLP-1 released from NTS PPG neurons may act downstream of 
cholinergic neurons to increase sympathetic output and decrease food intake (Jo et al. 2002). 
I did not address whether carbachol leads to direct activation of AChRs on PPG neurons and did 
not investigate whether the receptors involved were nicotinic or muscarinic. However, Kalappa 
et al. (2011) demonstrated that AChR-mediated activation of neurons in the caudal NTS is 
dependent on stimulation of presynaptic nicotinic receptors leading to enhanced release of 
glutamate onto NTS neurons. Similarly, Yettefti et al. (1997) demonstrated that peripheral 
nicotine indirectly activates NTS neurons. It is likely that PPG neurons are activated by carbachol 
in a similar way. This is supported by the lack of response in all neurons, suggesting some cells 
were lacking the necessary input. Future experiments should address this possibility by including 
TTX and DNQX in the experimental solutions.  
The link between AChR signalling and PPG neuron activity described also provides an interesting 
potential mechanism for GLP-1-mediated suppression of reward and addiction. In addition to its 
well-known role in the regulation of food intake, GLP-1 has anti-addictive actions (Erreger et al. 
2012; Egecioglu et al. 2013b; Graham et al. 2013) and reduces intake and reward of nicotine 
(Egecioglu et al. 2013a; Tuesta et al. 2017). The data presented encourage further investigations 
into the link between AChR activation, and in particular detection of nicotine, and PPG neuron 
activity. Future experiments should investigate the role of PPG neurons in nicotine-mediated 
autonomic control and appetite regulation and the potential for GLP-1-based therapies in the 
treatment of addiction.  
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3.3.5 Serotonergic modulation of NTS PPG neurons  
In collaboration with Ida Llewellyn-Smith, I explored anatomical and functional links between 5-
HT and NTS PPG neurons. Although, two thirds of NTS PPG neurons received somatic or proximal 
dendritic close appositions from serotonergic neurons, only 10% of PPG neurons increased 
somatic [Ca2+] in response to 5-HT. In fact, [Ca2+] increases in response to 5-HT were mainly 
observed in dendrites with no propagation of the Ca2+ signal to somata (Fig 3.10). TTX and DNQX 
did not affect the dendritic [Ca2+] spikes, suggesting postsynaptic 5-HT receptors rather than 
presynaptic receptors are responsible for the responses, in contrast with what was observed for 
5-HT effects on A2 NTS neurons (Cui et al. 2012)  
Activation of 5-HT3 receptors or inhibition of these receptors during 5-HT application did not 
affect dendritic [Ca2+] spikes in PPG neurons (Fig 3.14). This indicates that PPG neurons do not 
express 5-HT3 receptors. In contrast, I demonstrated that 5-HT induces dendritic [Ca2+] spikes in 
PPG neurons via 5-HT2 receptors and that 5-HT2C-receptor activation increases dendritic [Ca2+] 
in NTS PPG neurons (Fig 3.15). 5-HT2C receptors reduce food intake via the melanocortin system 
in the hypothalamus (Lam et al. 2008). Whether PPG neurons are involved in the anorexic 
response to the 5-HT2C receptor agonist lorcaserin is a key next question. Interestingly, the 
hypophagic effect of GLP-1R activation was lost in 5-HT2C receptor knockout mice (Asarian 2009). 
However, these results appear to support a role of GLP-1 upstream from 5-HT2C receptors, rather 
than downstream as explored in this study.  
Activation of 5-HT2C receptors on PPG neurons evoked [Ca2+] spikes in dendrites, but failed to 
affect somatic [Ca2+]. 5-HT2C receptors are G-protein coupled receptors and lead to intracellular 
signalling via Gαq. Although their activation on PPG dendrites presumably leads to 
depolarisation, opening of voltage-gated Ca2+ channels, and influx of Ca2+, this Ca2+ signal does 
not propagate to the cell body. Importantly, the intracellular [Ca2+] is tightly controlled in 
dendritic spines (Higley and Sabatini 2012) and dendritic [Ca2+] transients are in some neurons 
prevented from propagating to the soma (Jarsky et al. 2005; Sjostrom et al. 2008; Higley and 
Sabatini 2012).  
The lack of propagation of the response to 5-HT to somata could have several causes. Since 200 
µM 5-HT failed to enhance the response to 5-HT, I reject that 20 µM is subthreshold for somatic 
activation. Alternatively, local depolarisation occurs on dendrites via 5-HT2C receptors, but 
simultaneous activation of inhibitory 5-HT receptors prevents the signal from reaching the soma. 
I reject this as well, since selective activation of 5-HT2C receptors did not affect somatic [Ca2+] 
and suppression of 5-HT1A receptor-mediated inhibition of PPG neurons did not allow 
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propagation of [Ca2+] spikes to cell bodies. I propose instead that 5-HT activates 5-HT2C receptors 
on distal dendrites leading to compartmentalised increases in [Ca2+]. Local [Ca2+] transient have 
been implicated in synaptic plasticity, enhancing somatic spike precision, and dendritic release 
of neuropeptides (Sjostrom et al. 2008). 
In accordance with 5-HT only increasing [Ca2+] in few somata, firing rate increased in only 25% 
of recorded neurons under 5-HT. Almost half of the tested PPG cells decreased action potential 
frequency in response to 5-HT and this inhibitory response was dependent on 5-HT1A receptors 
(Figs 3.16 and 3.17). These data raise the question why PPG neurons are excited by 5-HT at the 
dendritic level, but inhibited at the somatic level. I propose two, not mutually exclusive, 
explanations: 1) There exist separate populations of PPG neurons which respond oppositely to 
5-HT, and 2) the dendritic compartment is functionally isolated from the soma, meaning that 
robust dendritic [Ca2+] spikes do not result in excitation of PPG cell bodies.  
The heterogenous responses to 5-HT on PPG neurons align with the physiological roles of the 5-
HT2C and 5-HT1A receptors. Indeed, 5-HT1A receptor inhibition suppresses feeding (Dill et al. 
2013), as disinhibition of PPG neurons is expected to. Loss of 5-HT2C receptors increases food 
intake (Nonogaki et al. 1998), suggesting that 5-HT2C receptor activation reduces appetite. 
Similarly, chemogenetic activation of PPG neurons dramatically suppresses feeding, as I will 
show in Chapter 4 and as has recently been demonstrated by others (Gaykema et al. 2017). 
Future experiments should build on the discoveries made here by investigating the need for PPG 
neurons in the hypophagic response to 5-HT1A receptor antagonists and 5-HT2C receptor 
agonists, respectively.  
In summary, PPG neurons respond to a range of neurotransmitter and metabolic signals with an 
increase in intracellular [Ca2+]. All the tested compounds have been implicated in the control of 
food intake and many of them signal changes in homeostasis, be it energy balance or 
inflammation. There was a clear correlation between electrical activity and intracellular [Ca2+], 
encouraging the investigation of potential inhibitory responses. Future studies should 
investigate known hunger-stimulating compounds such as orexin and endocannabinoid receptor 
agonists. With their anatomical properties, PPG neurons are ideally situated to receive and relay 
these signals. Future studies should work on elucidating the physiological importance of the 





4. The physiological role of PPG neurons in food intake 
4.1 Background 
The role of central GLP-1 in food intake has been the topic of intense research for decades. Most 
studies have delivered GLP-1 or its analogues exogenously. As discussed in the Introduction (see 
Table 1.1), intraparenchymal injection of GLP-1 or analogues in a number of brain areas results 
in decreased food intake (Turton et al. 1996; Zhao et al. 2012; Mietlicki-Baase et al. 2013; 
Alhadeff et al. 2014; Secher et al. 2014). This hypophagia most likely mimics several different 
aspects of feeding, including stress-related hypophagia, hedonic feeding, and homeostatic 
feeding. For the purpose of this thesis, normal feeding will refer to food intake occurring 
throughout the day, primarily at dark onset, with no other stimuli than the normal circadian 
rhythm.  
Studies using GLP-1R agonists are crucial in identifying brain areas involved in GLP-1-induced 
satiety. They do not, however, address the physiological role of central GLP-1. In particular, the 
approach fails to investigate the role of the source of central GLP-1, the PPG neurons, in appetite 
regulation. Exogenous GLP-1 is often delivered in supraphysiological doses and GLP-1R agonism 
does not take into account release of co-transmitters from PPG neurons, including glutamate 
and GLP-2.  
Studies in which the GLP-1R antagonist, Ex9, is infused directly into the brain tissue, come 
somewhat closer to investigating the physiological role of GLP-1 in feeding (Turton et al. 1996; 
Alhadeff et al. 2012; Dossat et al. 2013). This approach aims to inhibit the actions of 
endogenously released GLP-1 onto GLP-1Rs in distinct brain nuclei, making it possible to assess 
the importance of different brain regions in GLP-1-mediated satiety in a physiological context.  
As described in the Introduction, the most likely source of GLP-1 acting on central GLP-1Rs is 
PPG neurons in the lower brainstem. In Chapter 3, I investigated the modulation of PPG neuron 
activity by a range of compounds. In this chapter, I investigate another three aspects of the 
physiology of NTS PPG neurons:  
1) Are NTS PPG neurons sufficient to reduce feeding?  
2) Are NTS PPG neurons necessary to reduce feeding?  
3) Is the homeostatic and psychological state of the animal important for recruitment of 
PPG neurons? 
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I approach these questions by chemogenetically manipulating the activity of NTS PPG neurons 
in vivo and measuring food intake in the following hours. I follow up these three initial questions 
with further investigations of downstream targets of PPG neurons, both anatomically and 
functionally. 
Several different food intake paradigms were used in an effort to thoroughly investigate in which 
physiological context PPG neurons play a role: 
• Short fast: Three hours fast prior to dark onset for studying normal food intake. The 
short fast was included to ensure simultaneous onset of feeding for all animals at dark 
onset. A brief fast is not expected to significantly affect hunger levels and is used 
routinely in food intake studies (Grill et al. 2002; Jensen et al. 2013; Terrill et al. 2016). 
• Prolonged fast: Food-deprivation for 18 hours prior to dark onset puts the mice into 
negative energy balance, thus encouraging intake of a large meal at the beginning of the 
dark phase.  
• Ensure preload: Following a short fast, vanilla milkshake was given to encourage 
consumption of a large meal in a short period of time. Ensure is a highly palatable liquid, 
which mice quickly learn to drink in large quantities. 
• Acute restraint stress: Mice were subjected to 30 mins restraint before food intake 
measurements. As explained in the Introduction, this is a stimulus, which induces acute 
psychogenic stress and which may engage the central GLP-1 system.  
All food intake measurements were instigated at the onset of dark phase and intake was 
measured during the dark phase. This is the time of day mice forage (Ellacott et al. 2010; Jensen 
et al. 2013) and their activity increases, as I will demonstrate in Chapter 5.  




4.2.1 Activation of PPG neurons in vivo dramatically reduces feeding 
I set out to determine whether PPG neurons are sufficient to reduce dark onset feeding in mice, 
as was recently shown by Gaykema et al. (2017). To this end, I chemogenetically activated NTS 
PPG neurons and monitored feeding. By selectively expressing the Gαq-coupled DREADD HM3Dq 
in NTS PPG neurons, I was able to activate them in vitro and in vivo with CNO, as illustrated in 
Fig 4.1. I hypothesised that this activation leads to release of GLP-1 and co-transmitters, such as 
glutamate, from terminals (Zheng et al. 2015b), resulting ultimately in reduced food intake. This 
would confirm the sufficiency of PPG neurons to reduce food intake. 
 
NTS PPG neurons were infected with AAV2-FLEX-HM3Dq:mCherry or AAV1/2-FLEX-Perceval as 
control through bilateral, stereotaxic injection of 200 nl AAV into the NTS (Fig 4.2A). This led to 
clear expression of HM3Dq:mCherry or Perceval in PPG neurons only, visualized here by 
immunohistochemistry for either mCherry or Perceval (Fig 4.2B).  
Fig 4.1 Diagram illustrating the hypothesis for hypophagia following activation of NTS PPG neurons. 
Expression of HM3Dq receptor (In blue) on cell surface of PPG neurons allows activation using the 
selective drug CNO. This leads to release of GLP-1 (and co-transmitters) in forebrain nuclei. Here GLP-
1Rs are activated on downstream neurons resulting in decreased food intake. 









Fig 4.2 Selective expression of HM3Dq in NTS PPG neurons using viral gene delivery. A) The 
hypothesis described in Fig 4.1 was tested by injecting an AAV encoding HM3Dq receptor fused with 
mCherry (HM3Dq:mCherry) into the NTS. Left panel: Sagittal view of the stereotaxic injection. Right 
panel: Coronal section showing site of stereotaxic injection. Both adapted from Paxinos and Franklin’s 
‘The mouse brain in stereotaxic coordinates’ (Franklin and Paxinos 2008). B) Immunofluorescent 
images showing expression of HM3Dq:mCherry or Perceval in PPG neurons in the NTS. Top panels: 
HM3Dq:mCherry expression was detected using an anti-dsRed antibody, displayed in magenta. PPG 
neurons expressing GCaMP3 were detected using an anti-GFP antibody, shown in green. Bottom 
panels: Perceval was detected using an anti-GFP antibody, shown in green. PPG neurons expressing 
tdRFP were detected using an anti-dsRed antibody, shown in magenta. Scale bars: 100 µm. 
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Having successfully targeted the expression of HM3Dq to NTS PPG neurons, I verified in vitro 
that this approach allows activation of PPG neurons. PPG-Cre/GCaMP3 mice were injected with 
AAV2-FLEX-HM3Dq:mCherry into the NTS as shown in Fig 4.2A. As explained in Chapter 3, 
GCaMP3 is stably expressed from the Rosa26 locus in PPG neurons in these mice. Co-expression 
with HM3Dq made it possible to monitor intracellular [Ca2+] while activating HM3Dq with CNO. 
As demonstrated in Chapter 3, GCaMP3 fluorescence intensity positively correlates with firing 
rate of PPG neurons and can therefore be used as a surrogate marker for neuronal activity.  
Three weeks after injection, mice were anaesthetised and decapitated and brainstem slices 
were sectioned for in vitro Ca2+ imaging. HM3Dq-expressing cells were identified as mCherry-
positive throughout the NTS and overlapped with GCaMP3 expression. GCaMP3 expression was 
noticeably reduced in these sections as compared to non-transduced mice used for the 
h 
Fig 4.3 PPG neurons expressing HM3Dq increase intracellular [Ca2+] in response to CNO. A) 
Fluorescence intensity levels of one pseudocoloured, representative GCaMP3+/HM3Dq+ cell during 
baseline (top), superfusion with 1 µM CNO (middle), and after washout of CNO (Bottom). Blue 
corresponds to Fmin and red to Fmax as shown in the bar above the images. Scale bar: 10 µm. B) Traces 
(top panel) and heat map (bottom panel) showing 11 individual cells responding to 1 µM CNO with an 
increase in intracellular [Ca2+]. Top panel: Individual cells shown in grey and the average trace shown 
in green. Bottom panel: Heat map with blue denoting Fmin and red denoting Fmax showing the same 11 
cells as in the top panel responding to 1 µM CNO. Each cell is represented by a row in the map. 
Application of 1 µM CNO is indicated with a black bar and applies to both the top and bottom panel. 
The heat map pseudocolouring levels are indicated by the bar on the right.  
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recordings in Chapter 3. This was most likely due to overexpression of HM3Dq:mCherry and 
resulting downregulation of the expression of GCaMP3. However, with short incubation times 
after stereotaxic injection to limit overexpression (no more than 21 days), GCaMP3 was clearly 
detectable in brainstem slices.  
Fig 4.3A shows a representative, pseudocoloured GCaMP3-expressing cell responding to 1 µM 
CNO with an increase in intracellular [Ca2+]. Intracellular [Ca2+] increased in all 11 cells recorded 
here, as displayed in two different ways in Fig 4.3B. [Ca2+] peaked in the minutes following CNO 
application and subsequently declined, most likely due to Ca2+ buffering. Importantly, after CNO 
stimulation, intracellular [Ca2+] remained higher than baseline for most cells during the 
recording, suggesting the effect does not readily wash out. 
Having established that HM3Dq-expressing PPG neurons increase intracellular [Ca2+] in response 
to CNO in vitro, I next determined the effect of PPG neuron activation on feeding. Eight PPG-
Cre/tdRFP mice were injected into the caudal NTS (200 nl bilaterally) with either AAV2-FLEX-
HM3Dq:mCherry or AAV1/2-FLEX-Perceval as control. Perceval is a modified EGFP designed to 
detect changes in the ATP/ADP ratio. Since Perceval does not affect the activity of neurons it 
was used in this study as a control for viral expression (Berg et al. 2009; Tantama et al. 2013). 
Expression of the two transgenes was confirmed immunohistologically at the end of the 
experiment (Fig 4.2B). All animals expressed the expected transgene, no animals were excluded 
due to lack of expression.  
All animals received both 2 mg/kg CNO and vehicle. Prior to the food intake experiments, mice 
were habituated to i.p. injections of 5 ml/kg saline. On the day of the experiment, food was 
removed for three hours until dark onset. This mild fast was to ensure all mice had their first 
meal at dark onset. Mice were injected i.p. 30 mins before dark onset with either saline or 2 
mg/kg CNO. Food was returned at dark onset and intake measured at one and two hours after 
dark onset (Fig 4.4).  
Three-way mixed model ANOVA revealed no significant interaction, time x drug x virus (F(1, 6) = 
0.439, p=0.532), whereas there was a significant two-way interaction between drug and virus 
(F(1,2) = 22.92, p<0.0001). Two-way mixed-model ANOVA at both hour 1 and hour 2 revealed 
significant interactions between drug and virus (Hour 1: F(1, 6) = 17.19, p=0.006; Hour 2: F(1, 6) 
= 8.647, p=0.0259), suggesting i.p. injection of CNO affects food intake differently in control and 
HM3Dq-expressing mice.   




Importantly, Perceval and HM3Dq mice injected with saline ate similar amounts of chow in both 
hour 1 and hour 2 (p=0.30 and p=0.93, respectively), suggesting expression of HM3Dq does not 
affect food intake in the absence of stimulation with CNO. Similarly, i.p. injection of 2 mg/kg 
CNO had no effect on food intake in mice expressing the control virus, Perceval, at both hour 1 
(p=0.81) and hour 2 (p=0.82). In contrast, i.p. injection of 2 mg/kg CNO significantly reduced 
food intake in HM3Dq-expressing mice. In hour 1, activation of NTS PPG neurons reduced food 
intake by 94±6 % (p=0.0038). Similarly, food intake was reduced by 77±16 % in hour 2 (p=0.024). 
I draw three crucial conclusions from these data:  
1) The expression of HM3Dq in itself does not affect food intake, since there was no 
difference between chow consumption of HM3Dq and Perceval mice.  
2) CNO in itself does not affect chow intake, as there was no difference in chow intake 
between saline and CNO in the control group. This is an important observation 
considering a recent report that the CNO metabolite, clozapine, is the active ligand for 
HM3Dq (Gomez et al. 2017) and that clozapine may have off-target effects (MacLaren 
et al. 2016).  
3) Chemogenetic activation of PPG neurons dramatically reduces feeding in mice.  
To expand on these data, I injected another cohort of nine animals with AAV2-FLEX-
HM3Dq:mCherry only. Since expression of HM3Dq and i.p. injection of CNO do not affect food 
Fig 4.4 Chemogenetic activation of PPG neurons reduces dark onset feeding. 
Chow intake during the first hour (left panel) and second hour (right panel) 
after dark onset in mice expressing either HMD3q (green, N=4) or Perceval 
(grey, N=4) and injected i.p. with 2 mg/kg CNO or saline only. Data from mice 
are shown as individual data points and lines connect data from the same 
mouse. **p<0.01, ***p>0.001, n.s.: not significant. **p<0.01, ***p<0.001, 
n.s.: not significant according to Sidak’s multiple comparions test.  
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intake, the control group was omitted in this experiment. The study was performed following a 
counterbalanced, crossover design with each animal receiving both 2 mg/kg CNO and saline 
alone.  
  
Chow intake was significantly reduced up to four hours after dark onset (Fig 4.5). Repeated 
measures two-way ANOVA of data from the first four hours revealed a significant interaction 
between time and drug treatment (F(2,16)=5.626, p=0.0141) and Sidak’s multiple comparisons 
test yielded a statistically significant effect of CNO at one, two, and four hours (p=0.0005, 
p<0.0001, and p<0.0001, respectively, Fig 4.5A). NTS PPG activation reduced food intake by as 
much as 83±7 % in the first hour and some animals did not eat at all in the first four hours. 
Interestingly, the effect of CNO had disappeared the following day with cumulative daily chow 
intake unaffected by PPG activation (p=0.20, Fig 4.5B). These data suggest mice compensate 
following the initial decrease in chow intake. 
Analysis of the non-cumulative data revealed a transient decrease in dark phase food intake 
over the first four hours following PPG activation (Fig 4.6). Repeated-measures two-way ANOVA 
of the non-cumulative data revealed a significant effect of drug treatment (F(1,8)=17.31, 
p=0.0032) and of time (F(2,16)=20.62, p<0.0001), but no interaction between the two (F(2, 16) 
= 2.897, p=0.0844). PPG activation affected chow intake in the first (p=0.0005) and second 
(p=0.013) hour after dark onset, but the effect had faded during hours 3-4 (p=0.15) (Fig 4.6A). 
Fig 4.5 PPG neurons are sufficient to reduce food intake four hours into the dark phase. A) 
Mean cumulative chow intake 1, 2, and 4 hours into the dark phase following saline (black) or 
2 mg/kg CNO (green). Data are displayed as mean±SEM. B) Mean daily cumulative chow intake 
following saline (grey) or 2 mg/kg CNO (green) measured 21 hours after dark onset. Data from 
individual mice are shown as circles and paired data connected with lines. ***p<0.001, 
****p<0.0001, n.s.: not significant according to Sidak’s multiple comparisons test. 
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Interestingly, the effect appeared to reverse overnight (hours 5-21) so that mice ate 16±11 % 
more after being injected with CNO compared to saline, although this did not reach statistical 
significance (Fig 4.6B, p=0.17).  
These data demonstrate that PPG activation is a strong driver of hypophagia and that even when 
mice are most likely to eat, during the beginning of dark phase, activation of NTS PPG neurons 
is sufficient to dramatically reduce chow intake. 
4.2.2 Ablation of PPG neurons does not affect normal dark onset feeding 
Having established that activation of NTS PPG neurons is sufficient to decrease dark onset 
feeding in mice, I next investigated the necessity of NTS PPG neurons in the regulation of 
feeding. To this end, I employed two different models of PPG neuron inactivation: ablation and 
acute inhibition. I hypothesised that they would both increase food intake (Fig 4.7).  
As described in the Introduction, in the first approach NTS PPG neurons were ablated by 
inhibiting protein synthesis, ultimately leading to cell death (Fig 1.4). For this, I used a Cre-
dependent virus, AAV8-mCherry-FLEX-DTA, to express DTA selectively in PPG neurons. This virus 
also leads to expression of the fluorescent protein mCherry. All cells infected with the virus 
express mCherry, with the exception of PPG neurons. In these cells, Cre mediates homologous 
recombination, mCherry expression is turned off, and DTA expression is turned on (Wu et al. 
2014). This means only cells positive for Cre will die, allowing selective ablation of PPG neurons.  
 
Fig 4.6 Chow intake is reduced following PPG activation, but recovers overnight. A) Mean non-
cumulative chow intake at hours 1, 2, and 3-4 after onset of the dark phase following i.p. injection of 
2 mg/kg CNO (green) and saline (black). B) Mean overnight (hours 5-21) non-cumulative chow intake. 
Data are displayed as mean±SEM. Data from individual mice are shown as circles connected with lines. 
*p<0.05, ***p<0.001, n.s.: not significant according to Sidak’s multiple comparisons test. 
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The second model uses the inhibitory DREADD, HM4Di, to acutely inactivate PPG neurons 
(Armbruster et al. 2007). Expression of HM4Di is Cre-dependent, allowing selective expression 
in NTS PPG neurons. I use a virus, AAV2-FLEX-HM4Di:mCherry in which the fluorescent reporter 
mCherry is fused to HM4Di to facilitate identification of HM4Di-expressing cells. Both these 




I first confirmed that expression of DTA leads to selective ablation of NTS PPG neurons. To 
establish the time course of ablation following viral injections, three PPG-Cre/GCaMP3 mice 
were injected unilaterally with 50 nl AAV8-mCherry-FLEX-DTA. The mice were perfuse-fixed 
four, seven, or 14 days after injection and coronal brainstem sections were immunostained for 
both mCherry and the fluorescent marker for PPG neurons, GCaMP3.  
Fig 4.7 Hypotheses for the effect of PPG inactivation or ablation on feeding. Top panel: Ablation with 
AAV8-mCherry-FLEX-DTA leads to loss of NTS PPG neurons. This results in no release of GLP-1 or co-
transmitters in forebrain nuclei and increased food intake as compared to control mice. Bottom panel: 
In this model the inhibitory DREADD, HM4Di:mCherry, is selectively expressed in PPG neurons. 
Activation of HM4Di with CNO leads to inactivation of PPG neurons and reduced synaptic release of 
GLP-1 and co-transmitters. Ultimately, this blocks the hypophagic effect and leads to an increase in 
food intake as compared to control mice. 








Cells expressing mCherry were detected in the NTS as early as four days after injection (Fig 4.8). 
The expression was more diffuse at days 7 and 14, suggesting mCherry was reaching axonal and 
dendritic fibres around cell bodies. At day 4, many GCaMP3-expressing PPG neurons were still 
visible at the side of injection, despite surrounding cells clearly expressing mCherry. At day 7, 
very few GCaMP3-positive cells were seen on the side of injection and the contralateral side 
seemed to be affected as well with some mCherry expression visible. A similar pattern was seen 
at day 14, when all PPG neurons had been ablated on the side of injection and very few were 
visible on the contralateral side.  
No double-positive cells were observed, in agreement with the mechanism of the AAV8-
mCherry-FLEX-DTA described above. In PPG neurons, where Cre is present, mCherry expression 
is turned off while DTA expression is turned on through homologous recombination. The reason 
Fig 4.8 Time course of ablation of NTS PPG neurons with AAV8-mCherry-FLEX-DTA. Coronal sections 
from three PPG-Cre/GCaMP3 mice injected unilaterally into the NTS on the left side with 50-100 nl 
AAV8-mCherry-FLEX-DTA at day 0 and perfuse-fixed at day 4, 7, and 14, respectively. Top panel: 
Immunohistochemistry for GCaMP3 in green detecting PPG neurons in the NTS. Scale bar: 100 µm. CC: 
Central canal. Second from top panel: Immunohistochemistry for mCherry in magenta showing the 
spread of the AAV8-mCherry-FLEX-DTA virus from the injection site. Third from top panel: Composite of 
the first two panels showing an overlay of GCaMP3- and mCherry-positive cells in the NTS. Bottom panel: 
Inserts indicated in merged images. GCaMP3-positive cells are clearly seen at day 4, only a few at day 7, 
and none at day 14. Scale bar: 20 µm. Arrowheads point to GCaMP3-positive PPG neurons. 
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for no double-positive neurons is therefore that the AAV8-mCherry-FLEX-DTA has successfully 
infected cells throughout the NTS including PPG neurons, but that Cre expressed in PPG neurons 
has turned off mCherry expression. This also implies that DTA expression has been turned on in 
the same cells. The fact that the cells are still visible suggests that the DTA-mediated prevention 
of protein synthesis has yet to result in cell death at day 4. These data suggest that infection and 
expression from this virus happen within four days of injection and that PPG cells are successfully 
ablated within 14 days of incubation of the virus. Using the PPG ablation model, our laboratory 
has found that up to 80% of hypothalamic GLP-1 is lost following NTS PPG ablation, 
demonstrating that the PPG neurons are the main source of central GLP-1 (James E. Richards 
and Stefan Trapp, unpublished data).  
The data discussed above demonstrate that injection of AAV8-mCherry-FLEX-DTA leads to 
selective ablation of PPG neurons in the NTS. To investigate the effect of loss of NTS PPG neurons 
on food intake, I injected 14 PPG-Cre/RFP mice bilaterally with 250 nl of either AAV8-mCherry-
FLEX-DTA or AAV1/2-FLEX-Perceval as control.  
In 2011, Barrera et al. demonstrated that siRNA-mediated knock-down of GLP-1 in rat brainstem 
leads to increased body weight gain. Considering these results and the bulk of evidence for a 
role of central GLP-1 in satiety (Tang-Christensen et al. 1996; Turton et al. 1996; Larsen et al. 
1997b; Williams et al. 2009), I monitored body weight changes over 80 days following 
transduction with AAV8-mCherry-FLEX-DTA to determine whether loss of PPG neurons affects 
body weight.  




Following stereotaxic injections mice lose up to 10% bodyweight. Since this decrease in 
bodyweight happens mainly over the first day post-surgery, body weights were normalised to 
the first day after surgery. Keeping in mind that PPG neurons are still present four days after 
surgery (Fig 4.8), virus type should not have a phenotypic effect the first day following surgery. 
Body weight increased over 80 days to a similar degree for control and DTA mice (Fig 4.9A). 
Indeed, mixed-model two-way ANOVA revealed a significant main effect of time on bodyweight 
(F(25,300)=116.8, p<0.0001), but there was no difference in the body weight gain of control and 
DTA animals (F(1,12)=0.08578, p=0.7746). Accordingly, there was no significant difference in 
daily cumulative chow intake with control animals eating 4.66±0.3 g and DTA mice eating 
4.4±0.14 g (Fig 4.9B, unpaired t-test: p=0.45).  
Although no overall effects on bodyweight or daily food intake were observed, it is possible that 
the effect is only on early dark phase meals, as was seen in the case of PPG activation with 
HM3Dq (Fig 4.6). To investigate this possibility, I monitored normal, dark onset feeding of the 
same group of PPG-ablated and control mice (Fig 4.10).  
Fig 4.9 Ablation of NTS PPG neurons does not affect body weight or daily food intake. A) Mean 
relative bodyweight gain following injection of either AAV1/2-FLEX-Perceval (Control, grey, N=7) or 
AAV8-mCherry-FLEX-DTA (DTA, red, N=7). Bodyweights were normalised to the first day after 
surgery. One data point displaying mean±SEM every three days starting on day one. B) Mean daily 
cumulative food intake of AAV1/2-FLEX-Perceval (control, grey, N=7) or AAV8-mCherry-FLEX-DTA 
(DTA, red, N=6). Data from individual mice are shown as circles. n.s.: not significant. Data from one 
DTA mouse were excluded as an outlier as described in Materials and Methods. 




Cumulative food intake was unaffected by PPG ablation (Fig 4.10A). A mixed-model two-way 
ANOVA yielded no significant interaction between time and virus type (F(2,22)=0.5406, 
p=0.5900). There was a significant main effect of time (F(2,22)=124.7, p<0.0001) as expected 
from cumulative food intake data, but no main effect of virus type (F(1,11)=0.01224, p=0.9139). 
Similarly, analysis of the non-cumulative chow intake using mixed-model two-way ANOVA 
revealed no interaction between time and virus (F(2,22)=0.834, p=0.4476). There was a main 
effect of time (F(2,22)=8.845, p=0.0015), but again no effect of virus (F(1,11)=0.1472, p=0.7085) 
(Fig 4.10B). These data suggest loss of NTS PPG neurons does not affect feeding in mice.  
4.2.3 Acute inhibition of PPG activity has no effect on normal feeding 
Importantly, PPG ablation could have led to compensation over the three weeks of incubation, 
allowing the animal to rely on other satiety systems to regulate feeding. To rule out any 
confounding factors from such compensation, I also used an acute model of inactivation, as 
described in Fig. 4.7. I performed stereotaxic, bilateral injections of 250 nl AAV2-FLEX-EGFP or 
AAV2-FLEX-HM4Di:mCherry on 23 PPG-Cre/GCaMP3 and PPG-Cre/tdRFP mice. Mice belonged 
to an EGFP (control) group or an HM4Di group and received saline and CNO in a counterbalanced 
manner.  
Mice were perfuse-fixed following feeding studies and, as seen in Fig 4.11, there was clear 
expression of HM4Di:mCherry in PPG neurons in the NTS. This was seen in all animals, no animals 
Fig 4.10 Ablation of NTS PPG neurons does not affect dark onset feeding. A) Mean cumulative food 
intake 1, 2, and 4 hours after dark onset. Perceval (Control) data in black and DTA data in red. B) 
Normal dark onset feeding in Perceval (Control, grey) and DTA (red) mice. Summary data represent 
the mean±SEM. Data from individual mice are shown as circles. n.s.: Not significant. N=7 (control), 
N=6 (DTA). Data from one DTA mouse were excluded as described in Materials and Methods. 
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were excluded due to lack of expression of the desired transgene (HM4Di:mCherry or EGFP). 
Surprisingly, a few cells were found to be mCherry-positive without obvious expression of 
GCaMP3. As mentioned previously, overexpression of a virally-delivered transgene was found 
to reduce expression of the fluorescent reporter, GCaMP3 (see section 4.2.1). This could explain 
the lack of GCaMP3 expression in HM4Di-expressing cells. Importantly, I found no impact of this 
on phenotype both in vitro and in vivo. At higher magnification, the HM4Di:mCherry signal had 
a punctate morphology, suggesting some of the fusion protein was present in intracellular 
compartments (Fig 4.11). Patch-clamp electrophysiology confirmed that 1 µM CNO attenuated 
action potential firing in HM4Di-expressing PPG neurons (N=5 cells, experiments performed by 




Fig 4.11 Selective expression of HM4Di:mCherry in NTS PPG neurons. Immunofluorescence images 
showing expression of HM4Di:mCherry in PPG neurons in the NTS. HM4Di:mCherry expression was 
detected using an anti-dsRed antibody, displayed in magenta. PPG neurons expressing GCaMP3 were 
detected using an anti-GFP antibody and are shown in green. Low magnification images (scale bar: 
100 µm) are shown on the left. High magnification images (scale bar: 10 µm) are shown on the right. 
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Two weeks days after stereotaxic surgery, mice were habituated to i.p. injection and food intake 
measurements until the stress of handling no longer affected food intake and body weight 
(Ellacott et al. 2010). Following habituation, food intake was measured as before.  
Cumulative food intake did not vary between any of the groups and PPG inhibition had no effect 
on food intake (Fig 4.12A). There was no three-way interaction between virus, drug and time 
(Table 4.1, p=0.84). In addition, there were no significant two-way interactions and only one 
significant main effect was found: a main effect of time (p<0.0001) as expected from cumulative 
food intake data. There was also no effect of PPG inhibition on daily chow intake (Fig 4.12B).  
 
 
Fig 4.12 Acute inhibition of NTS PPG neurons does not affect cumulative food intake. A) EGFP (black 
and grey) and HM4Di-expressing (blue) mice were injected i.p. with 2 mg/kg CNO or saline 30 mins 
before dark onset and food intake was measured one, two, and four hours later. Cumulative data 
are shown here as mean±SEM. B) Daily food intake following 2 mg/kg CNO in EGFP (grey, N=10) and 
HM4Di (blue, N=12) mice. Data from individual mice are shown as circles and paired data connected 
with lines. One EGFP animal was excluded as an outlier as described in Materials and Methods. n.s.: 
not significant. 
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 Source of variability F statistic p-value Significance 
Time x Virus x Drug F(1.249, 26.229) = 0.074 p=0.841 n.s. 
Time x Virus F(1.1859, 40) = 0.058 p=0.933 n.s. 
Time x Drug F(1.249, 26.229) = 0.016 p=0.938 n.s. 
Virus x Drug F(1, 21) = 0.304 p=0.587 n.s. 
Time F(1.149, 24.123) = 132.918 p>0.001 *** 
Drug F(1, 21) = 0.002 p=0.964 n.s. 
Virus F(1, 21) = 1.188 p=0.288 n.s. 
Fig 4.13 shows the non-cumulative food intake data from the same experiment. In accordance 
with the data shown above there were no obvious differences between the groups. Control and 
HM4Di-expressing mice ate similar amounts of chow under both saline and CNO conditions. As 
with the cumulative data, there was no three-way interaction time x virus x drug, no two-way 
interactions were found and only one main effect: time (p<0.0001) (Table 4.2). These data 
provide two important conclusions:  
1) Expression of HM4Di in the absence of CNO does not affect feeding. 
2) Acute PPG inhibition has no impact on feeding during the dark phase.   
 
 
Table 4.1 Three-way mixed model ANOVA result of HM4Di cumulative data. Data failed Mauchly’s 
test of sphericity and Greenhouse-Geisser adjustment was applied. N=10 (EGFP), N=12 (HM4Di). One 
EGFP animal was excluded as an outlier as described in Materials and Methods. n.s.: not significant.  
Fig 4.13 Acute inhibition of NTS PPG neurons does not affect feeding. Non-cumulative chow intake 
during hour one, two and hours 3-4 after dark onset. Both EGFP (grey) and HM4Di (blue) mice were 
injected with 2 mg/kg CNO 30 mins before dark onset. N=10 (EGFP), N=12 (HM4Di). One EGFP animal 
was excluded as an outlier as described in Materials and Methods. n.s.: Not significant. 
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Source of variability F statistic p-value Significance 
Time x Virus x Drug F(1.390, 27.793) = 0.061 p=0.881 n.s. 
Time x Virus F(1.863, 37.266) = 0.389  p=0.666 n.s. 
Time x Drug F(1.390, 27.739) = 0.157 p=0.776 n.s. 
Virus x Drug F(1, 20) = 0.045 p=0.834 n.s. 
Time F(1.863, 37.266) = 31.341 p<0.001 *** 
Drug F(1, 20) = 0.045 p= 0.834 n.s. 
Virus F(1, 20) = 0.108 p=0.746 n.s. 
s 
The data presented here demonstrate that both chronic ablation and acute inactivation of NTS 
PPG neurons have little impact on food intake during the dark phase, suggesting PPG neurons 
do not play a role in the regulation of normal feeding. This was surprising, considering the robust 
effect of activation of PPG neurons on dark onset feeding. It is worth noting that activation with 
HM3Dq simply demonstrates the sufficiency of PPG neurons in suppressing food intake. It does 
not prove a role in physiological regulation of appetite. By inhibiting PPG activity in two different 
ways, I demonstrate here that PPG neuron activity is not necessary for regulation of normal food 
intake.  
4.2.4 PPG neurons regulate hyperphagia following a large meal 
I next wondered whether PPG neurons may need stimulation beyond normal feeding to be 
recruited. In rats, GLP-1-expressing neurons only become significantly activated following a very 
large meal (Kreisler et al. 2014; Kreisler and Rinaman 2016). I hypothesised that a large meal 
following a prolonged fast would engage the brain GLP-1 system. If correct, PPG inactivation 
would increase food intake under these conditions. To investigate this, DTA and control mice 
were food-deprived for 18 hours to induce energy deficiency and drive feeding. Chow was 
returned at dark onset and their intake was measured in the following hours as before.  
After a prolonged food-deprivation, mice ate larger meals than observed with a short fast of 
three hours. Following 18 hours without access to food, control animals ate 0.6±0.05 g chow in 
the first hour compared to 0.4±0.06 g when food-restricted only briefly (Fig 4.14 and Fig 4.10, 
respectively). Intriguingly, in the first hour, DTA animals ate 0.9±0.11 g with some animals eating 
as much as 1.2 g of chow (Fig 4.14). Two-way mixed model ANOVA of the non-cumulative data 
Table 4.2 Three-way mixed model ANOVA result of HM4Di non-cumulative data. Data failed 
Mauchly’s test of sphericity and the Greenhouse-Geisser adjustment was used. N=10 (EGFP), N=12 
(HM4Di). One EGFP animal was excluded as an outlier as described in Materials and Methods. n.s.: 
not significant.  
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yielded no significant interaction between time and virus (F(2, 22) = 0.7462, p=0.49) and there 
was no main effect of time (F(2, 22) = 0.3227, p=0.7276), suggesting intake was similar at all 
timepoints measured as displayed in Fig 4.14. However, there was a main effect of virus on 
feeding (F(1, 11) = 6.099, p=0.0311) with DTA animals eating on average 0.18 g more than 
control animals at each timepoint (hour 1, hour 2, and hours 3-4). The largest effect was seen in 
hour 1, where DTA animals ate 0.29±0.13 g more than control animals. These data suggest PPG 
ablated animals eat consistently more following a prolonged fast than control animals. 
 
Turning to the cumulative data, I found that the consistently higher intake over the first hours 
after dark onset resulted in PPG-ablated animals eating in total 0.54±0.22 g more than control 
animals over four hours (Fig 4.15A). Two-way mixed model ANOVA yielded no significant 
interaction (F(2, 22) = 1.81, p=0.19), but a significant main effect of time (F(2, 22) = 215.5, 
p<0.0001). As with the non-cumulative data, this analysis also revealed a significant effect of 
virus on feeding (F(1, 11) = 7.994, p=0.016), suggesting that at all timepoints DTA animals had 
significantly higher intake. In addition, daily chow intake was 0.83 g higher in DTA mice, although 
this did not reach significance (Fig 4.15B, p=0.056).  
Fig 4.14 Ablation of PPG neurons increases feeding after a prolonged fast. 
A) Food intake of Perceval (control, black, N=6) and DTA (red, N=7) mice 
following 18 hour fast at hours 1, 2 and 3-4 after dark onset. One control 
animal was excluded as an outlier as described in Materials and Methods. 
*p<0.05, main effect of virus according to two-way mixed-model ANOVA. 
There was no interaction (p=0.49) and no main effect of time (p=0.73). 




In conclusion, loss of NTS PPG neurons increases normal chow intake over several hours 
following refeeding after a long fast. These results point to a role for PPG neurons in the 
prevention of overconsumption. To confirm these findings in a model of acute PPG inhibition, I 
repeated this experiment in mice expressing HM4Di. Again, to encourage intake of a large meal, 
I food-deprived mice for 18 hours and injected (i.p.) them with 2 mg/kg CNO or saline 30 mins 
prior to dark onset.  
As in the previous experiment, control mice ate a large meal following a prolonged fast. EGFP 
mice injected with saline ate 0.85±0.1 g of chow (Fig 4.16), which was substantially more than 
the 0.37±0.05 g eaten following a brief fast of three hours (Fig 4.13). Similarly, HM4Di mice 
injected with saline ate 0.68±0.08 g of chow (Fig 4.16) as compared to 0.29±0.04 g after a shorter 
fast of three hours (Fig 4.13), demonstrating that a prolonged fast drives intake of a larger meal 
independent of the viral transgene expressed.  
 
Fig 4.15 Ablation of PPG neurons increases refeeding following prolonged 
fasting. A) Cumulative food intake of Perceval (control, black, N=6) and DTA (red, 
N=7) mice following 18-hour fast at one, two and four hours after dark onset. 
*p<0.05, main effect of virus according to two-way mixed-model ANOVA B) Daily 
chow intake (21 hours post dark onset) following 18 hours fast. Student’s t-test. 
One control animal was excluded as an outlier as described in Materials and 
Methods 





Source of variability F statistic p-value Significance 
Time x Virus x Drug F(2, 42) = 2.227 p=0.120 n.s. 
Time x Virus F(2, 42) = 1.063 p=0.355 n.s. 
Time x Drug F(2, 42) = 2.569 p=0.089 n.s. 
Virus x Drug F(1, 21) = 5.369 p=0.031 * 
Time F(2, 42) = 23.635 p<0.001 *** 
Drug F(1, 21) = 0.588 p= 0.452 n.s. 
Virus F(1, 21) = 0.838 p=0.370 n.s. 
s 
The effect of acute PPG inhibition on refeeding after a long fast was less pronounced and 
shorter-lived than that of chronic ablation (Fig 4.16 and Fig 4.14). There was no significant three-
way interaction between drug, time, and virus (Table 4.3, p=0.120). However, the analysis 
revealed a significant two-way interaction between virus and drug (p=0.031), suggesting the 
effect of CNO varies between EGFP- and HM4Di-expressing mice. This interaction is difficult to 
interpret independently of time, so I analysed each timepoint individually.  
Table 4.3 Three-way mixed model ANOVA result of HM4Di refeeding non-cumulative data. 
Data passed Mauchly’s test of sphericity. N=11 (EGFP) and N=12 (HM4Di). n.s.: not significant. 
Fig 4.16 The effect of PPG inhibition on hourly food intake following a long fast. A) Non-cumulative 
food intake of HM4Di mice following 18 hours fast. EGFP (grey, N=11) and HM4Di (blue, N=12) mice 
were injected with either saline or 2 mg/kg CNO and intake was measured at hours one, two and 
three-four after dark onset. In the event of a significant interaction virus x drug, main effects were 
tested post-hoc using Sidak’s multiple comparisons test. *p<0.05, n.s.: not significant according to 
Sidak’s multiple comparisons test or two-way mixed model ANOVA. 
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During hour 1, HM4Di mice ate 0.23±0.1 g more after PPG inhibition than after a saline injection 
(Fig 4.16 Hour 1). Two-way mixed-model ANOVA revealed a statistically significant interaction 
between virus and drug (F(1, 21) = 4.733, p=0.0411). At this timepoint, CNO did not affect food 
intake in the EGFP group (p=0.81). In contrast, HM4Di-expressing mice had significantly higher 
intakes after CNO compared to saline (p=0.038), demonstrating that inhibition of PPG neurons 
leads to increased food intake following a long fast. There were no significant interactions and 
no significant main effects on chow intake at hour 2 and hours 3-4 (Fig 4.16). These data suggest 
the effect of acute inhibition of PPG neurons on refeeding following a long fast is limited to the 
first hour following dark onset.  
To confirm the effect of PPG inhibition is sustained over several hours, I inspected the 
cumulative data. Intake was increased over four hours after dark phase in the PPG inhibited 
animals as compared to HM4Di animals injected with saline only (Fig 4.17A). In contrast, EGFP 
animals injected with CNO did not increase their food intake. 
There was no three-way interaction between virus, drug, and time (Table 4.4, p=0.194). There 
was, however, two significant two-way interactions: time x drug (p=0.043) and drug x virus 
(p=0.039). I therefore conducted further two-way ANOVAs at each timepoint, which revealed a 
significant interaction between virus and drug at hour 1, corresponding to what was seen in the 
non-cumulative data in Fig 4.16 ((F(1, 21) = 4.733, p=0.0411). There was no difference two and 
four hours after dark onset, suggesting the effect of PPG inhibition is not sustained over several 
hours. Similarly, there was no effect of PPG inhibition on 21-hour chow intake (Fig 4.17B).  
These results support the data from the previous experiment, in which ablation of NTS PPG 
neurons increased dark onset feeding following a long fast. Based on these sets of data, I 
conclude that, although PPG neurons may not be important in the regulation of normal feeding, 
a large meal following a long fast recruits NTS PPG neurons to suppress feeding. Importantly, 
both PPG ablation and acute inhibition resulted in increased chow intake following a long fast. 
 





Source of variability F statistic p-value Significance 
Time x Virus x Drug F(1.488, 31.257) = 1.761 p=0.194 n.s. 
Time x Virus F(1.359, 28.541) = 1-486 p=0.240 n.s. 
Time x Drug F(1.488, 31.257) = 3.859 p=0.043 * 
Virus x Drug F(1, 21) = 4.859 p=0.039 * 
Time F(1.359, 28.541) = 299.694 p<0.001 *** 
Drug F(1, 21) = 0.057 p= 0.814 n.s. 
Virus F(1, 21) = 0.303 p=0.588 n.s. 
s 
4.2.5 PPG ablation blunts preload-induced hypophagia 
From the data shown here, we know that PPG neurons are sufficient but not necessary for 
suppression of feeding during dark onset. It is also clear from two experiments involving 
inhibition of endogenous PPG activity that prolonged food-deprivation can encourage the intake 
of a large meal and that this may recruit PPG neurons to limit overeating. The next experiment 
Fig 4.17 The effect of PPG inhibition on food intake following a long fast. A) Cumulative food intake 
of HM4Di mice following 18-hour fast. EGFP (N=11, black and grey) and HM4Di (N=12, light and dark 
blue) mice were injected with either saline (grey and light blue) or 2 mg/kg CNO (black and dark blue) 
and intake was measured at one, two and four hours after dark onset. B) Daily chow intake (21 hours 
post dark onset) following 18 hours fast in EGFP (grey, N=11) and HM4Di (blue, N=12) animals. 
*p<0.05 according to Sidak’s multiple comparisons test. n.s.: no significant interaction or main effects 
according to two-way ANOVA. 
Table 4.4 Three-way mixed model ANOVA result of HM4Di refeeding cumulative data. Data did not 
pass Mauchly’s test of sphericity and the Greenhouse-Geisser adjustment was used. N=11 (EGFP) and 
N=12 (HM4Di). n.s.: not significant. *p<0.05 ****p<0.0001. 
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confirms that a large meal activates NTS PPG neurons. I encouraged intake of a large meal, in 
this experiment not by fasting the mice for a long time, but by providing them with highly-
palatable diet before measuring chow intake. Ensure liquid diet tastes of vanilla and mice are 
quickly habituated to drinking a large amount over a short period of time.  
To start, animals were trained to consume a large preload of Ensure. DTA and control mice were 
fasted for three hours and given Ensure in place of drinking water for 15 mins at dark onset. 
During the first training session, DTA and control mice drank 0.45±0.06 g of Ensure (Fig 4.18A). 
At this stage, there was no difference in the consumption of Ensure between the two groups 
(p=0.31). The intake increased during the following three sessions and stabilised at 1.4±0.04 g. 
After stabilisation of preload intake, there was still no difference in the intake between DTA and 
control mice (Fig 4.18B, p=0.70).  
Following 15 mins of Ensure access, the liquid diet was removed and water and chow returned 
to the cages. An hour later, chow intake was measured. Intake was lower in the control group 
than usually seen for the first hour of dark phase with control mice eating roughly half their 
normal intake (Fig 4.18C, 0.21±0.06 g in comparison with 0.4±0.06 g as in Fig 4.10). In contrast, 
DTA animals ate significantly more than control animals with 0.61±0.1 g of chow eaten in the 
hour following the Ensure preload (Fig 4.18C, p=0.0052).  
I conclude from these data that a large meal at dark onset decreases food intake in the following 
hour as would be expected if satiety systems are engaged. However, this decrease was only seen 
in control animals. In animals lacking NTS PPG neurons, intake was higher. Interestingly, the 
 
Fig 4.18 PPG ablation increases chow intake following a preload. A) Training of control (black, N=7) 
and DTA (red, N=7) mice to drink Ensure over 15 mins at dark onset. B) 15 mins Ensure intake in control 
(grey) and DTA (red) mice at dark onset. n.s.: no significant interaction or main effects according to 
two-way ANOVA. C) Chow intake one hour after 15 mins Ensure preload. **p<0.01 according to 
Student’s t-test. 
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intake of Ensure, a highly palatable diet, was itself unaffected by the lack of NTS PPG neurons, 
which could suggest that these neurons are not involved in the regulation of hedonic feeding in 
mice, although this would need further experimental evidence. Importantly, these results 
confirm the previous study in which DTA mice were less sensitive to satiety elicited by the intake 
of a large meal after a long fast. Taken together this suggests NTS PPG neurons could play a role 
in the prevention of overeating, and may be less essential in the control of normal feeding.   
4.2.6 Central GLP-1 drives stress-induced hypophagia 
Evidence is mounting for a role of central GLP-1 in the regulation of stress (Ghosal et al. 2013; 
Maniscalco et al. 2015; Holt and Trapp 2016; Kreisler and Rinaman 2016). When subjected to 
acute restraint stress, rats suppress their food intake significantly (Krahn et al. 1990). 
Interestingly, restraint stress is known to activate GLP-1-producing neurons in the rat 
(Maniscalco et al. 2015). On this basis, I hypothesised acute restraint stress activates NTS PPG 
neurons which release GLP-1 into forebrain nuclei leading to a reduction in food intake (Fig 4.19).  
 
To test this hypothesis, I returned to the acute inhibition model using HM4Di. The same 23 mice 
expressing either HM4Di or EGFP were exposed to acute stress in the following way: Food was 
removed three hours before dark onset. 45 mins prior to dark onset all animals were injected 
with 2 mg/kg CNO. The experiment was designed without a control injection of saline so as to 
only expose animals to stress once. Importantly, earlier experiments confirmed that injection of 
2 mg/kg CNO alone does not affect chow intake in mice expressing a control virus (Fig 4.4 and 
4.13). Half an hour before dark onset (15 mins after the injection of 2 mg/kg CNO), mice were 
either left undisturbed in their cages or exposed to restraint stress. For stress exposure, mice 
were placed tightly in transparent conical plastic bags with a breathing hole at the front as 
described in Materials and Methods. Their movement was restricted this way for 30 mins. At 
dark onset, all mice were returned to their cages and given chow.  
Fig 4.19 Hypothesis of PPG neuron control of stress-induced hypophagia. Restraint stress for 30 
mins activates NTS PPG neurons, which then release GLP-1 (and co-transmitters) into forebrain 
nuclei. Activation of GLP-1 and co-transmitter receptors ultimately leads to a decrease in food intake. 
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Acute restraint stress was sufficient to reduce dark onset feeding over four hours in the EGFP 
group (Fig 4.20A). A two-way within-subjects ANOVA revealed a significant effect of both time 
(F(2, 16) = 123.9, p<0.0001) and stress (F(1, 8) = 14.14, p=0.0055), but no interaction between 
the two (F(2, 16) = 0.4299, p=0.6578). In contrast, HM4Di mice exposed to stress on average did 
not reduce their intake with mice eating only 4±8 % less at each of the three timepoints following 
restraint stress (Fig 4.20A). Indeed, a two-way within-subjects ANOVA revealed a significant 
effect of time (F(2, 22) = 134.5, p<0.0001), but no effect of stress (F(1, 11) = 0.8684, p=0.37) and 
no interaction between the two (F(2, 22) = 0.212, p=0.81). These data suggest that acute stress 
does not suppress feeding in the absence of PPG activity.  
 
To further investigate at which timepoints the effect of PPG inhibition is most pronounced, I 
investigated the non-cumulative data (Fig 4.21). Three-way ANOVA did not reveal a significant 
interaction between time, virus, and stress (Table 4.5, p=0.51). There was however a significant 
two-way interaction between stress and time (Table 4.5, p=0.041).  
At hour 1, there was a significant interaction between stress and virus (F(1, 19) = 4.906, 
p=0.0392). Acute stress suppressed food intake in EGFP mice by 50±8 % (p=0.0008). In contrast, 
there was no effect of stress in the HM4Di group in the first hour (p=0.2516). There was no 
interaction between stress and virus at hours 2 and 3-4 (F(1, 19) = 0.09128, p=0.7658 and F(1, 
18) = 0.08055, p=0.7798, respectively) and the effect of stress had disappeared in hour 2 and 
hours 3-4 (F(1, 19) = 1.164, p=0.2941 and F(1, 19) = 0.05775, p=0.8127, respectively). 
Fig 4.20 Acute stress reduces food 
intake in control animals, an effect 
which was attenuated in PPG inhibited 
mice. 30 mins restraint stress induced 
clear hypophagia sustained over four 
hours in EGFP mice (in grey and black, 
N=9), but not in HM4Di (light and dark 
blue, N=12) mice. Data from two EGFP 
mice were as outliers as described in 
Materials and Methods. **p<0.01, n.s.: 
not significant, main effect of stress 
(two-way ANOVA). 





The data shown here suggest that during the first hour following acute stress, PPG activity is 
necessary for suppression of feeding. Since there was no effect of acute stress on food intake at 
hours 2 and 3-4 it is difficult to determine whether PPG inhibition would have an effect at those 
timepoints. These data encourage further exploration of the involvement of NTS PPG neurons 
in the regulation of stress-induced hypophagia.  
Source of variability F statistic p-value Significance 
Time x Virus x Stress F(1.583, 30.08) = 0.625 p=0.506 n.s. 
Time x Virus F(1.581, 30.031) =2.654 p=0.098 n.s. 
Time x Stress F(1.583, 30.08) = 3.869 p=0.041 * 
Virus x Stress F(1, 19) = 2.029 p=0.171 n.s. 
Time F(1.581, 30.031) = 15.970 p<0.0001 **** 
Stress F(1, 19) = 3.714 p= 0.069 n.s. 
Virus F(1, 19) = 0.396 p=0.537 n.s. 
s 
Table 4.5 Three-way mixed model ANOVA result of HM4Di and EGFP non-cumulative data under 
acute stress. Data from hour 1, hour 2, and hours 3-4. The data failed the test of sphericity and the 
Greenhouse-Geisser adjustment was used. N=9 (EGFP), N=12 (HM4Di). Data from two EGFP mice 
were excluded as outliers as described in Materials and Methods. n.s.: not significant.  
Fig 4.21 PPG inhibition suppresses stress-induced hypophagia. Non-cumulative data from hours 1, 
2, and 3-4 after onset of dark. EGFP (grey, N=9) and HM4Di (blue, N=12) mice were left undisturbed 
(-) or exposed to acute restraint stress for 30 mins prior to dark phase. All animals were injected with 
2 mg/kg CNO. Data from two EGFP mice were excluded as outliers as described in Materials and 
Methods. In the event of a significant interaction stress x virus, effects were tested using Sidak’s 
multiple comparisons test. n.s.: not significant. *p<0.05, ***p<0.001. 
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Until this point, I have addressed the question of the physiological role of NTS PPG neurons in 
the regulation of food intake. I have explored different types of feeding: normal dark onset chow 
intake, intake following a prolonged fast, intake after a large preload of liquid diet, and intake 
following acute restraint stress. I found that NTS PPG neurons are not involved in regulation of 
normal feeding, but that after certain challenges, such as a very large meal or following acute 
stress, PPG neurons play a role in satiety.  
4.2.7 Neurons in the dLS express GLP-1R 
Having revealed a possible role for PPG neurons in stress-induced hypophagia, I was interested 
in the relevant downstream targets of PPG neurons. As discussed in the Introduction, PPG 
neurons project widely and GLP-1Rs are found throughout the brain. Of particular interest for 
this study was the dLS, due to its established involvement in the regulation of stress, fear, and 
anxiety (Reis et al. 2010; Singewald et al. 2011; Anthony et al. 2014) and its ability to suppress 
feeding in response to GLP-1 (Terrill et al. 2016).  
To investigate the importance of dLS GLP-1Rs in stress-induced hypophagia, I used another 
transgenic mouse strain, GLP-1R-Cre/tdRFP, which expresses Cre under the control of the GLP-
1R promoter (Richards et al. 2014; Cork et al. 2015). In these mice, GLP-1R-expressing cells also 
produce Cre and consequently the fluorescent reporter tdRFP (Luche et al. 2007) as explained 
in the Introduction. This model allows both visualisation of these cells via tdRFP and selective 
transgene expression using Cre-dependent viruses. We have previously shown that GLP-1R-
expressing cells are located throughout the dLS (Cork et al. 2015).  
To be able to further characterise these cells, anatomically and functionally, I created and 
produced a rAAV encoding the GCaMP3 open reading frame (ORF) in a Cre-dependent manner. 
The GCaMP3 ORF was cloned into the Cre-dependent plasmid, pAAV-CBA-FLEX (Murray et al. 
2011) as shown in Fig 4.22. 




rAAV particles were packaged in AD293T cells and purified on a heparin column as described in 
Materials and Methods. The purified virus was injected into the NTS of PPG-Cre/tdRFP mice to 
confirm Cre-dependent expression. Images in Fig 4.23 are representative images from live 
brainstem slices showing four tdRFP- and GCaMP3-expressing cells in the NTS. Expression of 
tdRFP filled the cell bodies of PPG neurons in the NTS.  As with the transgenic PPG-Cre/GCaMP3 
mouse, GCaMP3 expression was seen throughout the cytosol and was excluded from the 
nucleus (Fig 4.23). There was no expression of GCaMP3 in tdRFP-negative cells. 
 
To confirm functionality of the GCaMP3 construct, I exposed in vitro brainstem slices to 100 µM 
glutamate and monitored GCaMP3 fluorescence intensity as a surrogate marker for neuronal 
Fig 4.22 Cloning strategy for creating Cre-dependent pAAV-FLEX-GCaMP3. The GCaMP3 ORF was 
amplified from PPG-Cre/GCaMP3 brainstem tissue. Restriction enzyme sites were incorporated at 
the time of ORF amplification. EcoRV was added to the 5’ end, whereas EcoRI was added to the 3’ 
end of the amplicon. The GCaMP3 ORF was ligated into the backbone so that the ORF was in the 
reverse orientation with relation to the promoter ensuring that no functional GCaMP3 protein would 
be produced in the absence of Cre. In the presence of Cre, two recombination events between lox 
sites lead to inversion of the GCaMP3 ORF and successful expression of the protein. Sequencing of 
the flanking regions and insert confirmed correct (reverse) orientation of the insert. 
Fig 4.23 Selective expression of AAV1/2-FLEX-GCaMP3 in NTS PPG neurons. Live brainstem slice 
with four cells co-expressing the fluorescent reporter tdRFP (red, left) and the viral transgene 
GCaMP3 (green, right). GCaMP3 expression was strongest in the cytoplasm and was largely excluded 
from the nucleus. Scale bar: 10 µm.  
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activity. Fig 4.24A shows a representative cell responding to 100 µM glutamate with an increase 
in intracellular [Ca2+]. As seen in Fig 4.24B, fluorescence intensity decreased after washout of 
glutamate. However, cytosolic [Ca2+] did not immediately return to baseline. The response to 
glutamate was biphasic with an initial peak in fluorescence followed by a slight decrease and a 
second smaller peak. Increases in intracellular Ca2+ were observed in five independent PPG 
neurons with a median peak response of 0.7 ΔF/F0, confirming that expression of GCaMP3 from 
a viral vector can be used to monitor intracellular [Ca2+] as seen with the transgenic model PPG-
Cre/GCaMP3 in Chapter 3.  
 
  
Next, I set out to investigate the properties of GLP-1R-expressing neurons in the dLS. I first 
confirmed that GCaMP3 can be successfully expressed from the viral vector in dLS GLP-1R-
expressing neurons. I unilaterally injected GLP-1R-Cre/tdRFP mice with AAV1/2-FLEX-GCaMP3 
into the dLS. Three weeks days later, the mice were transcardially perfuse-fixed and coronal 
sections were stained for both tdRFP and GCaMP3. Fig 4.25 shows the overlapping expression 
of tdRFP and GCaMP3 at two sites of the dLS along the rostrocaudal axis. At both sites, dLS GLP-
1R-producing neurons were expressing GCaMP3. Not all tdRFP positive neurons were also 
Fig 4.24 Representative PPG neuron responding to 100 µM glutamate with an increase in 
intracellular [Ca2+]. A) Images of live brainstem slice with one pseudocoloured PPG neuron 
transduced with AAV1/2-FLEX-GCaMP3. During baseline (i. Baseline), glutamate (ii. 100 µM glut) 
and after washout of glut (iii. Wash). Scale bar: 10 µm. B) Trace showing fluorescence intensity 
changes of cell in A). i, ii and iii indicate timepoints shown in A). I.U.: Intensity units. C) Relative 
change in fluorescence intensity from baseline following stimulation with 100 µM glutamate in 
five cells from one mouse shown as individual data points. The line indicates the median. 
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positive for GCaMP3, in particular those in the more dorsal part of the dLS, suggesting the virus 
had not spread throughout the entire dLS.  
A few neurons were found to be GCaMP3-positive, but tdRFP-negative. The Cre-dependence of 
GCaMP3-expression from the AAV1/2-FLEX-GCaMP3 construct was confirmed both in HEK293 
cells in vitro and in sections from animals stereotaxically injected into the NTS with AAV1/2-
FLEX-GCaMP3, suggesting this is not the cause of GCaMP3 expression in cells seemingly not 
expressing GLP-1R. Rather I propose that overexpression of a virally delivered transgene leads 
to a decrease in expression of the other fluorescent reporter. I have observed this phenomenon 
using several different constructs. As mentioned previously, when discussing the expression of 
HM4Di:mCherry in PPG neurons, this could imply that transgene overexpression from viral 
particles leads to suppression of expression of other proteins. The implications for cell function 
are not known, although both PPG and dLS GLP-1R cells were still responsive to activation and I 
have not observed any in vivo phenotypes of viral transduction (Fig 4.24 and 4.26).  
  S
Fig 4.25 Selective expression of AAV1/2-FLEX-GCaMP3 in dLS GLP-1R neurons. Immunostaining of GLP-
1R-expressing neurons transduced with AAV1/2-FLEX-GCaMP3. Images were taken of both the rostral 
and caudal dLS. The fluorescent reporter for GLP-1-expressing cells, tdRFP, was detected using an anti-
dsRed antibody and is pseudocoloured in magenta. Cre-dependent GCaMP3 expression from AAV1/2-
FLEX-GCaMP3 was detected using an anti-GFP antibody and is pseudocoloured in green. Merged images 
are seen on the right. White colour indicates overlap of magenta and green. Scale bar: 100 µm. 
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In vitro calcium imaging was performed on GLP-1R-expressing neurons in the dLS with the final 
aim of determining the responsiveness of these neurons to GLP-1 in vitro. GLP-1R-Cre/tdRFP 
mice were unilaterally injected into the dLS with AAV1/2-FLEX-GCaMP3. Three weeks later, live 
brainstem sections were obtained and in vitro Ca2+ imaging was performed. Sections were 
superfused with ACSF and exposed to 15 mM KCl for 15 s to induce robust depolarisation.  
 
Fig 4.26A shows a dLS GLP-1R-expressing neuron responding to 15 mM KCl with an increase in 
intracellular [Ca2+]. Following washout of KCl intracellular [Ca2+] decreased to levels lower than 
baseline, presumably due to Ca2+ buffering, although some contribution from bleaching cannot 
be excluded. In Fig 4.26B these changes in intracellular [Ca2+] are clearly seen with 15 mM KCl 
stimulating a rise in intracellular [Ca2+]. After washout of KCl, intracellular [Ca2+] quickly 
decreased to a level lower than baseline and slowly recovered towards baseline. Intracellular 
[Ca2+] was recorded from four different dLS GLP-1R neurons, which all exhibited similar 
responses to 15 mM KCl with a median peak response of 0.29 ΔF/F0. These data demonstrate 
that viral delivery of AAV1/2-FLEX-GCaMP3 is a useful tool to investigate the cellular properties 
of dLS GLP-1R-expressing neurons. Future experiments should assess the response to GLP-1.  
Fig 4.26 In vitro Ca2+ imaging of dLS GLP-1R-expressing neurons. A) One 
representative, pseudocoloured dLS GLP-1R-expressing neuron transduced with 
AAV1/2-FLEX-GCaMP3. Fluorescence intensity is shown before (i. Baseline), during (ii. 
15 mM KCl) and after washout of KCl (iii. Wash). Scale bar: 10 µm. B) Trace showing 
fluorescence intensity changes of cell in A). i, ii and iii indicate timepoints shown in A). 
I.U.: Intensity units. C) Relative change in fluorescence intensity from baseline following 
stimulation with 15 mM KCl in four individual cells shown as data points. The line 
indicates the median. 
Chapter 4 – The physiological role of PPG neurons in food intake 
113 
 
4.2.8 Endogenous GLP-1 in the dLS mediates stress-induced hypophagia 
We know from the previous sections that inhibition of NTS PPG neuron activity attenuates the 
hypophagia following acute restraint stress (Fig 4.20 and Fig 4.21). Next, I investigated whether 
GLP-1 released into the dLS mediates this hypophagia. The following experiments were 
conducted at Florida State University in collaboration with Dr Diana Williams. I implanted 
unilateral cannulae into the dLS as described in Materials and Methods and hypothesised that 
by inhibiting GLP-1Rs in the dLS, I could attenuate the suppression in food intake following acute 
stress (Fig 4.27).  
As in previous experiments, mice were exposed to restraint stress once. Consequently, the study 
was a counter-balanced mixed-model design, with drug infusion as the between-subject factor 
and stress exposure as the within-subject factor. Control mice had infusions of saline and 
confirmed the ability of acute stress to suppress feeding, a well-known phenomenon (Ellacott et 
al. 2010; Maniscalco et al. 2015). The experimental group received infusions of 10 µg Ex9.  
 
Cannula placements were verified at the end of the experiment and only mice with correct 
placements into the dLS were included in the final analysis. A representative image from one 
cannulated mouse is shown in Fig 4.28. Damage from the injector is clearly seen on the right 
hand side at the most dorsal part of the dLS just ventral of the corpus callosum (arrow).  
Fig 4.27 Hypothesis for the role of dLS GLP-1 in the hypophagic response to acute stress. 30 mins 
restraint stress leads to activation of PPG neurons in the caudal brainstem. This results in release of 
GLP-1 into the dLS. Activation of downstream GLP-1R-expressing neurons (GLP-1R) results in 
suppression of food intake. I hypothesise that this hypophagia can be blunted by infusing the GLP-1R 
antagonist Ex9 into the dLS. 









Fig 4.28 Representative cannula placement for infusions into the dLS. Representative image at 4x 
(left) and 10x (right, inset) magnification. Sections were stained with thionin and images captured on 
a brightfield microscope. Tissue damage from the injector is indicated with a black arrow just ventral 
of the corpus callosum. dLS: dorsal lateral septum; LV: lateral ventricle. 
Fig 4.29 Cannula placements for infusions into the dLS. Schematics of 
forebrain sections containing the dLS and indicating successful targeting of 
dLS with infusions of either saline (control mice, n=5, green) or Ex9 (Ex9 mice, 
n=7, yellow). Numbers refer to rostrocaudal distance from Bregma with 
positive numbers being rostral and negative being caudal of Bregma. 
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The most ventral damage to tissue created by the injector was located in each mouse. Fig 4.29 
shows a schematic of the injector sites in mice included in the final analysis. Data were included 
from mice with injector damage in the dLS between -0.34 mm and +0.74 mm from Bregma. Five 
control and three Ex9 mice were excluded on the basis of incorrectly placed cannula 
implantations.   
On each experimental day, mice were fasted for three hours prior to dark onset. Saline or Ex9 
were infused 60-45 mins prior to dark onset. Mice were exposed to restraint stress 15 mins later 
or left undisturbed in their cages. At dark onset, chow was returned. Restraint stress induced a 
clear reduction in food intake at hours 1, 2, and 3-4 after dark onset in both saline and Ex9-
infused mice, confirming again the ability of acute stress to reduce food intake (Fig 4.30). I noted 
that acute stress had a more sustained suppressive effect on feeding in the experiments 
conducted at Florida State University than the ones described in section 4.2.5. This is most likely 
due to differences in the environment and the conical bags used to induce stress. 
There was a significant three-way interaction, stress x time x drug treatment (Table 4.6, p=0.042) 
and a significant two-way interaction between drug and stress at hours 5-21 (F(1, 10) = 6.052, 
p=0.0337). At this timepoint, stress significantly suppressed intake in saline-treated mice 
(p=0.0049), but failed to affect intake in the Ex9-infused group (Fig 4.30, p=0.60). There were no 
significant two-way interactions at hours 1, 2, and 3-4. Ex9 infusions had no effect on chow 
intake in the absence of stress (p=0.35). These data demonstrate that suppression of 
endogenous GLP-1 in the dLS does not affect normal feeding, but attenuates the hypophagic 
response to acute stress at later timepoints. 





Fig 4.30 Inhibition of dLS GLP-1Rs attenuates stress-induced hypophagia. 
Effect of restraint stress on non-cumulative food intake at hours 1, 2, 3-4, and 
5-21 after dark onset. saline- (grey) and Ex9-infused (magenta) mice were left 
undisturbed (-) or exposed to acute restraint stress for 30 mins prior to dark 
phase. N=5 (Saline), N=7 (Ex9). Two-way mixed-model ANOVA was conducted 
at each timepoint. In the event of a significant interaction stress x drug, main 
effects were tested post-hoc using Sidak’s multiple comparisons test. **p<0.01. 
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This conclusion was supported by the cumulative data from the same experiment (Fig 4.31A). 
Acute restraint stress induced hypophagia in saline-infused animals. Food intake remained 
suppressed overnight (4.31B). The suppression was more pronounced in saline-infused than 
Ex9-infused mice. In support, there was a significant three-way interaction time x stress x drug 
treatment (Table 4.7). There were no significant interactions between stress and drug treatment 
at one, two, and four hours. There was however a significant main effect of stress at all these 
timepoints, suggesting stress reduces food intake in both saline and Ex9 mice at the beginning 
of dark phase. In contrast, at 21 hours after dark onset, there was a significant interaction 
between stress and drug (F(1, 10) = 6.943, p=0.0249). At this late timepoint, there remained an 
intake-suppressive effect of stress in the saline-infused mice (Fig 4.31B, p=0.0009). In contrast, 
mice infused with Ex9 exhibited no hypophagia at 21 hours (p=0.15).  
These results demonstrate that unilateral infusion of the GLP-1R antagonist, Ex9, into the dLS 
attenuates stress-induced hypophagia in mice, suggesting endogenous GLP-1 within the dLS is 
involved in suppression of feeding in response to stress.  
Source of variability F statistic p-value Significance 
Time x Drug x Stress F(1.250, 12.496) = 4.792 p=0.042 * 
Time x Drug F(1.5472, 14.719) =0.295 p=0.682 n.s. 
Time x Stress F(1.250, 12.496) = 7.975 p=0.041 n.s. 
Drug x Stress F(1, 10) = 6.943 p=0.025 * 
Time F(1.472, 14.719) = 205.549 p<0.0001 **** 
Stress F(1, 10) = 26.715 P<0.0001 **** 
Drug F(1, 10) = 1.157 p=0.307 n.s. 
s 
Table 4.6 Three-way mixed model ANOVA result of Ex9 and saline-infusions under acute stress - non-
cumulative data. Data from hour 1, hour 2, hours 3-4, and hours 5-21. Data failed the test of sphericity 
and the Greenhouse-Geisser adjustment was used. N=5 (saline), N=7 (Ex9). n.s.: not significant. 





Source of variability F statistic p-value Significance 
Time x Treatment x Stress F(1.172, 11.720) = 6.444 p=0.023 * 
Time x Treatment F(1.320, 13.202) =0.729 p=0.446 n.s. 
Time x Stress F(1.172, 11.720) = 19.515 p=0.001 ** 
Treatment x Stress F(1, 10) = 5.340 p=0.043 * 
Time F(1.320, 13.203) = 437.298 p<0.001 **** 
Stress F(1, 10) = 35.069 P<0.001 **** 
Treatment F(1, 10) = 2.424 p=0.151 n.s. 
s 
Fig 4.31 Infusion of Ex9 into the dLS attenuates the hypophagic response to acute restraint stress. 
Mice were infused into the dLS with either saline (N=5) or Ex9 (N=7) and subsequently exposed to 30 
mins restraint stress or left in their cages. A) Acute stress reduced cumulative food intake over 4 hours 
in animals infused with saline, but not in animals infused with Ex9. B) Daily (21 hours) cumulative food 
intake was significantly reduced following acute stress in animals infused with saline into the dLS. 
Inhibition of dLS GLP-1Rs attenuated the stress-induced hypophagia resulting in no effect of stress on 
daily food intake. Main effects were tested post-hoc using Sidak’s multiple comparisons test. 
***p<0.001.  
Table 4.7 Three-way mixed model ANOVA result of Ex9 and saline-infusions under acute stress - 
cumulative data. Data from hour 1, hour 2, hours 3-4, and hours 5-21. Data failed the test of sphericity 
and the Greenhouse-Geisser adjustment was used. N=5 (saline), N=7 (Ex9). n.s.: not significant. 




Given the importance of both NTS PPG neurons and dLS GLP-1Rs in the hypophagic response to 
stress, I was interested in the downstream targets of this stress circuit. Coronal forebrain 
sections from GLP-1R-Cre/tdRFP mice previously transduced with AAV1/2-FLEX-GCaMP3 were 
immunostained for tdRFP and GCaMP3 (Fig 4.32).  
As shown in Fig 4.25, GCaMP3 was clearly expressed in dLS GLP-1R-expressing neurons. 
GCaMP3-positive non-varicose axons extended through the intermediate LS and terminated in 
the preoptic area (POA). GCaMP3-positive axons were also detected in the lateral hypothalamus 
(LH) (Fig 4.32), whereas no GCaMP3-positive terminals were found in the PVN (not shown). The 
connections from GLP-1R-expressing neurons in the dLS to these two hypothalamic areas could 
be important in the physiological responses to stress, including suppression of appetite.  
Fig 4.32 Projections of dLS GLP-1R-expressing neurons. Unilateral transduction of dLS GLP-
1R-expressing neurons with AAV1/2-FLEX-GCaMP3. See Fig 4.25 for image of transduced dLS 
cells bodies. Axonal fibres and terminals were identified in the lateral septum (LS), lateral 
hypothalamus (LH), and the preoptic area of the hypothalamus (POA). GCaMP3-expressing 
GLP-1R neuronal fibres were detected with an anti-GFP antibody and are shown in green. 
Expression of tdRFP was detected with an anti-dsRed antibody and is shown in magenta. 
Scale bars: 200 µm (LS and POA) and 100 µm (LH). 




In this chapter, I explored the role of PPG neurons in the regulation of feeding. Chemogenetic 
activation of PPG neurons robustly suppressed food intake. On the other hand, loss or inhibition 
of PPG neurons did not increase normal feeding. I discovered that PPG neurons are necessary 
for satiety following a large meal, suggesting these neurons are mainly involved in the regulation 
of overeating, not daily feeding. This was further substantiated, when I found that acute 
restraint stress suppresses food intake in a PPG neuron-dependent manner. Experimental 
evidence in this chapter suggests that stress-induced anorexia is mediated by GLP-1 released 
into the dLS and that GLP-1R-expressing neurons project from there to several hypothalamic 
areas. 
4.3.1 NTS PPG neurons have the ability to suppress feeding   
I show here that acute chemogenetic activation of NTS PPG neurons is sufficient to produce 
robust anorexia in mice (Fig 4.4-4.6). This hypophagic effect was mainly visible in the first two 
hours following dark onset, similar to what was recently reported in a parallel study by Gaykema 
et al. (2017). It is unclear whether the fading of the effect reflects activation of compensatory 
mechanisms preventing extended hypophagia, or if it is a result of the half-life of CNO. CNO is 
present for up to two hours after i.p. injection in mice (Guettier et al. 2009), but behavioural 
effects of CNO activation of virally expressed HM3Dq-receptors have been reported to last for 
up to eight hours in neurons expressing AgRP (Krashes et al. 2011). Additionally, although 
observing a time-limitation on the response in lean animals, Gaykema et al. reported (2017) 
clear hypophagic effects at four hours in diet-induced obese mice. This evidence suggests the 
most likely explanation for the lack of lasting effects is activation of compensatory mechanisms, 
which ensure sufficient food intake. Indeed, in my experiments, the effect of PPG activation 
appeared to reverse overnight with PPG activated mice eating more than controls, suggesting 
some level of compensation (Fig 4.6). 
Although the in vivo effects of PPG activation observed by Gaykema et al. (2017) were similar to 
those presented here, I observed more robust in vitro responses. Gaykema et al. (2017) 
observed no effect of 1 µM CNO on electrophysiological properties of HM3Dq-expressing PPG 
neurons and reported only very small increases in activity following 9 µM CNO for ten minutes. 
This is surprising, considering the robust increase in intracellular [Ca2+] in response to 1 µM CNO, 
demonstrated here (Fig 4.3) as well as the dramatic in vivo effects observed by me and Gaykema 
et al. (2017). Importantly, it is difficult to compare electrophysiological and Ca2+ imaging data 
and I have not categorically shown that HM3Dq-mediated activation of PPG neurons leads to an 
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increase in firing frequency. However, I observed a clear correlation between change in firing 
rate and intracellular [Ca2+] in Chapter 3 and Alexander et al. (2009) convincingly demonstrated 
an increase in firing frequency in hippocampal neurons expressing HM3Dq. I am surprised by 
the lack of spontaneous firing in any of the cells recorded from by Gaykema et al. (2017). In our 
hands, PPG neurons in vitro have resting firing rates of 1.5-2 Hz with 124 of 135 recorded PPG 
neurons being spontaneously active (Hisadome et al. 2010; Holt et al. 2017). Notably, Gaykema 
et al. (2017) performed whole-cell recordings, whereas Hisadome et al. (2010, 2011) recorded 
in perforated-patch and my recordings were done in the cell-attached configuration. It is 
possible that in the whole-cell recordings presented by Gaykema et al. (2017), dilution of 
intracellular ATP into the electrode leads to opening of KATP channels and resulting 
hyperpolarisation.  
4.3.2 PPG neurons are not necessary for the regulation of normal feeding 
The sufficiency of PPG neurons to reduce food intake does not prove that these neurons are 
necessary for the regulation of feeding. It is unclear whether activation using HM3Dq 
recapitulates endogenous stimulation of PPG neurons by afferent neurons and circulating 
peptides. On the other hand, PPG inactivation or ablation prevents the endogenous release of 
GLP-1 in response to physiological stimuli. There is significant strength in having two different 
approaches to inactivation. Ablation using viral delivery of DTA is irreversible and not reliant on 
injection of CNO. As such, minimal handling of the animal is needed. HM4Di-mediated inhibition 
is a complementary technique achieving the same final goal of inactivation, while avoiding any 
risks of compensatory mechanisms developing due to chronic loss of GLP-1 signalling.   
Loss or inactivation of NTS PPG neurons did not affect normal feeding during the dark phase 
(Figs 4.10, 4.12-4.13) and NTS PPG neurons were not necessary for bodyweight regulation (Fig 
4.9). In support of my findings, global and central knockdown of GLP-1R was found to have little 
impact on food intake and body weight in mice (Scrocchi et al. 1996; Sisley et al. 2014). 
Somewhat surprisingly, a recent study in mice found that hypothalamic GLP-1Rs are necessary 
for satiety (Burmeister et al. 2017). This is difficult to reconcile with a lack of effect of global and 
brain knock-out of GLP-1R on food intake and bodyweight and does not align with my findings 
that permanent loss of PPG neurons has no effect on ad libitum feeding.  
In rats, Barrera et al. (2011) found that shRNA-mediated knockdown of GLP-1 in the hindbrain 
led to hyperphagia and increased bodyweight. Furthermore, two recent studies in rats 
demonstrated that GLP-1Rs in the NTS (Alhadeff et al. 2017) and LH (López-Ferreras et al. 2017) 
are essential for satiety and food reward. GLP-1R knockdown using virally delivered shRNA in 
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these areas led to increased food intake and heightened motivation to work for food, in 
accordance with the effects seen following exogenous delivery of GLP-1 into these areas. 
Notably, the effects on bodyweight observed by Barrera et al. (2011) were measured soon after 
stereotaxic surgery and could be confounded by surgery-induced inflammation. However, these 
discrepancies could also reflect species differences between mice and rats and should be kept 
in mind when interpreting data and comparing studies conducted in different species. 
Importantly, GLP-1R inhibition did not affect food intake in humans (Melhorn et al. 2014; 
Steinert et al. 2014), supporting the results from mice presented here and by Scrocchi et al. 
(1996) and Sisley et al. (2014).   
4.3.3 NTS PPG neurons are necessary for the prevention of overeating 
I demonstrate here that, after overnight food deprivation, NTS PPG neurons play a role in the 
regulation of food intake. Both PPG-ablated and PPG-inhibited mice had significantly elevated 
intakes, compared to control mice, when food was returned after 18 hours of food deprivation 
(Figs 4.14-4.17). There is some evidence to suggest the energy balance of the animal is important 
for the effect of both GLP-1R stimulation and inhibition. In their milestone paper, Turton et al. 
(1996) observed hyperphagia in response to central GLP-1R blockade only in sated, not food-
deprived, rats. Similarly, GLP-1 and Ex4-induced hypophagia disappeared following a 24-hour 
fast (Williams et al. 2006) and activation of GLP-1 neurons in response to CCK-8 or restraint 
stress is attenuated after overnight food deprivation (Maniscalco and Rinaman 2013; Maniscalco 
et al. 2015).  
Fasting could silence the central GLP-1 system through several different mechanisms: 1) food-
deprivation may reduce the activity of PPG neurons and the release of GLP-1, and 2) it may 
reduce sensitivity at the level of the GLP-1Rs by suppressing expression or availability at the cell 
membrane. It is possible that a large meal in turn activates NTS PPG neurons sufficiently to have 
an impact on food intake (Kreisler et al. 2014) and I therefore propose that the timing of 
interventions and measurements is essential. In support of this, 40 mins of refeeding after a 
prolonged fast was found to re-sensitise rats to GLP-1-induced hypophagia (Ronveaux et al. 
2014). Furthermore, hindbrain GLP-1R blockade had no effect on food intake in food-deprived 
rats, whereas Ex9 attenuated hypophagia following a large meal (Hayes et al. 2009). I therefore 
hypothesised that intake of a large meal leads to recruitment of NTS PPG neurons.  
In support of this, I found that although PPG ablation did not affect the intake of Ensure itself, 
chow intake in the next hour was significantly larger in mice lacking NTS PPG neurons (Fig 4.18). 
GLP-1R stimulation has previously been shown to decrease intake of highly-palatable food 
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(Dossat et al. 2011, 2013; Alhadeff et al. 2012; Dickson et al. 2012; Mietlicki-Baase et al. 2013, 
2014), nicotine (Tuesta et al. 2017), and cocaine (Graham et al. 2013; Schmidt et al. 2016). The 
lack of effect of PPG ablation on Ensure intake is most likely due to 15 mins being insufficient 
time to detect a robust effect of recruitment of the central GLP-1 system. Importantly, I did not 
directly test the animals’ willingness to work for food. Future studies could reveal the 
importance of PPG neurons in addiction by exposing PPG-ablated mice to operant conditioning 
and conditioned place preference experiments.  
Taken together these data point to a role for PPG neurons in appetite control. Interestingly, PPG 
neurons are not important for the regulation of normal feeding, in contrast to POMC, AgRP and 
CGRP neurons. Rather, they prevent overconsumption of food. Intake of large meals is disruptive 
to the interior environment of the organism and can lead to nausea and malaise (Woods 1991). 
The importance of PPG neurons in the prevention of overeating could be indicative of a role in 
the response to homeostatic disruptions, including overconsumption of food. Challenges to 
well-being are not necessarily related to food intake and could include interoceptive stress in 
the form of visceral illness as well as psychogenic stress (Rinaman 1999b; Kinzig et al. 2003; Holt 
and Trapp 2016; Kreisler and Rinaman 2016).  
4.3.4 Acute stress suppresses food intake via NTS PPG neurons and the dLS  
To investigate the role of PPG neurons in the response to psychogenic stress, I exposed PPG-
inhibited mice to acute restraint stress. PPG neuron activity was necessary for the hypophagic 
effects of restraint stress (Fig 4.20-4.21), demonstrating for the first time the importance of PPG 
neurons in the regulation of stress-induced hypophagia. In support of this, acute stress activates 
GLP-1-producing neurons (Maniscalco et al. 2015) and central GLP-1R signalling is required for 
the hypophagic, neuroendocrine, and cardiovascular responses to stress (Kinzig et al. 2003; 
Maniscalco et al. 2012; Ghosal et al. 2017).  
I found that endogenous GLP-1 released into the dLS mediates the anorectic response to acute 
stress (Fig 4.30-4.31), revealing a novel site for modulation of stress by central GLP-1 in addition 
to the already established PVN and amygdala (Kinzig et al. 2003; Ghosal et al. 2017). Surprisingly, 
although the anorexic effect of restraint was evident after one hour, the effect of Ex9 on stress-
induced hypophagia was only significant much later than that of PPG inactivation. This 
observation has several potential explanations. First, there could be a delay in the time it takes 
for Ex9 to have its effect on GLP-1Rs in the nucleus. However, other studies have shown much 
faster effects of Ex9, suggesting this is not the case (Williams et al. 2009; Alhadeff et al. 2012; 
Terrill et al. 2016). Second, it is conceivable the release of co-transmitters from PPG neurons 
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contributes to a much earlier hypophagic response than that of GLP-1. This would mean that 
inactivation of PPG neurons attenuates an early and late phase of stress-induced hypophagia 
whereas Ex9 blockade of dLS GLP-1Rs only inhibits the late phase of anorexia. Third, I cannot 
exclude that the Ex9-stress experiments were underpowered and that larger numbers of mice 
would reveal an earlier effect of dLS GLP-1R blockade on food intake suppression. Future 
experiments should aim to reproduce these findings before expanding further.  
Surprisingly, acute restraint stress had a shorter-lived effect on food intake when measured in 
our facilities at University College London, compared to Florida State University. This 
discrepancy is most likely due to differences between the two environments, including 
temperature, ambient stressors, and slight variances in the equipment used. It is worth noting 
that HM4Di-mice tended to eat marginally less than control mice in both normal feeding and 
stress experiments (Figs. 4.12-13 and 4.20-21). This difference in intake was not statistically 
significant as demonstrated in Figs 4.12-4.13 and was consistent over several experiments, 
suggesting this group of mice simply had marginally lower intakes than the control group. In the 
future, stress experiments could be performed as within-subject designs in which HM4Di-
expressing mice are either left undisturbed or exposed to stress following CNO or saline only. 
However, the experiments described here were deliberately not designed in this way due to the 
risk of habituating animals to stress through repeated exposures (Krahn et al. 1990).   
To further investigate the cellular properties of GLP-1R-expressing neurons in the dLS, I created 
a Cre-dependent virus encoding GCaMP3. Selective expression of GCaMP3 in dLS GLP-1R 
allowed recordings of intracellular [Ca2+] and revealed a robust response to a strong depolarising 
stimulus, 15 mM KCl (Fig 4.26). Future experiments will investigate the sensitivity of these 
neurons to GLP-1. Activation of the GLP-1R has been largely thought to be stimulatory via 
coupling to Gαs and increased levels of cAMP (Drucker et al. 1987; Thorens 1992; Zhang et al. 
2017). Indeed, GLP-1 has been demonstrated to depolarise vagal neurons (Holmes et al. 2009). 
However, Ong et al. (2017) recently found that neurons in the paraventricular nucleus of the 
thalamus are in fact inhibited by GLP-1. Similarly, we have observed both excitatory and 
inhibitory responses to GLP-1 in the hippocampus and BNST (Cork et al. 2015; I E Edwards and S 
Trapp, unpublished). These findings suggest the effects of GLP-1R stimulation could be 
heterogenous and may depend on the tissue or site being investigated.  
Neurons within the LS are primarily GABAergic (Zhao et al. 2013) and project to the PVN, LH, and 
POA (Meibach and Siegel 1977; Swanson and Cowan 1979; Berk and Finkelstein 1981). 
Surprisingly, I did not see any evidence for dLSGLP-1R → PVN connections, whereas there were 
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clear fibres of passage through the LS terminating in the POA and LH (Fig 4.32). The importance 
of each of these circuits in stress-induced hypophagia is an interesting topic for further research. 
This could be investigated using circuit-specific expression of chemo- or optogenetic tools as 
described for the appetite-suppressing circuit between neurons in the PBN and the central 
amygdala (Carter et al. 2013).  
Importantly, without knowing whether GLP-1 excites or inhibits individual neurons in the dLS, 
and whether this is in fact a heterogeneous response, it is difficult to decide on a strategy for 
chemogenetic manipulation of dLS GLP-1R-expressing neurons. In the case of a heterogenous 
response to GLP-1 it may not be desirable to manipulate the whole population simultaneously. 
The same caution may be necessary when investigating other neuronal targets of GLP-1.  
In this chapter, I used state-of-the-art chemogenetic tools to manipulate the activity of NTS PPG 
neurons. Because viral transduction was confined to the NTS and rarely spread further ventral 
(Fig 4.8), I did not target PPG neurons found in the IRT and along the midline (Merchenthaler et 
al. 1999; Llewellyn-Smith et al. 2011). It is possible that only few neurons are needed to maintain 
satiety in response to normal food intake and that complete loss or inactivation of PPG neurons, 
including those in the IRT, would reveal a role in normal feeding. The cataplexy phenotype, a 
symptom of narcolepsy, was only observed in mice after loss of 90% orexin neurons, suggesting 
some systems only need few neurons to uphold normal function (Tabuchi et al. 2014). I also 
cannot exclude that more sensitive methods of monitoring food intake could reveal subtle 
differences in meal patterns between PPG-inactivated and control mice.  
Viral delivery of HM4Di, HM3Dq, and GCaMP3 all decreased expression of other fluorescent 
reporters. Importantly, these changes in reporter expression did not affect spontaneous firing 
frequency (1.5-2 Hz) or responsiveness to 15 mM KCl and 100 µM glutamate of the cells and 
there was no in vivo phenotype suggesting the cells function as normal.  
The data presented in this chapter clarify the role of PPG neurons in food intake and specifically 
reveal that NTS PPG neurons are important for satiety in the context of overeating. Central 
infusions of GLP-1 have been shown to induce conditioned taste aversion in rodents (Thiele et 
al. 1997; Lachey et al. 2005), although the brain nuclei responsible for this seem to be distinct 
from the sites mediating the food-intake suppressive effects (McMahon and Wellman 1998; 
Kinzig et al. 2002). Future investigations should address the potential initiation of nausea in 
response to a large meal and whether PPG neurons are involved in initiation of malaise and 
conditioned taste aversion after overeating. Additionally, I identified a role for PPG neurons and 
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dLS GLP-1Rs in the regulation of stress-induced hypophagia. Future experiments should 
investigate whether this NTSPPG → dLS circuit is sufficient to induce hypophagia and whether it 
is necessary for stress-induced hypophagia. 
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5. The role of PPG neurons in cardiovascular control 
5.1 Background 
The role of GLP-1 within the brain is not limited to regulation of food intake. Rather, the 
hypophagic effects of central GLP-1 may be part of a complex physiological response to acute 
stress (Ghosal et al. 2013; Holt and Trapp 2016). In Chapter 4, I demonstrated that PPG neuron 
activity is necessary for the hypophagic response to acute stress. In this chapter, I expand on 
those findings by investigating the role of GLP-1 in cardiovascular control.  
Peripheral (i.p. or i.v.) or central (i.c.v.) administration of GLP-1 or its analogues increases heart 
rate in rats (Barragán et al. 1994; Yamamoto et al. 2002), mice (Griffioen et al. 2011), cattle 
(Edwards et al. 1997), and humans (Mark et al. 1998; Robinson et al. 2013). In contrast, the 
effect of GLP-1R stimulation on blood pressure has been variable with some studies observing 
robust hypertensive effects of GLP-1 analogues (Barragán et al. 1994; Yamamoto et al. 2002), 
whereas others found little evidence for an effect on blood pressure (Edwards et al. 1997). These 
differences could arise from variability between species and to my knowledge no study has 
reported an effect of GLP-1R activation on blood pressure in mouse. 
Although the tachycardic effects of GLP-1R stimulation have proven robust and reproducible, 
the underlying mechanisms remain unclear. GLP-1R-mediated cardiovascular effects may 
involve a combination of peripheral and central pathways involving GLP-1Rs both in the brain 
and on the heart (Barragán et al. 1999; Gros et al. 2003; Hayes et al. 2008; Baggio et al. 2017). 
Furthermore, both the parasympathetic (Barragán et al. 1994, 1999; Cabou et al. 2008; Griffioen 
et al. 2011) and sympathetic nervous system (Yamamoto et al. 2002, 2003; Baggio et al. 2017; 
Ghosal et al. 2017) have been implicated in the tachycardic response to GLP-1R stimulation. 
Contributions from the autonomic nervous system to GLP-1-mediated tachycardia are therefore 
still controversial.   
Although important for the understanding of the effects of treatments with GLP-1 analogues, 
these studies do not address the question of the involvement of endogenous GLP-1. The 
literature is sparse when it comes to the role of endogenous GLP-1 in cardiovascular control. In 
1999, Barragan et al. found no effect of i.c.v. infusion of GLP-1R antagonist, Ex9, on heart rate 
and blood pressure (Barragán et al. 1999). However, these studies were done in anaesthetised 
rats in which autonomic function could be altered dependent on the choice of anaesthetic agent.  
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Genetic knockdown of GLP-1Rs had complicated effects on cardiovascular parameters. Although 
bradycardia was observed at two months of age, this effect disappeared in older mice (Gros et 
al. 2003). Importantly, results from genetic knockdown studies are confounded by the possibility 
of compensation occurring during development. Considering the robust effects of central and 
peripheral GLP-1R stimulation, I was curious if endogenous GLP-1 is relevant in cardiovascular 
control. In this chapter, I investigate the role of GLP-1 in cardiovascular control and, in particular, 
the contribution of NTS PPG neurons to regulation of heart rate and blood pressure. To this end, 
I address the following questions: 
1. Which is an appropriate experimental model for elucidating the role of NTS PPG neurons 
in cardiovascular control? 
2. What is the effect of systemic GLP-1R activation on heart rate, blood pressure, and 
activity in this model? 
3. Are PPG neurons necessary for maintenance of normal heart rate and blood pressure? 
4. How does diet-induced obesity affect cardiovascular parameters and do NTS PPG 
neurons play a role? 
5. Is NTS PPG neuron activity sufficient to increase heart rate? 
These questions were addressed using stereotaxic brainstem injections of Cre-dependent 
viruses and biotelemetry blood pressure probe implantation. In summary, I confirmed the 
tachycardic effects of peripheral injections of Ex4, but I found no evidence for a role of NTS PPG 
neurons in the physiological regulation of heart rate, although activation of PPG neurons was 
sufficient to increase heart rate in mice.  
  




5.2.1 Methods to measure heart rate and blood pressure in awake mice 
To begin, I had to determine the most appropriate method for monitoring heart rate and blood 
pressure in mice that would allow me to investigate the role of central GLP-1 in cardiovascular 
control. It was important to avoid any effects of anaesthesia on heart rate and blood pressure. 
Furthermore, I was interested in methods, which allow repeated measurements from the same 
mouse. I therefore explored two approaches:  
• Blood pressure recordings using a volume-pressure recording (VPR) tail-cuff system 
• Implantable biotelemetry in freely-behaving mice 
In the VPR tail-cuff system, awake mice are placed in tight plexiglass tubes with breathing holes 
as seen in Fig 5.1. An occlusion cuff is placed around the most proximal part of the tail and a 
recording cuff, which senses blood flow, is placed distally. The mouse is then placed on a heating 
pad to ensure stable core temperature and sufficient blood flow to the tail. Importantly, mice 
are conscious throughout the procedure allowing me to monitor heart rate and blood pressure 
without any effects of anaesthesia.  
Heart rate and blood pressure were recorded from five male adult mice (Fig 5.1B). Heart rate 
and mean arterial blood pressure (MAP) were averaged for each mouse over 18-24 consecutive 
recordings. Mean heart rate ranged from 523 to 637 bpm and MAP varied between 99.8 and 
135.5 mmHg (Fig 5.1B).  
  
Fig 5.1 VPR tail cuff for monitoring heart rate and blood pressure in awake mice. A) A mouse 
restrained in a transparent plexiglass tube during blood pressure recordings. The two cuffs for 
blood pressure measurements are indicated. The occlusion cuff (1) inflates and restricts blood 
flow to the tail. As pressure is released blood returns to the tail and is detected by the recording 
cuff (2). B) Five mice were exposed to 25 cycles of measurements resulting in 18-24 accepted 
cycles. Data from individual mice are displayed in shades of blue and means±SEM are indicated. 
Heart rate (HR) in beats per minute (bpm) and mean arterial blood pressure (MAP) are shown.  
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Fig 5.2 The biotelemetry system for monitoring heart rate and mean arterial blood pressure 
in awake, freely-behaving mice. A) Mean arterial blood pressure (MAP, blue, top), heart rate 
(HR, black, middle) and locomotor activity (red, bottom) measured from a single mouse over 24 
hours as indicated in zeitgeber time. Dark phase is indicated with a grey box with the gradient 
indicating a half hour “twilight” period in which lights were dimmed. Traces are running averages 
over 20 mins. B) Histogram displaying the distribution of heart rate values in 10 bpm bins 
recorded from a single mouse over 24 hours is shown in white bars. Notice the bimodal 
distribution of heart rate values. Overlain in red is a plot of the mean activity counts at the heart 
rate levels indicated on the x-axis. C) The distribution of heart rate values from B) split into two 
histograms according to activity levels with the distribution of heart rate values at inactivity 
(when activity=0) displayed in light red, and the distribution of heart rate values during active 
times in dark red. 
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I demonstrated in Chapter 4 that restraint stress profoundly reduces food intake. I was therefore 
concerned that restraint during VPR tail-cuff measurements would cause stress and thus affect 
heart rate and blood pressure of the mice. Furthermore, VPR tail cuff measurements were 
variable within the same mouse with the heart rate of one mouse ranging between 428 and 818 
bpm.  
For these reasons, I explored an implantable biotelemetry system for monitoring heart rate and 
blood pressure. Male mice, 7-10 weeks old, were implanted with biotelemetry blood pressure 
probes as described in Materials and Methods.  
Fig 5.2 shows an example of how MAP, heart rate, and activity fluctuate in a synchronised 
manner over 24 hours. The lowest values of MAP (~90 mmHg) and heart rate (~440 bpm) 
occurred at times of no activity and the highest levels of MAP (~135 mmHg) and heart rate (~750 
bpm) were found at times of prolonged intense activity. For example, at the onset of dark phase, 
high activity levels were more frequent and coincided with a rise in both MAP and heart rate 
(Fig 5.2A).  
Because of these fluctuations, it is not appropriate to simply report average heart rate and MAP 
for each mouse. As seen in Fig 5.2B, heart rate values recorded over 24 hours are not normally 
distributed, but rather follow a bimodal distribution. Based on the synchrony in heart rate and 
activity fluctuations observed in Fig 5.2A, I hypothesised that heart rate is positively correlated 
with activity. To confirm this, I binned heart rates in 20 bpm bins and calculated mean activity 
levels for each bin (Fig 5.2B). Activity levels were close to 0 at heart values between 390 and 570 
bpm. At higher heart rate values, between 590 and 800 bpm, mean activity levels were positively 
correlated with heart rate.  
To further investigate the relationship between activity and cardiovascular parameters, I filtered 
heart rate values according to activity levels. Inactivity was defined as any timepoint with 
Activity=0. Conversely, activity was defined as any timepoint with Activity>0. From this filtering, 
it was clear that the bimodal distribution could be split into two unimodal histograms (Fig 5.2C). 
Importantly, neither distribution was normal with inactive heart rate values skewed to the right 
and active heart rate values skewed to the left. For this reason, values reported in this chapter 
are all based on the median, with the exception of circadian fluctuations in heart rate and blood 
pressure which are displayed as averages every 30 mins over 24 hours. 
To begin with, I determined resting heart rate and MAP by extracting data from timepoints when 
the animals are inactive and computing the median. Although it is argued that animals subjected 
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to the VPR tail-cuff method are at rest, HR and blood pressure were both significantly higher in 
mice during VPR tail-cuff measurements than in animals in which blood pressure and heart rate 
were monitored with biotelemetry (Fig 5.3). Mice subjected to tail-cuff measurements had an 
average resting heart rate of 565±21 bpm, whereas mice implanted with biotelemetry probes 
had significantly lower resting heart rates of 505±12 bpm (Fig 5.3A, p=0.02). Similarly, resting 
MAP was significantly lower in mice with biotelemetry probes (103±1 mmHg) than mice 
subjected to VPR tail-cuff measurements (121±6 mmHg, p=0.0005). These findings suggest that 
the VPR tail-cuff method does not provide true resting values, most likely due to stress induced 
by the restraint during tail-cuff measurements. Furthermore, VPR tail-cuff measurements do not 
provide circadian data or any temporal resolution of responses, since measurements are only 
snapshots of cardiovascular parameters. I therefore continued my investigations using 
biotelemetry focussing on both resting and active median heart rate and MAP. 
 
5.2.2 Systemic Ex4 increases heart rate via the sympathetic nervous system 
Having identified an appropriate method for monitoring heart rate and blood pressure, I set out 
to investigate the role of GLP-1 in cardiovascular control. Knowing from previous studies that 
GLP-1R activation increases heart rate in both rats and mice (Barragán et al. 1994; Yamamoto et 
al. 2002; Griffioen et al. 2011), I wanted to confirm this tachycardia in the biotelemetry model. 
As seen in Fig 5.4, i.p. injection of 100 µl saline led to a rapid increase in heart rate as expected 
when inducing brief stress due to handling of the mouse. However, 30 mins later heart rate had 
returned to baseline and continued to fluctuate as normal with frequent returns to high values 
Fig 5.3 Resting HR and MAP as measured with biotelemetry and VPR tail 
cuff. Resting heart rate (HR, left) and MAP (right) measured using tail cuff 
(black symbols) or biotelemetry (grey symbols). N=5 (tail cuff) and N=12 
(biotelemetry). *p<0.05, ***p<0.001, Student’s unpaired t-test.  
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during dark phase as typically seen (Fig 5.4 top panel). Similarly, i.p. injection of 100 µg/kg GLP-
1 led to a transient increase in heart rate, which returned to baseline within 30 mins (Fig 5.4 
middle panel). Importantly, the tachycardic response to handling stress may have masked any 
GLP-1-induced effects on heart rate. In contrast, i.p. injection of the long-acting GLP-1 analogue, 
10 µg/kg Ex4, led to a sustained increase in heart rate over eight hours, which did not return to 
baseline until several hours into dark phase (Fig 5.4 bottom panel). Heart rate did not reach 
maximum values, since both handling stress and high activity during dark phase led to higher 
heart rate values. Ex4 appeared to increase the minimum level of heart rate, suggesting the 
effect was mainly on resting heart rate.  
The doses of GLP-1 (100 µg/kg) and Ex4 (10 µg/kg) were chosen based on previous studies 
finding significant effects on food intake at these levels (Mack et al. 2006; Barrera et al. 2009; 
Williams et al. 2009; Kanoski et al. 2011; Dickson et al. 2012; Jessen et al. 2012; Saito et al. 2016). 




This experiment was repeated in another three mice in a counterbalanced manner with a similar 
outcome. Fig 5.5 displays heart rate and blood pressure values averaged every 30 mins over a 
24-hour recording. Saline injections transiently increased heart rate, whereas 10 µg/kg Ex4 i.p. 
led to a sustained rise in heart rate which slowly decreased over the following eight hours. 
Interestingly, MAP was unaffected by GLP-1R activation and only displayed a brief increase 
following handling (Fig 5.5B). 
 
 
Fig 5.4 Systemic activation of GLP-1Rs induces tachycardia. Heart rate of a single mouse 
injected i.p. with either saline (black, top), 100 µg/kg GLP-1(7-36) (GLP-1, green, middle), 
and 10 µg/kg Ex4 (red, bottom) recorded over 24 hours as indicated by zeitgeber time at 
the bottom. Arrows indicate times of injection and the bar at the bottom indicates light 
(white bar) and dark (black bar) phases with a brief period of half-light indicated by a white 
to black gradient. Traces are running averages over 200 s.  




To quantify these responses, I calculated the median resting heart rates before and after drug 
treatments. To avoid any contribution to heart rate from the stress induced by handling of the 
mice, calculations were based on values 1-2 hours after injection (hours 5-6 into light phase). 
Furthermore, by only including heart rates during zero activity, any effects of changes in activity 
were avoided. I extracted heart rate values at inactivity during baseline (2-3 hours into light 
phase, 1-2 hours before injection) and 1-2 hours after drug injections (5-6 hours into light phase) 
(Fig 5.6A). Two-way repeated measures ANOVA revealed a significant interaction between time 
and treatment (F(1, 3) = 22.35, p=0.018). Sidak’s multiple comparisons test yielded no significant 
effect of saline (p=0.34) nor GLP-1 (p=0.29). In contrast, there was a statistically significant effect 
of Ex4 on heart rate with median resting heart rate increasing from 517.4±23 to 647.6±36 bpm 
(p<0.0001). 
Because mice have variable resting heart rate values, I calculated the change in resting heart 
rate from baseline (Fig 5.6B). Resting heart rate increased by significantly more bpm in response 
to 10 µg/kg Ex4, compared to saline (p=0.0043), whereas there was no difference in the effect 
of saline and GLP-1 treatment (p=0.997).  
Fig 5.5 I.p. injection of Ex4 increases heart rate but not MAP in freely-behaving animals. A) Heart 
rate and B) MAP of four mice exposed to saline (black) and 10 µg/kg Ex4 (red) four hours into light 
phase. Heart rate and MAP were averaged every 30 mins for each mouse. Shown here are 
mean±SEM of four mice taken every 30 mins over 24 hours as indicated by zeitgeber time on the x-
axis. Arrows indicate times of injection and the bars at the bottom indicate light (white bar) and dark 
(black bar) phases with a brief period of half-light indicated by a white to black gradient.  






Although GLP-1R activation has been shown to decrease locomotor activity (Mack et al. 2006; 
Erreger et al. 2012; Egecioglu et al. 2013a), I found no effect of i.p. Ex4 treatment on activity as 
compared to treatment with saline (Fig 5.7). To quantify this, I determined the time each animal 
spent active as a percentage of total time during baseline (hours 1-4) and after injection of saline 
or 10 µg/kg Ex4 (hours 5-8) (Fig 5.8). Mice spent 14±2% of their time active during baseline. This 
did not change in response to saline (14±3%) and was only marginally lower following Ex4 
treatment (11±2%) (Fig 5.8A). Indeed, two-way repeated measures ANOVA yielded no significant 
interaction between time and treatment (F(1,3) = 0.034, p=0.87) and there were no significant 
main effects (time: p=0.29, treatment: p=0.39). Importantly, the lack of effect on activity 
demonstrates that any cardiovascular consequences of GLP-1R stimulation are not secondary to 
changes in locomotor activity. 
As expected locomotor activity increased at the onset of dark phase. This increase was similar 
following saline (15±3% to 35±2%) and Ex4 treatment (14±2% to 35±6%) (Fig 5.8B). Two-way 
repeated measures ANOVA revealed no significant interaction between time and treatment 
(F(1, 3) = 0.09634, p=0.7766) and there was no main effect of treatment (p=0.83). However, the 
analysis did reveal a significant main effect of time (p=0.0058), suggesting both saline and Ex4-
Fig 5.6 I.p. injection of Ex4 increases resting heart rate in freely-behaving mice. A) Four mice 
implanted with biotelemetry probes were injected i.p. with saline (black), 100 µg/kg GLP-1 (green), 
and 10 µg/kg Ex4 (red) four hours into light phase. Median resting heart rates of individual mice 
were determined before (hours 2-3) and after (hours 5-6) i.p. injections. Matched data from 
individual mice are plotted as well as mean±SEM values (N=4). ****p<0.0001, n.s.: not significant, 
Sidak’s matched pairs multiple comparisons test. B) Change in heart rate from baseline determined 
from A) following injections of saline (black), GLP-1 (green), and Ex4 (red). Data from individual 
mice are shown as well as mean±SEM for each treatment (N=4).  **p<0.01, n.s.: not significant, 
Dunnett’s multiple comparisons test.  
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treated mice spent significantly more time active during early dark phase than during late light 
phase, but that systemic GLP-1R activation does not affect locomotor activity at dark onset. It is 
possible that Ex4 was no longer present at high enough concentrations at these later timepoints. 
To specifically investigate the effect of Ex4 on dark onset activity, future studies should inject 
the agonist immediately prior to the dark phase.   
 
 
Fig 5.7 I.p. injection of Ex4 does not affect locomotor activity. A) Four mice implanted with 
biotelemetry probes were injected i.p. with saline (left) or 10 µg/kg Ex4 (right) four hours into light 
phase. Activity levels were monitored over 12 hours during light (white bar) and twilight phase 
(gradient bar). Zeitgeber time is indicated at the bottom. Times of i.p. injections with either saline 
or Ex4 are indicated with dotted lines.  











The data presented here clearly demonstrate that systemic GLP-1R activation with 10 µg/kg Ex4 
leads to an increase in heart rate, but not MAP. GLP-1 increased heart rate only transiently, an 
effect which was indistinguishable from the stress-induced tachycardia seen after injection of 
saline. This is most likely due to rapid degradation of GLP-1 by DPP-IV in the bloodstream as 
explained in the Introduction.  
Tachycardic effects of GLP-1R activation have been attributed to changes in activity of either the 
parasympathetic or sympathetic nervous system (Yamamoto et al. 2002, 2003; Griffioen et al. 
2011). Furthermore, NTS PPG neurons project to sympathetic preganglionic neurons in the 
spinal cord (Llewellyn-Smith et al. 2015). To test whether the tachycardic effect observed in 
response to Ex4 was dependent on sympathetic outflow, Ex4 injections were repeated in the 
absence and presence of the β1-recepter antagonist, atenolol.  
Six mice implanted with biotelemetry probes were injected with 2 mg/kg atenolol or saline four 
hours into the light phase. This dose was chosen based on previous studies in which sympathetic 
input to the heart was significantly attenuated (Just et al. 2000; Khor et al. 2016). 15 mins after 
atenolol/saline treatment mice were injected i.p. with 10 µg/kg Ex4.  
Fig 5.8 I.p. injection of Ex4 does not affect the time mice spend active. Four mice implanted with 
biotelemetry probes were injected i.p. with saline (black) or 10 µg/kg Ex4 (red) four hours into light 
phase. A) Percentage time spent active before (Baseline, hours 1-4, open circles) and after 
(Saline/Ex4, hours 5-8, filled circles) drug treatment (N=4). n.s.: no significant interaction according 
to two-way repeated measures ANOVA. B) Percentage time spent active during light (open circles, 
hours 8-11) and dark phase (filled circles, hours 12-15) following injection of Ex4. **p<0.01 
indicating a main effect of time on activity levels in both treatment groups according to two-way 
ANOVA. 
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As described above, i.p. injections led to a brief rise in heart rate due to handling stress. Injection 
of 10 µg/kg Ex4, alone induced a sustained increase in heart rate over several hours (Fig 5.9 left 
panel). Pre-treatment with 2 mg/kg atenolol reduced the effect of handling stress on heart rate, 
consistent with a decrease in sympathetic outflow to the heart. Intriguingly, Ex4 failed to 
increase heart rate in the absence of β1-receptor activity, suggesting Ex4 induces tachycardia 
via an increase in sympathetic activity (Fig 5.9 right panel). 
 
  
These results were quantified by calculating median resting heart rates before (hours 2-3) and 
after (hours 5-6) i.p. injections. Fig 5.10A depicts the median resting heart rates in response to 
saline, 10 µg/kg Ex4, saline + 2 mg/kg atenolol, and 10 µg/kg Ex4 + 2 mg/kg atenolol. Two-way 
repeated measures ANOVA found a significant interaction between drug treatments (F(1, 6) = 
10.67, p=0.0171). Injection of 2 mg/kg atenolol alone did not significantly decrease heart rate as 
compared to saline (p=0.88). In the absence of 2 mg/kg atenolol, median resting heart rates 
were significantly increased in response to 10 µg/kg Ex4 as compared to saline (p=0.0041). In 
contrast, there was no effect of 10 µg/kg Ex4 in the presence of atenolol (p=0.55) and resting 
heart rates were comparable to following saline treatment (p=0.99). Furthermore, resting heart 
rates were significantly lower in response to Ex4 in mice pre-treated with atenolol as compared 
to mice with active β1-receptor signalling (p=0.0072).  
To avoid any potential effects of different baseline resting heart rate levels between treatments, 
I inspected the changes in resting heart rate from baseline (Fig 5.10B). The results echoed the 
observations from absolute resting heart rate levels. Two-way repeated measures ANOVA 
revealed a significant interaction between pre-treatment with atenolol and Ex4 (F(1, 6) = 13.84, 
Fig 5.9 β1-receptor antagonism prevents tachycardic effects of systemic GLP-1R activation. Mice 
implanted with biotelemetry probes were injected i.p. with saline (black and grey) or 10 µg/kg Ex4 
(red and blue) four hours into light phase in the absence (left panel) or presence (right panel) of 2 
mg/kg β1-receptor antagonist, atenolol. Shown here are mean±SEM taken every 30 mins over 24 
hours as indicated by zeitgeber time on the x-axis. Arrows indicate times of injection and the bars at 
the bottom indicate light (white bar) and dark (black bar) phases with a period of half-light indicated 
by a white to black gradient. N=7. 
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p=0.0099). In the absence of 2 mg/kg atenolol, resting heart rate increased by 117.2±12 bpm as 
compared to 7.3±11 bpm in response to saline. In contrast, the rise in resting heart rate was 
significantly attenuated in the presence of atenolol with a mean increase of only 37.5±25 bpm 
(p=0.0038; Ex4 vs Ex4+atenolol). This was not significantly different from the change in heart 
rate observed in response to saline only (p=0.26).  
  
 
The data presented in this section provide evidence for a tachycardic effect of systemic GLP-1R 
activation in freely-behaving mice, while GLP-1R agonism did not affect blood pressure or 
locomotor activity. Furthermore, these data demonstrate an involvement of the sympathetic 
nervous system in this response, as suggested previously by Yamamoto et al. (2002, 2003) and 
recently by Baggio et al. (2017).  
5.2.3 NTS PPG neurons are not necessary for cardiovascular control or regulation of 
locomotor activity 
In the previous section, I confirmed the tachycardic effect of GLP-1R activation and 
demonstrated an involvement of the sympathetic nervous system. Next, I was specifically 
interested in the involvement of central GLP-1 and the physiological role of NTS PPG neurons in 
cardiovascular control. In this section, I chronically ablate NTS PPG neurons and investigate the 
effect on cardiovascular parameters using biotelemetry in a longitudinal study.  
Fig 5.10 GLP-1-mediated increases in resting heart rate are dependent on the sympathetic 
nervous system. A) Absolute resting heart rates (5-6 hours) and B) change in resting heart rates 
from baseline (2-3 hours) in response to saline (black) or Ex4 (red) in the absence (empty circles) 
or presence (filled circles) of 2 mg/kg β1-receptor antagonist atenolol (N=7). **p>0.01, ***p<0.001 
and n.s.: not significant, Sidak’s multiple comparisons test. 
Chapter 5 – The role of PPG neurons in cardiovascular control 
141 
 
Biotelemetry probes were implanted into 12 male PPG-Cre/GCaMP3 or PPG-Cre/tdRFP mice. 
Baseline heart rate, blood pressure and activity were recorded and two weeks later mice were 
stereotaxically injected into the NTS with either AAV8-mCherry-FLEX-DTA or AAV1/2-FLEX-
Perceval as control (Fig 5.11A and B). It is clear from data shown in Chapter 4 (Fig 4.7) that DTA 
causes loss of PPG neurons by 14 days post-surgery. Heart rate and blood pressure were 
recorded again four and six weeks after viral gene delivery. At nine weeks, DTA and control 
animals received i.p. injections of saline and 10 µg/kg Ex4. One week later, mice were 
transferred to a high-fat diet (HFD, 60% caloric content from fat) for one month and blood 
pressure and heart rate were again recorded. A week later, at 15 weeks after surgery, saline and 
Ex4 injections were repeated (Fig 5.11A). At the end of the experiment, mice were transcardially 
perfuse-fixed and coronal brainstem sections were immunostained for the fluorescent reporters 
mCherry or Perceval as markers for successful transduction of NTS neurons (Fig 5.11C). All mice 
were expressing the expected transgene at the end of the experiment. 




Fig 5.11 Ablation of PPG neurons using AAV8-mCherry-FLEX-DTA for investigations of the 
physiological role of central GLP-1 in cardiovascular control. A) Work flow for DTA ablation of PPG 
neurons and biotelemetry monitoring of cardiovascular consequences. Heart rate and blood 
pressure were measured at times indicated with “Record”. B) Stereotaxic injections of the Cre-
dependent viruses AAV8-mCherry-FLEX-DTA or AAV1/2-FLEX-Perceval into the NTS to selectively 
target PPG neurons. C) Immunofluorescent images showing caudal brainstem tissue from a PPG-
Cre/GCaMP3 transgenic mouse injected with AAV8-mCherry-FLEX-DTA. Expression of mCherry 
was detected using an anti-dsRed antibody, displayed here in magenta. PPG neurons expressing 
GCaMP3 were completely lacking and could not be detected using an anti-GFP antibody (green). 
Scale bar: 100 µm. CC: Central canal, AP: Area postrema. 
 
There were no obvious biological effects of ablating PPG neurons on cardiovascular parameters 
or locomotor activity. Consequently, in this section, I systematically explore numerous 
parameters, which could be affected by PPG ablation. 
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There was no difference in heart rate and blood pressure recorded over 24 hours between the 
two cohorts before ablation, confirming that these mice did not have different heart rate and 
MAP prior to any intervention (Fig 5.12). Furthermore, heart rate and MAP increased at the 
onset of dark to a similar level in both cohorts. At four and six weeks, no significant difference 
was seen between control and DTA animals, suggesting ablation of PPG neurons does not affect 
the normal regulation of blood pressure and heart rate (Fig 5.12).  
 
Fig 5.12 Ablation of PPG neurons has no effect on 24-hour heart rate and blood pressure. Heart 
rate (panels on left) and mean arterial blood pressure (MAP, panels on right) were recorded before 
DTA ablation of NTS PPG neurons (Baseline, top panel) and at four (middle panel) and six weeks 
(bottom panel) after surgery. Traces display average±SEM heart rate and blood pressure every 30 
mins for control (black squares) and DTA mice (red circles). Light (white bar), twilight (gradient bar) 
and dark phase (black bar) are indicated at the bottom along with Zeitgeber time.  
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Because GLP-1R activation was found to increase heart rate at times of rest, I investigated 
whether PPG ablation affected resting heart rate in these mice. To explore this possibility, I 
extracted heart rate and MAP from periods of inactivity of at least 10 mins. Values were taken 
from across the 24-hour recording period. Heart rate and blood pressure do not return to 
baseline immediately following activity. To avoid any contamination of heart rate and MAP from 
recent activity, I ignored the first three minutes of the 10 mins periods of inactivity. Heart rate 
and MAP values from the last seven minutes of these inactive periods were combined and 








Prior to PPG ablation, there was no difference in resting heart rate between the control 
(482.5±16 bpm) and DTA cohorts (478.0±22 bpm) (Fig 5.13A, p=0.78, Sidak’s multiple 
comparisons test). Furthermore, there was little change in resting heart rate over time. At six 
weeks control animals had resting heart rates of 469.8±15 bpm and DTA mice had resting heart 
rates of 488.6±8 bpm. Two-way mixed model ANOVA yielded no significant interaction between 
virus and time (F (2, 20) = 2.178, p=0.14) and no main effects of virus (p=0.78) or time (p=0.74). 
Similarly, there was no difference in resting MAP between control (99.9±0.9 mmHg) and DTA 
cohorts (99.2±1.1 mmHg) prior to surgery (Fig 5.13B, p=0.93, Sidak’s multiple comparisons test). 
PPG ablation had no effect on resting MAP, which did not change substantially in DTA animals 
from 99.2±1.1 mmHg to 102.1±0.8 mmHg at six weeks. There was no two-way interaction 
between time and virus (F(2, 20) = 1.522, p=0.2426) and no main effects of virus (p=0.77) or time 
(p=0.14).  
Fig 5.13 Resting heart rate and blood pressure are unaffected by PPG neuron ablation. A) Median 
resting heart rate (HR) and B) MAP of PPG-Cre/GCaMP3 or PPG-Cre/tdRFP transgenic mice 
transduced with either AAV1/2-FLEX-Perceval (Control, black squares) or AAV8-mCherry-FLEX-
DTA (DTA, red circles) at baseline, 4 weeks, and 6 weeks after surgery. n.s.: no significant 
interaction or main effects according to two-way mixed model ANOVA. 
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These data suggest that control of resting heart rate and MAP does not require NTS PPG neuron 
activity. To investigate whether active heart rate and blood pressure were affected by loss of 
NTS PPG neurons, I extracted heart rate and MAP values from times of activity, defined as any 
time when activity was higher than zero. As expected, active heart rate was higher than resting 
heart rate with control mice having an active heart rate of 665.0±15 bpm as compared to a 
resting heart rate of 482.5±16 bpm (Fig 5.13A and 5.14A, p<0.0001, Student’s paired t-test). 
Two-way mixed model yielded no significant interaction between virus and time (F(2, 20) = 
0.0835, p=0.9202) and no main effects of virus (p=0.36) or time (p=0.37). Active heart rate 
remained similar from baseline to six weeks and there was no difference between control 
(661.1±11 bpm) and DTA animals (681.8±21 bpm) at six weeks after surgery (p=0.76, Sidak’s 
multiple comparisons test).  
  
Similarly, there was no effect of DTA ablation on active MAP (Fig 5.14). As with heart rate, MAP 
was significantly higher during activity than during rest (p<0.0001, Student’s paired t-test). Two-
way mixed model ANOVA yielded no significant interaction between time and virus (F(2, 20) = 
0.1653, p=0.85) and no main effect of virus (p=0.43) or time (p=0.65), suggesting NTS PPG 
neuron activity is not required for regulation of resting and active heart rate and blood pressure.  
Next, I explored if loss of NTS PPG neurons affects locomotor activity. Fig 5.15 shows plots of 
activity over 24 hours for two control and two DTA mice at baseline and six weeks post-surgery. 
There was no clear difference between control and DTA animals at baseline or at six weeks, and 
no discernible change in the level or pattern of locomotor activity between baseline and six 
weeks in either group.  
Fig 5.14 Active heart rate and blood pressure are unaffected by ablation of PPG. A) Median active 
heart rates and B) MAP of PPG-Cre/GCaMP3 or PPG-Cre/tdRFP transgenic mice transduced with 
either AAV1/2-FLEX-Perceval (Control, black squares) or AAV8-mCherry-FLEX-DTA (DTA, red 
circles) at baseline, 4 weeks, and 6 weeks after surgery. n.s.: no significant interaction or main 
effects according to two-way mixed model ANOVA. 




I quantified this by calculating the time spent inactive during light phase and dark phase, 
respectively (Fig 5.16). PPG ablation did not affect activity levels and six weeks post-surgery, 
there was no difference between the time control (88.3±1%) and DTA mice (89.1±1%) spent 
inactive during light phase (Fig 5.16A, p=0.98, Sidak’s multiple comparisons test).  
Fig 5.15 Ablation of NTS PPG neurons does not affect locomotor activity. Activity levels were 
monitored over 24 hours at Baseline and six weeks after stereotaxic injection of either AAV1/2-
FLEX-Perceval (Control, two top panels) or AAV8-mCherry-FLEX-DTA (DTA, two bottom panels). 
Here are shown plots from four representative mice. Light (white bars), twilight (gradient bar), 
dark phase (black bar) are indicated at the bottom along with Zeitgeber time. 
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During dark phase, mice spent less time inactive with control mice spending only 65±3% of their 
time inactive in comparison with 85.9±2% during light phase (Fig 5.16B). This pattern was similar 
at all timepoints for both control and DTA mice (Fig 5.16B). At six weeks, control mice spent 
64.3±3% of their time inactive during dark phase, similar to DTA mice, which spent 62.9±4% of 
their time inactive (p=0.99, Sidak’s multiple comparisons test). These data suggest that loss of 
NTS PPG neurons does not affect locomotor activity, although future studies should address this 
in more detail.  
 
 
As demonstrated previously (Fig 5.2) heart rate and activity are positively correlated. To assess 
whether this correlation is affected by PPG neuron ablation, I analysed heart rate change in 
response to increasing activity. This confirmed a clear correlation between activity and heart 
rate for both control and DTA mice (Fig 5.17A and B). At low activity levels heart rate increased 
rapidly, whereas at higher activity levels increases in heart rate followed a linear regression. This 
correlation did not change with PPG ablation. At six weeks, linear regression slopes were similar 
for control and DTA mice (Fig 5.17C). 
Furthermore, when inspecting the longitudinal data, no effect was found of PPG ablation (Fig 
5.17D). In control mice, heart rate increased by 2.0±0.2 bpm per activity count at baseline. This 
was unchanged at six weeks when the slope was found to be 2.3±0.4 bpm per activity count 
(p=0.67, Sidak’s multiple comparisons test). DTA mice had marginally attenuated increases in 
Fig 5.16 Ablation of PPG neurons has no effect on locomotor activity. Percentage of time spent 
inactive during light phase (A) and dark phase (B). Activity of PPG-Cre/GCaMP3 or PPG-Cre/tdRFP 
transgenic mice transduced with either AAV1/2-FLEX-Perceval (Control, black squares) or AAV8-
mCherry-FLEX-DTA (DTA, red circles) at baseline, 4 weeks, and 6 weeks after surgery. n.s.: no 
significant interaction or main effects according to two-way mixed model ANOVA. Light phase: Two-
way mixed model ANOVA: No significant interaction time x virus (F(2, 20) = 0.9748, p=0.39) and no 
main effect of virus (p=0.25) or time (p=0.71). Dark phase: No significant interaction time x virus 
(F(2, 20) = 0.006161, p=0.9939) and no main effects of virus (p=0.65) or time (p=0.44). 
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heart rate in response to activity at six weeks (1.8±0.3 bpm per activity count) compared to 
baseline (2.6±0.4 bpm per activity count). However, this did not reach significance (p=0.20, 
Sidak’s multiple comparisons test) and there was no two-way interaction between virus and 
time although it did approach statistical significance (F(2, 20) = 2.872, p=0.08).  
Taken together these data suggest that NTS PPG neurons have no physiological role in 
cardiovascular control or regulation of locomotor activity. Furthermore, NTS PPG neurons were 
not important for increasing heart rate during rising activity. 
 
5.2.4 Ex4-induced tachycardia is independent of NTS PPG neuron activity 
Having found no evidence for a physiological role of NTS PPG neurons in cardiovascular control, 
I next investigated whether Ex4-induced tachycardia is altered following loss of the central 
Fig 5.17 Ablation of PPG neurons has no effect on heart rate changes in response to increase in 
activity. Heart rate at increasing levels of activity at Baseline (black), four weeks (blue), and six 
weeks (red) from a representative control mouse (A) and DTA mouse (B). Linear regressions were 
fitted for activity levels higher than 10. C) Plot of fitted linear regressions at six weeks after surgery 
from Control (black solid lines) and DTA mice (red dotted lines). D) Slopes from fitted linear 
regressions at Baseline, four weeks, and six weeks after surgery from Control (black squares) and 
DTA mice (red circles). n.s.: no significant interaction or main effects according to two-way mixed 
model ANOVA. 
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source of GLP-1. To investigate this, I injected control and DTA animals with 10 µg/kg Ex4 i.p. 
nine weeks post-surgery. 
As seen previously, i.p. injection with 10 µg/kg Ex4 led to an increase in heart rate with an initial 
stress-induced peak followed by a gradually declining elevated heart rate (Fig 5.18A). The 
response was similar in control and DTA animals. Indeed, analysis of the change in resting heart 
rate in response to saline and 10 µg/kg Ex4 revealed no significant difference between control 
and DTA mice in the response to both (Fig 5.18B and C). Two-way mixed model ANOVA yielded 
no significant interaction between treatment and virus (F(1, 7) = 0.3287, p=0.5844). There was 
no main effect of virus (p=0.7610), while there was a significant main effect of treatment 































5.2.5 High-fat diet for eight weeks induces weight gain, glucose intolerance, and 
tachycardia in C57BL/6 mice 
In the next two sections, I investigate whether giving mice a metabolic challenge in the form of 
diet-induced obesity could unveil a physiological role for NTS PPG neurons in cardiovascular 
control. Previous studies have shown that HFD reduces the sensitivity of rats to the food intake-
suppressive effects of Ex4 and GLP-1 (Williams et al. 2011; Duca et al. 2013; Mul et al. 2013), 
Fig 5.18 Ex4 increases heart rate independently of PPG neuron activity. A) 
Heart rate of control (black squares) and DTA mice (red circles) injected i.p. 
with 10 µg/kg Ex4 four hours into light phase. Shown here are mean±SEM of 
control (n=4, black) and DTA mice (n=5, red) mice taken every 30 mins over 24 
hours as indicated by Zeitgeber time on the x-axis. The arrow indicates time 
of injection and the bars at the bottom indicate light (white bar) and dark 
(black bar) phases with a brief period of half-light indicated by a white to black 
gradient. B) and C) two different graphs showing the change in resting heart 
rate of control (black squares) and DTA mice (red circles) in response to saline 
(open symbols) and 10 µg/kg Ex4 (filled symbols). n.s.: not significant 
according to Sidak’s multiple comparisons test.  
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suggesting a link between diet and the GLP-1 system. Furthermore, HFD has been shown to 
increase the levels of GLP-1 in the bloodstream (Wu et al. 2015).  
To establish a model for diet-induced obesity in our laboratory, I fed a cohort of naïve, male 
C57BL/6 mice either normal chow or HFD for eight weeks (60% caloric content from fat). Mice 
kept on normal chow maintained their body weight over a period of 57 days with only a small 
increase in body weight at the end of the experiment (Fig 5.19). Two-way mixed model ANOVA 
revealed a significant interaction between diet and time (F(16, 128) = 9.072, p<0.0001). At 57 
days, mice fed a HFD weighed significantly more than control mice (p=0.001, Fig 5.19A). 
Similarly, the percentage increase in bodyweight of HFD fed mice was significantly larger than 
that of mice fed normal chow with HFD fed mice gaining up to 44% of their initial bodyweight 
(Fig 5.19B, p=0.0067, Student’s t-test).  
 
I next explored whether eight weeks of HFD was sufficient to induce glucose intolerance in these 
mice. Mice were given i.p. glucose tolerance tests (1 g/kg glucose load) at baseline and after 
eight weeks of HFD or normal chow (Fig 5.20A). There was a significant three-way interaction 
between timepoint, diet and time (F(5, 5) = 2.398, p=0.0428). I followed up with two separate 
two-way ANOVAs comparing data from normal chow and high-fat fed mice at baseline and 8 
weeks. At baseline, there was no significant two-way interaction between time and diet, as 
expected (F(5, 40) = 0.5283, p=0.7535), and no main effect of diet (p=0.12). However, at eight 
weeks, two-way ANOVA revealed a significant interaction between time and diet (F(5, 40) = 5.41, 
Fig 5.19 High-fat diet induces obesity in naïve C57BL/6 mice. A) Bodyweights of ten mice fed either 
normal chow (open circles, N=5) or HFD (filled triangles, N=5) were monitored over 57 days. *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001, Sidak’s multiple comparisons test. B) Percentage change in 
bodyweight from day 0 after 57 days for mice kept on normal chow (open circles) and mice fed a 
high-fat diet (filled triangles). **p<0.01, Student’s t-test.  
Chapter 5 – The role of PPG neurons in cardiovascular control 
152 
 
p=0.0007). Mice fed a HFD had significantly higher blood glucose levels after 15 mins (p<0.0001). 
This elevated blood glucose concentration failed to return to baseline over two hours (Fig 5.20A, 
p=0.02).  
Two-way ANOVA of the AUCs revealed a significant interaction between timepoint and diet (F(1, 
8) = 18.64, p=0.0026). At baseline, before mice had been given HFD or normal chow, there was 
no significant difference between the two groups (Fig 5.20B, p=0.41). In contrast, after eight 
weeks of HFD the AUC of the blood glucose response was significantly larger as compared to the 
AUC of mice kept on normal chow (p=0.0006). This demonstrates that eight weeks of HFD is 




Next, I investigated whether maintenance on HFD for eight weeks resulted in increased heart 
rate and blood pressure. Both were measured non-invasively using the tail-cuff system 
described previously. MAP, systolic, and diastolic pressure were unaffected by HFD (Fig 5.21A, 
p=0.77, p=0.84, and p=0.59, respectively). In contrast, heart rate was significantly elevated in 
mice fed a HFD for eight weeks as compared to mice on normal chow (Fig 5.21B, p=0.032). 
In summary, eight weeks of HFD is sufficient to induce significant weight gain and glucose 
intolerance in male C57BL/6 mice. In addition, diet-induced obesity resulted in tachycardia 
without affecting blood pressure.  
Fig 5.20 Diet-induced obesity leads to glucose intolerance in naïve C57BL/6 mice. A) Blood 
glucose concentrations following i.p. glucose tolerance test. Mice were tested before (Baseline, 
open symbols) and after (closed symbols) 8 weeks of HFD (triangles) or normal chow (circles). 
*p<0.05, **p<0.01, ****p<0.0001 as compared to Chow – 8 weeks, Sidak’s multiple comparisons 
test. B) Quantification of A). Area under the curve (AUC) of glucose curves in A) for mice kept on 
normal chow (circles) and mice fed a high-fat diet (triangles) at Baseline and 8 weeks. n.s.: not 
significant. ***p<0.001, Sidak’s multiple comparisons test.  




5.2.6 Diet-induced obesity leads to tachycardia and high blood pressure 
independently of PPG neuron activity 
In the previous section, I demonstrated how switching to a HFD for two months induces obesity, 
glucose intolerance and tachycardia in male C57BL/6 mice. Having established a model for 
obesity-related cardiovascular pathology, I asked if tachycardia was dependent on the activity 
of NTS PPG neurons. To answer this, I transferred four control and five PPG-ablated mice from 
normal chow to HFD. After one month, control animals had gained 37±4% bodyweight and DTA 
mice had gained 49±9% bodyweight. This difference in bodyweight gain did not reach statistical 
significance (p=0.15).  
Following one month of HFD, mice were significantly less active during dark phase as seen from 
two representative plots in Fig 5.22A. There was no obvious difference between control and DTA 
animals. Light phase activity was unaffected by HFD with mice spending between 85% and 92% 
of their time inactive after one month of HFD (Fig 5.22B). There was no two-way interaction 
between diet and virus (F(1, 15) = 0.001386, p=0.9708) and no main effect of HFD (p=0.58). In 
contrast, HFD decreased locomotor activity during dark phase (Fig 5.22B). Control mice spent 
76±2% of their time inactive after HFD compared to 65±4% before diet-induced obesity. HFD 
decreased dark phase locomotor activity similarly in both groups (Fig 5.22B, p=0.018, main effect 
of diet in two-way ANOVA). There was no significant two-way interaction between diet and virus 
(F(1, 15) = 0.04044, p=0.84) and no main effect of virus (p=0.45), suggesting the decrease in dark 
phase locomotor activity is independent of PPG neuron activity.  
Fig 5.21 High-fat diet induces tachycardia, without affecting blood pressure, in naïve C57BL/6 mice. 
A) Mean arterial (MAP), systolic, and diastolic blood pressure, and B) mean heart rate (HR) of mice 
kept on normal chow (Chow, open circles) or fed a high-fat diet for 8 weeks (HFD, filled triangles). 
Mean±SEM are indicated. *p<0.05, n.s.: not significant, Student’s t-test. 
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Fig 5.22 High-fat diet increases the time mice spend inactive independently of NTS PPG neuron 
activity. A) Activity plotted over 24 hours in a representative control (top panel) and DTA mouse 
(bottom panel) before (Pre-HFD, left panels) and after one month of HFD (Post-HFD, right panels). 
Light (white bar), twilight (gradient bar) and dark phase (black bar) are indicated at the bottom 
along with Zeitgeber time. B) Percentage of time spent inactive in control (squares) and DTA mice 
(circles) before (Pre-HFD, black open symbols) and after high-fat diet (Post-HFD, orange filled 
symbols). *p<0.05, main effect of diet in two-way ANOVA. 
 
After only one month of HFD, both control and DTA mice had significantly elevated heart rate 
(Fig 5.23). In particular, heart rates were higher during light phase (Fig 5.23A). This difference in 
light phase and dark phase was hypothesised to be due to lower activity during light phase, 
which unmasks effects on resting heart rate. Indeed, when resting heart rate values were 
computed and their distributions plotted, it became clear that diet-induced obesity induced a 
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shift in the distributions towards higher resting heart rate values (Fig 5.23B) and resting heart 
rate was significantly increased in both control and DTA mice (Fig 5.23C). There was no two-way 
interaction between virus and diet (F(1, 15) = 2.349, p=0.15) and no main effect of virus (p=0.28). 
There was, however, a main effect of diet (p<0.0001), suggesting HFD induces tachycardia 
similarly in both control and DTA mice.   
  
Similarly, HFD led to an increase in resting MAP (Fig 5.24C). This was not detected with VPR tail-
cuff measurements even after two months of HFD (Fig 5.21), suggesting the biotelemetry system 
is more sensitive than the tail-cuff system. The elevated MAP was most pronounced in control 
mice (Fig 5.24A). However, closer inspection of the distributions of resting MAP values revealed 
no obvious differences in the shift in the distributions after one month of HFD (Fig 5.24B). Both 
control and DTA mice displayed a shift towards higher resting MAP values. Indeed, analysis of 
Fig 5.23 HFD induces tachycardia independently of PPG neuron activity. A) Mean heart rate taken 
every 30 mins over 24 hours in control (left panel) and DTA mice (right panel) before (Pre-HFD, 
black circles) and after one month of HFD (Post-HFD, orange triangles). Traces display 
average±SEM. Light (white bar), twilight (gradient bar) and dark phase (black bar) are indicated at 
the bottom along with Zeitgeber time. N=5 and 3 (Control, Pre-HFD and Post-HFD); N=6 and 5 (DTA, 
Pre-HFD and Post-HFD) B) Representative densities of resting heart rate (HR) from one control (left 
panel) and one DTA mouse (right panel) before (Pre-HFD, black) and after high-fat diet (Post-HFD, 
orange). Total density areas of individual histograms are 100. C) Resting HR of control (squares) 
and DTA mice (circles) Pre-HFD (empty black symbols) and after one month of high-fat diet (Post-
HFD, orange symbols). ****p<0.0001, main effect of diet in two-way ANOVA. 
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the resting median MAP yielded no significant two-way interaction between virus and diet (F(1, 
15) = 0.9044, p=0.3567) and no main effect of virus (Fig 5.24C, p=0.47), whereas there was a 
main effect of HFD (p=0.0018). 
Taken together, these results suggest that one month of HFD is sufficient to induce elevations 
in both resting heart rate and MAP, but that NTS PPG neurons play no physiological role in these 
changes.  
 
5.2.7 Ex4 increases heart rate following high-fat diet 
Having found no evidence for recruitment of NTS PPG neurons in response to diet-induced 
obesity, I next investigated if HFD affects the tachycardic response to systemic GLP-1R 
Fig 5.24 Diet-induced obesity increases MAP independently of PPG neuron activity. A) Mean 
MAP over 24 hours in control (left panel) and DTA mice (right panel) before (Pre-HFD, black 
circles) and after one month of HFD (Post-HFD, orange triangles). Traces display mean±SEM 
taken every 30 mins. Light (white bar), twilight (gradient bar) and dark phase (black bar) are 
indicated at the bottom along with Zeitgeber time. N=5 and 3 (Control, Pre-HFD and Post-HFD); 
N=6 and 5 (DTA, Pre-HFD and Post-HFD). B) Representative histograms showing densities of 
resting MAP values from one control (left panel) and one DTA mouse (right panel) before (Pre-
HFD, black) and after one month of high-fat diet (Post-HFD, orange). Total density areas of 
individual histograms are 100. C) Resting MAP of control (squares) and DTA mice (circles) Pre-
HFD (empty black symbols) and after one month of high-fat diet (Post-HFD, orange symbols). 
***p<0.001, main effect of diet in two-way ANOVA. 
Chapter 5 – The role of PPG neurons in cardiovascular control 
157 
 
activation. Previous studies has suggested that maintenance on HFD desensitises rats to the 
food intake-suppressive effects of GLP-1R stimulation (Williams et al. 2011; Mul et al. 2013).  
Ex4 (10 µg/kg), injected i.p. four hours into light phase, increased heart rate in both control and 
DTA animals after HFD to a similar level as seen before HFD (Fig 5.25A). The change in resting 
heart rate from baseline in response to Ex4 was significantly reduced in both control and DTA 
animals following one month of HFD (Fig 5.25B, p=0.001, main effect of diet). There was no two-
way interaction between diet and virus (F(1, 7) = 1.519, p=0.26) and no main effect of virus 
(p=0.86).  
These data appear to suggest that diet-induced obesity attenuates the tachycardic effect of Ex4. 
However, the difference in the Ex4 responses could be due to an increase in baseline resting 
heart rate after one month of HFD as described in the previous section. Therefore, I also 
analysed the absolute heart rate in response to Ex4 and found that Ex4 increased resting heart 
rate to a similar level before and after diet-induced obesity (Fig 5.25C). In support of this, two-
way repeated measures ANOVA revealed no interaction between diet and virus (F(1, 6) = 0.2924, 
p=0.61) and no main effects of diet (p=0.38) or virus (p=0.81). 





5.2.8 Chemogenetic activation of NTS PPG neurons increases heart rate in freely-
behaving mice 
The data presented here do not support a physiological role for NTS PPG neurons in the 
regulation of heart rate and blood pressure. However, the sympathetic involvement in the 
tachycardic response to systemic GLP-1R activation suggests that central GLP-1Rs do have the 
potential to regulate heart rate. I therefore investigated if selective activation of NTS PPG 
neurons is sufficient to increase heart rate.  
To this end, I injected three PPG-Cre/GCaMP3 transgenic mice with AAV2-FLEX-HM3Dq:mCherry 
and three PPG-Cre/GCaMP3 mice with AAV2-FLEX-EGFP as control. Two weeks later, I confirmed 
the effect of PPG activation on feeding. Since food intake is robustly suppressed following PPG 
activation as demonstrated in chapter 4, hypophagia in response to 2 mg/kg CNO was used as a 
Fig 5.25 High-fat diet does not alter the tachycardic effect of systemic GLP-1R activation. A) 
Mean heart rate over 24 hours in control (left panel) and DTA mice (right panel) in response to 
10 µg/kg Ex4 before (Pre-HFD, black circles) and after one month of HFD (Post-HFD, orange 
triangles). Traces display mean±SEM taken every 30 mins. Light (white bar), twilight (gradient 
bar), and dark phase (black bar) are indicated at the bottom along with Zeitgeber time. N=4 and 
3 (Control, Pre-HFD and Post-HFD); N=6 and 5 (DTA, Pre-HFD and Post-HFD). Change in (B) and 
absolute (C) resting heart rate in response to 10 µg/kg Ex4 in control (squares) and DTA mice 
(circles) before (Pre-HFD, black empty symbols) and after one month of high-fat diet (Post-HFD, 
filled orange symbols). **p<0.01, n.s.: not significant, main effect of diet in two-way ANOVA.  
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positive control for successful transduction of NTS PPG neurons with HM3Dq:mCherry. Indeed, 
control mice ate 1.6±0.09 g of chow in the first four hours, whereas HM3Dq-expressing mice ate 
only 0.7±0.15 g of chow (p=0.0006, Sidak’s multiple comparisons test, Fig 5.26). Two-way mixed 
model ANOVA yielded no significant interaction between time and virus (F(3, 12) = 2.821, 
p=0.0839), but did reveal a significant main effect of both time (p<0.0001) and virus (p=0.0092), 
confirming that chemogenetic activation of NTS PPG neurons reduces food intake over several 
hours.  







Having confirmed successful transduction of NTS PPG neurons in these mice, I implanted 
biotelemetry probes in the three control and three HM3Dq-expressing mice. After the recovery 
period, two of the biotelemetry probes implanted into control mice were blocked and therefore 
no longer detected meaningful blood pressure changes. I continued with one control mouse and 
three HM3Dq mice.  
Mice were injected i.p. with 2 mg/kg CNO or saline 7.5 hours into light phase. As shown 
previously, injection of saline led to a transient increase in heart rate (Fig 5.27). At dark onset, 
heart rate rose as activity increased. When the same HM3Dq-expressing mouse was injected i.p. 
with 2 mg/kg CNO heart rate rose as with saline injection. However, heart rate did not return to 
baseline and remained elevated until onset of dark phase, suggesting activation of NTS PPG 
neurons increases heart rate (Fig 5.27). Locomotor activity was reduced in this animal following 
Fig 5.26 Selective activation of NTS PPG neurons induces 
hypophagia. Cumulative food intake measured over 21 
hours following NTS PPG activation. Both control (black 
squares, N=3) and HM3Dq-expressing mice (green circles, 
N=3) were injected i.p. with 2 mg/kg CNO 30 mins prior to 
dark onset. **p<0.01, main effect of virus on food intake 
according to two-way mixed model ANOVA.  
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2 mg/kg CNO compared to saline injection, demonstrating that the elevated heart rate cannot 








I quantified this tachycardia in three HM3Dq-expressing mice by extracting resting heart rates 
after saline and CNO, respectively. These values were taken from hours 8.5-10.5 to avoid 
contamination of resting heart rates with heart rate values during handling stress. As seen from 
the histogram in Fig 5.28A, the distribution of heart rate values following saline was skewed to 
the right with a median resting heart rate of 550 bpm. Chemogenetic activation of NTS PPG 
neurons resulted in a shift in the histogram towards higher heart rate values and a median 
resting heart rate of 631 bpm (Fig 5.28A).  
To further compare the responses to saline and CNO, I calculated median resting heart rate at 
baseline and after i.p. injections of either saline or 2 mg/kg CNO. Baseline values were taken two 
hours prior to i.p. injection (hours 5-7) and response heart rates were taken from hours 8.5-10.5 
as above. Resting heart rate was increased following saline by 41±11 bpm in HM3Dq-expressing 
mice (Fig 5.28B). However, injection of 2 mg/kg CNO increased heart rate by 108±10 bpm, which 
Fig 5.27 Chemogenetic activation of NTS PPG neurons increases heart rate in awake, behaving 
mice. Heart rate (top) and locomotor activity (bottom) of one mouse injected i.p. with either saline 
(black, left) or 2 mg/kg CNO (green, right) recorded over 24 hours as indicated by zeitgeber time 
at the bottom. Dotted lines indicate times of injection and the bar at the bottom indicates light 
(white bar) and dark (black bar) phases with a brief period of half-light indicated by a white to 
black gradient. Traces are running averages over 30 mins. 
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was significantly more than that observed following saline (p=0.02, Student’s pair t-test). In 
comparison, heart rate was slightly decreased following 2 mg/kg CNO in the control mouse (Fig 
5.28B). Although I observed a reduction in locomotor activity in two HM3Dq-expressing mice 
following 2 mg/kg CNO as compared to saline, this decrease did not occur in the third HM3Dq-
expressing mouse and in fact a decrease in locomotor activity was also observed in the one 








These data indicate that chemogenetic activation of PPG neurons is sufficient to increase resting 
heart rate. However, a future study with increased numbers of mice is needed to verify these 
effects. Furthermore, I did not obtain any data on blood pressure changes in response to PPG 
neuron activation, because the biotelemetry probes were partially blocked giving blunted blood 
pressure measurements. This only allowed accurate extraction of heart rate values from the 
frequency of the peaks of blood pressure trace. However, in collaboration with Dan R. Cook, 
another PhD student in our group, we have confirmed that heart rate is significantly increased 
following chemogenetic activation of NTS PPG neurons in anaesthetised mice (N=5). For this 
study, I performed the stereotaxic injections of the viruses and Dan R. Cook measured heart rate 
in the anaesthetised mice three weeks later. Taken together these data suggest that PPG neuron 
activation is sufficient to increase heart rate in mice.   
Fig 5.28 Activation of PPG neurons in vivo induces tachycardia. A) Representative histogram 
showing densities of resting heart rate (HR) values following i.p. injections of either saline (black) or 
2 mg/kg CNO (green). Total density areas of individual histograms are 100. Change in resting HR (B) 
and time spent active (C) of control (squares, N=1) and HM3Dq-expressing mice (circles, N=3) in 
response to saline (empty black symbols) and 2 mg/ kg CNO (filled symbols). *p<0.05, paired t-test. 




The mechanisms underlying GLP-1R mediated tachycardia are controversial and the implications 
for the use of GLP-1 analogues in the treatment of both diabetes and obesity are unknown. This 
chapter gives new insight into the role of GLP-1 in cardiovascular control. I first identified 
implantable biotelemetry as the optimal approach to investigate this and confirmed previous 
findings that Ex4-induced tachycardia is mediated by sympathetic activation (Yamamoto et al. 
2002, 2003; Baggio et al. 2017) (Fig 5.9-5.10), but also demonstrated that it does not require 
PPG neuron engagement (Fig 5.18). Expanding on this, I found that ablation of NTS PPG neurons 
had little impact on heart rate and blood pressure, suggesting that central GLP-1 is not necessary 
for cardiovascular control (Fig 5.12-5.14). Tachycardia and hypertension following diet-induced 
obesity developed independently of PPG neuron activity (Fig 5.23-5.24). Finally, I found that 
selective activation of NTS PPG neurons was sufficient to increase heart rate (Fig. 5.28), 
suggesting that the central GLP-1 system does have the potential to modulate cardiovascular 
parameters.  
5.3.1 Choosing and understanding a method for measuring blood pressure and 
heart rate in conscious mice 
Accurate recordings of heart rate and blood pressure can be obtained using VPR tail-cuff systems 
(Feng et al. 2008). However, tail-cuff recordings require restraint, which causes stress and affects 
heart rate and blood pressure (Wilde et al. 2017). Importantly, the acute stress associated with 
handling and restraint does not disappear with training (Gross and Luft 2003). In comparison, 
biotelemetry does not require handling of the animal beyond the initial surgical intervention. 
Indeed, measurements of resting heart rate and MAP were consistently lower when measured 
using the biotelemetry system in comparison with the VPR tail-cuff system (Fig 5.3). Since these 
measurements were not done in the same mice or in the same environment, I cannot exclude 
that other factors contributed to the higher heart rate and MAP in tail-cuff measurements. 
However, similar results have been demonstrated previously with even larger effects of restraint 
and tail-cuff measurements (Wilde et al. 2017). Indeed, Gross & Luft (2003) argued that the tail-
cuff method should only be used when large differences in blood pressure and heart rate are 
expected from the experiment. Considering the putative role of central GLP-1 in stress (Kinzig et 
al. 2003; Maniscalco et al. 2012; Ghosal et al. 2013, 2017; Holt and Trapp 2016), I concluded that 
the relatively stress-free biotelemetry method was the most appropriate. 
Most studies using biotelemetry recordings of cardiovascular output simply report mean heart 
rate and blood pressure (Yamamoto et al. 2002, 2003; Griffioen et al. 2011). I demonstrate here 
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that the mean is not a meaningful measure of these parameters (Fig 5.2). Heart rate and MAP 
measurements did not follow a normal distribution and were dependent on activity levels as 
reported previously (Sheward et al. 2010). In fact, when I plotted heart rate values against 
activity (no activity versus any level of activity), I found that the bimodal distribution was made 
up of two unimodal distributions. Importantly, these distributions were not normal. Although 
Sheward et al. (2010) did investigate the distributions of heart rate and blood pressure values, 
they only reported mean values. As mentioned, most studies fail to acknowledge the non-
normal distribution of their measurements (Yamamoto et al. 2002; Griffioen et al. 2011). Based 
on the skewed distributions, I concluded that the mean values would not be meaningful and I 
instead calculated the medians.  
5.3.2 The tachycardic effect of Ex4 – peripheral and central contributions 
GLP-1R activation is well-known to induce robust tachycardia, whether the agonist is injected 
systemically (Barragán et al. 1994, 1996; Yamamoto et al. 2002; Hayes et al. 2008) or directly 
into the brain (Barragán et al. 1999; Yamamoto et al. 2002; Griffioen et al. 2011). Here, I 
confirmed those findings in mice implanted with biotelemetry probes (Fig 5.4-5.6). Peripheral 
injection of 10 µg/kg Ex4 dramatically increased heart rate without affecting locomotor activity, 
suggesting the tachycardic effects was not secondary to a change in activity, in accordance with 
previously published studies (Hayes et al. 2008; Griffioen et al. 2011). Interestingly, I found no 
effect of i.p. injections of GLP-1 on heart rate (Fig 5.4 and 5.6). However, this is most likely due 
to the short half-life of GLP-1 in the bloodstream. The stress-induced peak in heart rate and 
blood pressure observed with both saline and Ex4 injections would mask any effects of GLP-1 on 
heart rate. Indeed, Barragan et al. (1994, 1996) demonstrated potent tachycardic effects of 
intravenous GLP-1 in anaesthetised rats, but found that the effect was shorter lived than that of 
Ex4, although their recordings did not go beyond 30 mins after injection. In support of this, Dan 
R. Cook, another PhD student in our group, found that in the anaesthetised mouse, in the 
absence of stress-induced tachycardia, 100 µg/kg GLP-1 significantly elevated heart rate (N=5, 
unpublished).  
In the experiments presented here, Ex4 was injected i.p. and could work to increase heart rate 
via both peripheral and central GLP-1Rs. Literature on the mechanisms underlying Ex4’s 
tachycardic effects is controversial, with the most commonly proposed scenario involving both 
peripheral and central mechanisms (Barragán et al. 1999; Yamamoto et al. 2002; Baggio et al. 
2017). Current evidence is conflicting and fails to paint a clear picture. 
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A direct chronotropic effect of GLP-1R agonism on the heart has been proposed, but the 
evidence is sparse. GLP-1Rs are found on the heart of mice (Richards et al. 2014) and Baggio et 
al. (2017) recently demonstrated that mice lacking cardiac GLP-1Rs have reduced heart rate 
responses to treatment with liraglutide. However, this appeared to be mainly due to an increase 
in heart rate in response to vehicle injections in mice lacking cardiomyocyte GLP-1Rs. 
Furthermore, it was the opposite of what was found by the same group a few years earlier in an 
experiment where sensitivity to liraglutide was unaffected by genetic disruption of cardiac GLP-
1Rs (Ussher et al. 2014). In addition, they failed to show any direct effects of GLP-1R agonism on 
isolated hearts (Baggio et al. 2017), leaving the role of cardiac GLP-1R in GLP-1-mediated 
tachycardia elusive. 
In 1999, Barragan et al. investigated the relative contributions of peripheral and central GLP-1Rs 
to GLP-1-induced tachycardia. They found that the tachycardic effects of peripheral GLP-1R 
stimulation could be blocked with central infusions of the selective antagonist Ex9, suggesting 
central GLP-1Rs are responsible for the cardiovascular effects of GLP-1. In contrast, the effects 
of central GLP-1 could not be blocked by peripheral Ex9. Interestingly, however, peripheral GLP-
1 did increase heart rate and that effect was blocked by peripheral Ex9, suggesting some 
contribution by peripheral receptors. These data suggest a mechanism in which peripheral GLP-
1 activates peripheral GLP-1Rs leading to engagement of the central GLP-1 system. However, 
there is at present no other evidence for such a link and in fact one study found that central Ex9 
was not able to block the food intake-suppressive effects of peripheral GLP-1 (Williams et al. 
2009). As such, the contributions of peripheral GLP-1Rs to the effects of systemic GLP-1 remain 
unknown.  
There is some evidence for a neural link between peripheral GLP-1 and central pathways. 
Peripherally administered GLP-1 activates vagal afferents and GLP-1Rs are expressed in the 
nodose ganglion (Kakei et al. 2002; Nakagawa et al. 2004; Bucinskaite et al. 2009; Gaisano et al. 
2010; Richards et al. 2014). However, the physiological role of these GLP-1Rs remains uncertain 
with some reports suggesting no necessity for vagal afferents in the response to GLP-1 (Hayes 
et al. 2011b; Zhang and Ritter 2012; Reidelberger et al. 2014; Sisley et al. 2014), whereas other 
studies have found clear involvement of the vagus-brain communication (Abbott et al. 2005; 
Fujiwara et al. 2012; Krieger et al. 2015). However, none of these studies were performed in the 
context of cardiovascular control. This highlights the need for further research into the 
importance of vagal afferents in peripheral GLP-1’s effects and the downstream targets of GLP-
1-mediated vagal stimulation. 
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It is likely that peripherally administered Ex4 acts directly on central GLP-1Rs, diminishing the 
importance of the potential vagal pathways involved. This notion is supported by several pieces 
of evidence described in the introduction. It is likely that Ex4 crosses the blood brain barrier to 
reach receptors in the brain (Kastin and Akerstrom 2003; Secher et al. 2014). Furthermore, 
peripheral Ex9 has no impact on the cardiovascular and food intake-suppressive effects of 
peripheral Ex4 (Barragán et al. 1996; Kanoski et al. 2011), suggesting the effects are mediated 
by central GLP-1Rs, although it is unclear why Ex9, which is structurally similar to Ex4, should 
have no access to central GLP-1Rs. The question then remains why peripheral GLP-1, assuming 
it does not reach receptors in the brain due to its rapid degradation, is able to increase heart 
rate (Barragán et al. 1999). Peripheral injection of a GLP-1 analogue, albugon (Baggio et al. 
2004a), which cannot cross the blood-brain barrier, would partly address the question of a 
contribution of peripheral GLP-1Rs to tachycardia. 
5.3.3 Ex4-induced tachycardia is mediated by the sympathetic nervous system 
The involvement of the autonomic nervous system in GLP-1R-mediated tachycardia is a much-
disputed point. Although most data from rats have suggested a role of the sympathetic nervous 
system in GLP-1R-mediated tachycardia (Barragán et al. 1994; Yamamoto et al. 2002), a study in 
mice concluded that depression of the parasympathetic nervous system was in fact the cause of 
increased heart rate (Griffioen et al. 2011). The data presented in this chapter clearly 
demonstrated that i.p. Ex4 does not increase heart rate in the absence of sympathetic input to 
the heart (Fig 5.9 and 5.10). This finding corresponds with a recent publication by Baggio et al. 
(2017), in which propranolol, a non-selective β-blocker, abolished the heart rate response to 
liraglutide in mice.  
I did not find any evidence for an effect of i.p. 10 µg/kg Ex4 on locomotor activity in accordance 
with other studies in mice (Griffioen et al. 2011; Baggio et al. 2017), although there have been 
reports of decreased activity following i.p. injection of 2.4 µg/kg Ex4 in rats (Hayes et al. 2008). 
Importantly, the decrease observed in the latter study was only obvious when activity was 
elevated due to chronic decerebration. Similarly, Ex4 has been found to reduce locomotor 
activity in response to amphetamine (Erreger et al. 2012). Taken together, this suggests that Ex4 
has no effect when activity is otherwise low, but at times of high activity it may work to reduce 
locomotion. Whether this is a direct effect on activity or indirectly affects activity by suppressing 
food-seeking behaviour remains unclear. 
Additionally, I did not observe any difference in MAP after i.p. injection of Ex4. This is in contrast 
to what has been observed in rats (Barragán et al. 1994; Yamamoto et al. 2002) and could be 
Chapter 5 – The role of PPG neurons in cardiovascular control 
166 
 
the result of regulatory mechanisms preventing potentially detrimental increases in blood 
pressure. Previous studies in mice did not measure blood pressure in response to GLP-1R 
activation, although one study did find antihypertensive effects of liraglutide in mice with 
pharmacologically elevated blood pressure (Kim et al. 2013).  
The involvement of the sympathetic nervous system in Ex4-induced tachycardia and the 
evidence described above suggest that GLP-1R activation leads to increased heart rate, at least 
in part, through engagement of the central nervous system. Yamamoto et al. (2003) proposed 
that activation of catecholaminergic neurons in the AP, possibly via other areas in the brainstem, 
the PBN, VLM, and NTS, ultimately leads to increased sympathetic outflow. In support of a 
mechanism relying on the brainstem, a study by Hayes et al. (2008) using decerebrate rats 
concluded that no brainstem → forebrain communication was necessary for tachycardia 
induced by fourth ventricle infusions of Ex4, suggesting that brainstem → spinal cord circuits 
culminating in sympathetic activation are responsible for the increase in heart rate. Importantly, 
the findings by Hayes et al. (2008) can also be explained by direct activation of GLP-1Rs in the 
spinal cord, which would be accessible to fourth ventricle Ex4 in decerebrate rats. Interestingly, 
I show here that tachycardia induced by systemic Ex4 is not dependent on NTS PPG neurons (Fig 
5.18), suggesting a potential brainstem → spinal cord circuit does not include PPG neurons. This 
is most likely due to circumvention of these cells by Ex4, which acts directly on downstream 
central GLP-1Rs. Importantly, these findings do not exclude the possibility that NTS PPG neurons 
are essential regulators of heart rate and blood pressure in mice or that brainstem → forebrain 
circuits contribute to the impact of these neurons on cardiovascular control.   
5.3.4 NTS PPG neurons are not involved in normal cardiovascular control 
These pharmacological studies provide insight into the mechanisms by which GLP-1 analogues 
used in the treatment of diabetes and obesity lead to cardiovascular pathology (Robinson et al. 
2013). However, in normal physiology, GLP-1 from the periphery is unlikely to reach GLP-1Rs in 
the brain as discussed in the Introduction. I was therefore interested in the potential 
involvement of NTS PPG neurons in cardiovascular control. As in Chapter 4, I ablated PPG 
neurons in the NTS. Unpublished data from our laboratory show that PPG ablation results in 80% 
reduction in GLP-1 in the hypothalamus and spinal cord (James E. Richards and S. Trapp, 
unpublished). However, this loss of central GLP-1 did not affect heart rate and blood pressure at 
rest or during activity (Fig 5.12-5.14). Similarly, genetic disruption of GLP-1Rs has no effect on 
baseline cardiovascular parameters and lack of hypothalamic GLP-1Rs does not affect baseline 
heart rate (Gros et al. 2003; Ghosal et al. 2017). Notably, these studies failed to report how 
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baseline values were calculated and did not appear to acknowledge the strong correlation 
between activity and heart rate observed here. In this chapter, I report for the first time that 
NTS PPG neurons are not necessary for control of resting and active heart rate and blood 
pressure (Fig 5.13). More in-depth analysis of the relationship between heart rate and activity 
in control and PPG ablated mice revealed no difference in the heart rate response to increased 
activity although these findings should be substantiated by repeating the study with a larger 
cohort of mice (Fig 5.17).  
Ghosal et al. (2017) recently demonstrated that tachycardia induced by acute restraint stress is 
mediated by GLP-1Rs in Sim1-positive neurons in the hypothalamus. Although I did not 
specifically design an experiment to investigate the effect of lack of NTS PPG neurons on 
cardiovascular responses to stress, I did expose the mice to brief handling stress when injecting 
them. Both control and PPG ablated mice responded to i.p. injection of saline with a similar 
increase in resting heart rate (Fig 5.18). This suggests that PPG neurons are not necessary for 
the tachycardic response to acute stress. However, handling during i.p. injections is usually 
shorter than 1 min, which could be too brief to detect differences. In future experiments using 
PPG-ablated mice it would be interesting to expose them to acute restraint stress for 30 mins, 
as I did in Chapter 4. Based on the reports by Ghosal et al. (2017), I would expect PPG ablated 
mice to have blunted tachycardia in response to acute stress.  
5.3.5 NTS PPG neurons are not necessary for tachycardia and hypertension 
following diet-induced obesity 
Metabolic syndrome is the medical term for a combination of obesity, diabetes and 
hypertension. It can be caused by intake of HFD and puts humans at greater risk of coronary 
heart disease and stroke. Here, mice became obese, glucose intolerant, and tachycardic after 
only eight weeks of HFD as reported previously (Winzell and Ahren 2004). Blood pressure did 
not appear to be affected by HFD when measured using the VPR tail-cuff system. However, 
implantable biotelemetry revealed a clear, overall effect on both heart rate and blood pressure 
after only four weeks of HFD. This discrepancy could have several causes. Firstly, the increased 
sensitivity of the implantable biotelemetry system may allow me to calculate more accurate 
resting heart rate and blood pressure from undisturbed mice. Alternatively, these mice 
developed more severe metabolic syndromes after just one month of HFD. Although I can make 
no certain conclusions based on these data, I did observe that biotelemetry mice gained weight 
faster than mice in the preliminary HFD experiment. Notably, mice implanted with biotelemetry 
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probes were housed individually, which could lead to overeating and lower activity than mice 
group-housed as in the preliminary experiment (Bartolomucci et al. 2009).  
Alongside metabolic syndrome, PPG-ablated and control mice appeared to be less active during 
dark phase, when activity normally increases due to food-seeking behaviour, indicating a level 
of lethargy as a result of diet-induced obesity (Fig 5.22 and 5.8). My findings do not support a 
role for NTS PPG neurons in the hypertension and tachycardia following diet-induced obesity. 
Interestingly, our laboratory has data demonstrating maintenance on HFD approximately 
doubles brain GLP-1 levels (James E. Richards, S. Trapp, unpublished). It is curious that the 
increased expression levels did not affect cardiovascular control, since PPG-ablated and control 
mice developed tachycardia and hypertension to a similar degree. This could indicate that 
although expression is increased, GLP-1 is not released in significant amounts from PPG neurons 
during development of metabolic syndrome. Alternatively, downstream GLP-1Rs are 
desensitised to GLP-1 in diet-induced obesity.  
There is some evidence for reduced sensitivity to GLP-1 analogue treatment after HFD (Williams 
et al. 2011; Mul et al. 2013). This appeared to be partly due to reduced vagal sensitivity to GLP-
1 at the level of the nodose ganglion (Duca et al. 2013). In contrast, I did not observe any change 
in the tachycardic response to Ex4 following HFD in both control and PPG-ablated mice, 
suggesting the sensitivity of the downstream pathways is not compromised by the development 
of metabolic syndrome (Fig 5.25). If the effect of diet-induced obesity on GLP-1 sensitivity is 
partly due to decreased sensitivity of vagal afferents, it is likely that Ex4 would circumvent this 
by acting directly on brain GLP-1Rs. It is worth noting that in previous studies, the food intake-
suppressive effects of Ex4 have persisted after HFD and diet-induced obesity has mainly affected 
the temporal profile of the response to Ex4 (Williams et al. 2011; Mul et al. 2013). Considering 
the finding that HFD suppresses the expression of GLP-1R in the nodose ganglion, it is possible 
that only peripheral GLP-1 signalling is perturbed by HFD (Duca et al. 2013).  
5.3.6 NTS PPG neurons are sufficient to increase heart rate in mice  
It is surprising that Ex4 induces such a robust increase in heart rate when the central source of 
GLP-1 has no impact on normal heart rate and blood pressure. I reject the explanation that Ex4 
in fact increases heart rate via peripheral GLP-1Rs independent of the central GLP-1 system. 
There is substantial evidence for a role of central GLP-1Rs in the response to peripheral Ex4 
(Barragán et al. 1999; Yamamoto et al. 2002; Hayes et al. 2008; Griffioen et al. 2011), and in 
contrast little convincing data supporting a role of cardiac GLP-1Rs (Ussher et al. 2014; Baggio 
et al. 2017). In line with my observations, Gros et al. (2003) found no effect of genetic disruption 
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of the GLP-1R, suggesting the central GLP-1 system is not engaged in normal cardiovascular 
control. Is the tachycardia following i.p. Ex4 then simply a result of overactivation of GLP-1Rs, 
which does not occur in normal physiology? Acute stress appeared to reveal a role for 
hypothalamic GLP-1Rs in cardiovascular control, suggesting the central GLP-1 system needs a 
physiological push to become engaged, similar to what I observed in Chapter 4 in the context of 
food intake (Ghosal et al. 2017).  
My results from chemogenetic activation suggest that NTS PPG neurons do have the ability to 
increase heart rate (Figs 5.27-5.28). This corresponds with what we have observed in 
anaesthetised mice (Dan R Cook, unpublished), where chemogenetic activation of PPG neurons 
led to an increase in heart rate. Taken together, the evidence presented here demonstrates that 
NTS PPG neurons do have the ability to regulate heart rate, but do not affect cardiovascular 
parameters under normal conditions, nor do they contribute to the development of tachycardia 
and hypertension as a result of diet-induced obesity. The exact physiological context in which 
PPG neurons are relevant for cardiovascular control will need to be examined. The 
chemogenetic manipulation of PPG neurons is an important tool in this endeavour. Of particular 
interest is refeeding-induced tachycardia as described by Ussher et al. (2014) in mice lacking 
cardiomyocyte GLP-1Rs, as well as acute stress paradigms as described in Chapter 4 and in mice 
lacking hypothalamic GLP-1Rs (Ghosal et al. 2017). Considering the effects of PPG inactivation 
on food intake in those paradigms, this could unveil a physiological role for PPG neurons in 




6. Summary and Perspectives 
This thesis provides new insight into the physiological role of the central GLP-1 system. Whilst 
most studies have used pharmacological overactivation of GLP-1Rs to study the actions of GLP-
1 in the brain, here I addressed for the first time the physiological role of the source of 
endogenous GLP-1, PPG neurons. Although activation of GLP-1Rs in the CNS induces hypophagia 
and tachycardia, no studies have addressed the physiological role of PPG neurons in the 
regulation of food intake and heart rate. In the experiments presented here, I selectively 
manipulated the activity of PPG neurons and observed the impact on feeding and cardiovascular 
control. My findings clarify the role of PPG neurons in satiety and investigate for the first time 
the requirement for these cells in the regulation of heart rate and blood pressure. 
The data presented in Chapter 3 elucidated the signals detected by NTS PPG neurons and 
dissected the mechanisms underlying serotonergic modulation of these cells, which involved 5-
HT2c receptor-mediated dendritic activation and 5-HT1A receptor-mediated electrical inhibition. 
Experiments in Chapter 4 used selective manipulation of PPG neurons to demonstrate a role for 
PPG neurons in food intake. Interestingly, PPG neurons were not important in the control of 
normal feeding or bodyweight, but rather prevented overeating. I showed for the first time the 
importance of NTS PPG neuron activity in the hypophagic response to acute stress, highlighting 
the need for further studies into the role of central GLP-1 in stress. Finally, I established in 
Chapter 5 that although there is no requirement for endogenous GLP-1 signalling in normal 
cardiovascular control, PPG neurons do have the ability to increase heart rate. 
The data presented here support a role for PPG neurons in food intake and cardiovascular 
control. In the next sections, I propose how the evidence presented collectively indicates a 
crucial role for the central GLP-1 system in the physiological response to eating, illness, and 
stress, ultimately leading to decreased food intake and increased sympathetic outflow. 
6.1 NTS PPG neurons – integration of neural and humoral signals 
Experiments in Chapter 3 were designed to elucidate modulation of PPG neuron activity in vitro 
using a genetically encoded Ca2+ indicator. The results obtained have significantly expanded our 
knowledge of the regulation of PPG neuron activity and have revealed new potential links 
between satiety-regulatory systems. Notably, these data highlight the variety of inputs, which 
modulate PPG activity, including signals not traditionally associated with meal termination. 
Based on the widespread projections of PPG neurons, the diverse inputs regulating PPG activity, 
as well as the many effects of central GLP-1, I propose that PPG neurons integrate signals of both 
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long-term energy balance and short-term disruptions to homeostasis, including feeding, illness, 
and stress.  
Food intake is regulated by changes in caloric need (homeostatic feeding), the pleasure and 
reward associated with food intake (hedonic feeding), and by the presence of immediate or 
perceived threats to the well-being of the animal. For example, immediate danger or illness, may 
suppress feeding. I suggest that PPG neurons integrate signals of all of the above and relay this 
information to regulate food intake and sympathetic activity.  
6.1.1 PPG neurons integrate signals of satiety and energy homeostasis 
NTS PPG neurons were activated by peripheral signals of energy homeostasis and satiety, 
including leptin and CCK-8 (Hisadome et al. 2010, 2011; Holt et al. 2017). In addition, PPG neuron 
activity was modulated by 5-HT, a well-established central regulator of food intake (Holt et al. 
2017). Finally, AChR-mediated activation of PPG neurons may contribute to satiety as was shown 
for POMC neurons in the Arc (Mineur et al. 2011). Future experiments should investigate 
whether muscarinic or nicotine AChRs are involved in the carbachol-mediated increase in PPG 
neuron [Ca2+]. Considering the evidence for a role of central GLP-1 in nicotine reward and intake 
(Tuesta et al. 2017), it is also possible that the nicotinic AChR-mediated activation of PPG 
neurons reduces drug reward.  
In addition to detecting peripheral and central satiety signals, PPG neurons were activated by 
the cytokine IL-6 (Anesten et al. 2016). Keeping in mind the ability of interoceptive stressors LiCl, 
CCK-8, and LPS to activate rat GLP-1-producing neurons (Rinaman 1999b), these data suggest a 
role for PPG neurons in detecting visceral illness. Where CCK-8, LiCl, and LPS induce general 
discomfort and nausea, IL-6 signals inflammation. In healthy animals, IL-6 levels are low in both 
brain and blood. During disease, IL-6 acts via receptors in the brain to decrease food intake 
(Molotkov et al. 1998). It is uncertain whether low levels of IL-6 in healthy animals are sufficient 
to activate PPG neurons, or whether high levels, occurring at times of inflammation, are needed.  
6.2 PPG neurons in satiety 
The evidence presented above indicates a comprehensive role for PPG neurons in integrating 
signals of energy balance and well-being. Similarly, POMC and AgRP neurons in the Arc detect 
leptin, insulin, glucose, and nicotine (Belgardt et al. 2009) and have profound effects on 
homeostatic feeding. In fact, loss of AgRP neurons completely abolishes feeding leading to fatal 
starvation (Luquet et al. 2005). Whether PPG neurons play a similarly critical part in energy 
intake has been elusive until now.  
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As such, experiments in Chapter 4 were designed to test the hypothesis that PPG neurons are 
sufficient and essential for satiety. Chemogenetic activation of PPG neurons dramatically 
reduced feeding at dark onset, when mice are most likely to eat. Despite this strong hypophagic 
potential, two methods of PPG inactivation had no effect on daily food intake and body weight. 
Only when mice were refed after a long fast or were encouraged to eat a large meal did PPG 
activity become necessary for satiety.  
The finding that PPG neurons are necessary for the intake-suppressive response to a large meal 
suggests that these cells could be part of the counter-regulatory response to overeating. This is 
further supported by the finding that gastric distension activates PPG neurons (Vrang et al. 2003) 
and that the ensuing decrease in food intake is mediated by central GLP-1 signalling (Hayes et 
al. 2009).  
The large meals eaten by mice in this study were voluntary and can therefore not be considered 
supraphysiological. However, food intake in itself is a significant challenge to homeostasis 
(Woods 1991) and the neuroendocrine responses to feeding resemble that of stress (Al-Damluji 
et al. 1987). Notably, the neuronal response to overconsumption of chow is remarkably similar 
to that of aversive stimuli (Yamamoto et al. 1992; Rinaman et al. 1998; Zittel et al. 1999). The 
organism must rapidly deal with the post-prandial surge in nutrients to ensure maintenance of 
homeostasis. Because of this, stringent physiological processes are initiated in response to food 
intake. It was recently shown that overconsumption in rats results in a specific form of 
conditioned taste aversion leading to moderation of future intake (Tracy et al. 2016). Whether 
NTS PPG neurons are necessary for this adaptive response to overeating should be addressed. 
Specifically, future experiments could investigate the ability of PPG-ablated mice to develop 
aversion to large meals. 
6.2.1 GLP-1 in stress-induced hypophagia 
Further experiments presented in Chapter 4 were designed to investigate the physiological role 
of PPG neurons and central GLP-1 in stress-induced hypophagia. As well as physical stress in the 
form of a visceral illness or injury, the organism experiences psychogenic stress. The body has a 
remarkable ability to initiate anticipatory responses to a perceived threat (Ulrich-Lai and 
Herman 2009). Part of this response is to limit attention given to behavioural processes, such as 
food intake, which are not needed to cope with the immediate danger.  
I found that 30 mins restraint stress significantly reduced food intake, and that this stress-
induced hypophagia was dependent on PPG neuron activity. Considering the evidence that 
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stress activates rat GLP-1-producing neurons, these data suggest that NTS PPG neurons mediate 
anticipatory responses to perceived challenges by limiting food intake following a stressful 
stimulus. Stress-induced hypophagia was partly mediated by GLP-1 release into the dLS, a site 
known for its involvement in stress and anxiety (Singewald et al. 2011). Future experiments 
should investigate the role of this NTSPPG → dLS circuit in food intake and stress regulamon by 
targeting expression of excitatory and inhibitory DREADDs to the specific NTSPPG → dLS 
projections. 
6.2.2 Metabolic tuning of PPG neurons 
One avenue for future investigations is the impact of energy balance on PPG neuron 
recruitment. Interestingly, the ability of psychogenic stress or homeostatic stress to activate PPG 
neurons is dependent on nutritional status (Maniscalco and Rinaman 2013, 2017; Maniscalco et 
al. 2015). At times of negative energy balance hypophagia is a potentially detrimental 
phenomenon. Indeed, central GLP-1R blockade is only effective at times of plentiful energy, 
when rats are sated (Turton et al. 1996), but not in rats fasted for 24 hours, suggesting GLP-1 
release does not occur when energy is low. These data indicate that recruitment of the central 
GLP-1 system is metabolically tuned. When energy stores are low, PPG activity is kerbed. During 
these periods, anorexic responses to interoceptive or psychogenic stress are counterproductive 
and potentially harmful (Youngblood et al. 1997). The intake of a large meal following a 
prolonged fast then releases the brake on PPG neurons as demonstrated here, by Kreisler et al. 
(2016), and by Hayes et al. (2009). In future in vitro experiments, brainstem sections should be 
obtained from both food-deprived and ad libitum fed mice to investigate the responsiveness of 
PPG neurons at times of low and high energy availability. 
6.3 PPG neurons in cardiovascular control 
Evidence presented here and by others collectively suggests that PPG neurons sense changes in 
signals relating to appetite regulation, visceral illness, and stress. Furthermore, I have 
demonstrated that PPG neurons drive hypophagia in response to psychogenic stress. Acute 
stress elicits in the animal a concerted, physiological effort to cope with potential threats. 
Ultimately this relies on activation of the sympathetic nervous system. Following on from central 
GLP-1’s role in stress-induced hypophagia, I hypothesised that NTS PPG neurons are involved in 
broader responses to stress, including sympathetic activation. In particular, experiments in 
Chapter 5 were designed to elucidate the role of PPG neurons in cardiovascular control. This 
was based on numerous studies demonstrating a robust tachycardic response to GLP-1R 
activation. 
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I confirmed those findings and presented evidence that the tachycardic effect of systemic GLP-
1R activation is dependent on activation of the sympathetic nervous system. Additionally, I 
presented novel data demonstrating the ability of PPG neurons to increase heart rate in freely-
behaving mice. PPG neurons are unusual NTS cells in that they project directly to the spinal cord 
(Llewellyn-Smith et al. 2015) and future experiments should investigate the role of this recently 
discovered NTSPPG → IML/CAAChAT circuit in cardiovascular control. 
Despite the clear sympathoexcitation by Ex4 and the tachycardic effect of chemogenetic 
activation of PPG neurons, there was no obvious effect of loss of central GLP-1 on heart rate and 
blood pressure, suggesting these neurons do not contribute to normal cardiovascular control. 
However, I did not address the importance of PPG neurons in the tachycardic response to acute 
stress. This is a key experiment for elucidating the role of PPG neurons in stress and I expect it 
will reveal a dependency of stress-induced tachycardia on PPG neuron activity, since GLP-1Rs in 
the PVN were recently found to be essential for this response (Ghosal et al. 2017).  
6.4 Does central GLP-1 need a push?  
The conclusions from Chapter 4 and Chapter 5 are somewhat analogous. PPG neurons have the 
ability to induce significant hypophagia and tachycardia when chemogenetically activated, but 
they are not necessary for maintenance of daily satiety or heart rate. Based on food intake 
experiments it appears that these neurons need a physiological ‘push’ to be recruited, be it a 
large meal or restraint stress.  
It is unclear how this model fits with data obtained in rats, in which GLP-1R inhibition in several 
brain regions increases food intake, indicating release of GLP-1 in the absence of a physiological 
stimulus. Notably, food intake experiments are often conducted with varying lengths of fast and 
at different times of the day. Furthermore, different environments and handling protocols may 
induce varying levels of stress in the animals leading to activation of PPG neurons and release of 
GLP-1. The ablation model, in which no handling is needed and minimal stress elicited, is 
therefore an important tool in investigations of the central GLP-1 system.  
It is worth mentioning that, although PPG-ablation led to an 80% reduction in hypothalamic and 
spinal cord GLP-1, I did not ablate all brainstem PPG neurons. The IRT population was left intact, 
and it is therefore possible that the lack of effects was due to insufficient knockdown of central 
GLP-1 signalling. In view of this, future studies should include viral targeting of IRT PPG neurons. 
Importantly, my findings align with other studies in mice, in which genetic knockout of GLP-1R 
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has no impact on feeding, bodyweight, or cardiovascular control (Scrocchi et al. 1996; Gros et 
al. 2003; Sisley et al. 2014). 
6.5 Delineating circuits 
In this thesis, I took the first steps towards delineating a NTSPPG → dLS circuit regulating stress-
induced hypophagia. Similar efforts should be made to understand other circuits involved in PPG 
function. We can base these investigations on several pieces of evidence: 1) The inputs the cells 
receive; 2) their known projection pattern; 3) the expression of GLP-1Rs in known brain nuclei; 
and 4) the behavioural and physiological effects of GLP-1 microinjections into distinct brain 
regions.  
For example, projections to the LH and BNST may be important in reward, whereas an NTSPPG → 
CAA/IMLChAT circuit may be the main driver of sympathoexcitatory effects of central GLP-1. 
Similarly, an NTSPPG → PVNCRH circuit may mediate neuroendocrine responses to acute stress. 
These questions can be investigated by virally targeting DREADDs or Channelrhodopsin-2 to 
specific projections. Furthermore, it is currently unclear whether the co-transmitters released 
from PPG neurons contribute to the hypophagic and tachycardic effects observed in response 
to chemogenetic activation. This question should be answered by pharmacologically blocking 
GLP-1 release in CNS and seeing the effect on the PPG-elicited hypophagia or tachycardia. 
6.6 Central GLP-1 regulates diverse processes relating to food intake, 
stress, and reward  
Collectively, evidence presented in this thesis and by others demonstrates the diverse impact of 
central GLP-1 on homeostasis, including potent effects on feeding, stress, and reward (Fig 6.1). 
These proposed roles of central GLP-1 have several areas of overlap. Homeostatic feeding is 
initiated by the lack of sufficient calories. Satiation follows when the organism senses sufficient 
energy intake to maintain energy homeostasis. Hedonic food intake, on the other hand is driven 
by the activation of reward centres in the brain, a process not dissimilar to the reinforcement 
experienced following intake of psychostimulant drugs such as cocaine and amphetamine. PPG 
neurons may induce anorexia by both attenuating food reward and by relaying signals of 
sufficient caloric intake. Similarly, feeding is potently inhibited by stress and visceral illness and 
PPG neurons may be part of a general response to homeostatic and psychogenic stress leading 
to decreased food intake as well as activation of neuroendocrine responses to stress.  





6.6 Summary and conclusions 
This thesis presents the first evidence that PPG neurons are crucial mediators of satiety by 
specifically preventing overeating. I also demonstrated that NTS PPG neurons and endogenous 
GLP-1 within the dLS are crucial for hypophagia in response to acute restraint stress. 
Furthermore, these studies provided the first evidence that PPG neurons are able to increase 
heart rate, but that they are not involved in the normal regulation of heart rate and blood 
pressure. Finally, I have expanded our knowledge of the regulation of PPG neuron activity by a 
range of compounds, highlighting potential avenues for future research. These findings shed 
new light on the importance of NTS PPG neurons and encourage further investigations into the 
specific physiological context in which central GLP-1 plays its part. Collectively, data presented 
here and by others suggest that PPG neurons integrate signals of satiety and stress to reduce 
food intake and increase sympathetic outflow. Future studies should focus on interoceptive and 
psychogenic stress as the ‘push’ needed to recruit the central GLP-1 system.  
 
Fig. 6.1 The diverse roles of central 
GLP-1. Three physiological pheno-
mena are affected by central GLP-1 
signalling: Stress, reward, and 
feeding. Normal feeding is regulated 
by the availability of nutrients and is 
decreased in response to central 
GLP-1. However, food intake is also 
affected by reward and stress and 
GLP-1 plays a key role in regulating 
processes, which fall into these 
categories. GLP-1 increases heart 
rate, thermogenesis, and blood 
corticosterone, and central GLP-1 
mediates the hypophagic response 
to psychogenic and interoceptive 
stress. Brain GLP-1 also reduces the 
rewarding value of psychostimulant 
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